



CONGRESS




BERLIN

11-14 OCTOBER 2023

FINAL  
PROGRAMME

[eadvcongress2023.org](http://eadvcongress2023.org)



## TABLE OF CONTENTS

<u>EADV PRESIDENT'S WELCOME LETTER</u>	<u>3</u>
<u>WELCOME FROM THE SCIENTIFIC PROGRAMMING COMMITTEE</u>	<u>4</u>
<u>THE ACADEMY &amp; FUTURE EADV EVENTS</u>	<u>5</u>
<u>CONTINUING MEDICAL EDUCATION – CONTINUING PROFESSIONAL DEVELOPMENT (CME-CPD)</u>	<u>6</u>
<u>ABSTRACT REVIEWERS</u>	<u>7</u>
<u>WEDNESDAY 11 OCTOBER PROGRAMME</u>	<u>8</u>
<u>THURSDAY 12 OCTOBER PROGRAMME</u>	<u>39</u>
<u>FRIDAY 13 OCTOBER PROGRAMME</u>	<u>73</u>
<u>SATURDAY 14 OCTOBER PROGRAMME</u>	<u>104</u>
<u>PRACTICAL WORKSHOPS</u>	<u>124</u>
<u>GENERAL INFORMATION &amp; FLOORPLANS</u>	<u>128</u>
<u>HEALTHCARE PROFESSIONAL INFORMATION AND DEFINITION</u>	<u>149</u>
<u>INDUSTRY SESSIONS</u>	<u>152</u>
<u>EXHIBITOR LIST</u>	<u>162</u>
<u>MAIN SPONSORS</u>	<u>172</u>

**EDITORIAL/PUBLISHER**

European Academy of Dermatology  
and Venereology (EADV)

[www.eadv.org](http://www.eadv.org)

Find further information about the event

[eadvcongress2023.org](http://eadvcongress2023.org)

Follow us on social media and  
join the conversation using **#EADVCongress**



## EADV PRESIDENT'S WELCOME LETTER

Dear colleagues,

Welcome to the hybrid EADV Congress, hosted in Berlin and online.

The COVID pandemic and the subsequent EADV Congress in Milan highlighted the importance of engaging in activities and events with others. Berlin, renowned for its vibrant energy, serves as an ideal backdrop for this year's congress. The congress centre is thoughtfully designed to accommodate our fruitful exchanges alongside the extensive scientific lectures. In this environment, exchanges with our colleagues provide a much deeper, more critical and sustainable enrichment to our knowledge. What makes meeting in person so important? No other medical discipline is so rich and no other discipline changes so rapidly as dermatology. What other medical discipline is so present in the key medical journals, like the New England Journal of Medicine, the Lancet or Nature journals, as dermatology? Even for those who read regularly, it is almost impossible to remain fully updated on all significant developments. Moreover, none of us are individually able to thoroughly evaluate these changes and their consequences with a high level of critical analysis.


It is our duty towards our patients to help them, by recognising the most recently described diseases, use the most appropriate diagnostic standards, and provide them with the best treatment. Patients are increasingly informed about recent developments. The current therapeutic possibilities could not be predicted until recently. Yet, not all developments are appropriate for everyone. For instance, when penicillin was used as a food additive to prevent (all) infections, and cyclosporin A was used as a standard therapy for psoriasis even in young UV exposed patients, demonstrates that we should exercise caution and shouldn't implement all theoretically feasible measures. Even for diseases with a severe burden, it is our duty to guide our patients about the treatment possibilities they may research themselves or find on the internet.

Unlike the most infectious diseases, many skin conditions impose a lifelong burden, and ensuring drug safety is not a short-term consideration but rather a lifelong concern. What potential long-term risks are deemed acceptable to endure for many years, or even decades, in order to manage a disease that causes severe social stigma but does not lead to other comorbidities? How real are the possibilities and risks of novel diagnostic and therapeutic procedures? How far can we push the boundaries for disfiguring and deadly diseases? Where are our current limitations and possibilities? And most importantly, how can we improve our approaches for our patients?

In our daily practice, we confront these and similar questions, whether we take care of atopic dermatitis, psoriasis, new therapeutic options, paediatric dermatology, hair and nail diseases, skin cancers, melanomas, lymphomas squamous cell and other cancers, STIs or genetic diseases, or others. In order to gain a comprehensive understanding of our field, it is essential for all of us, including trainees, practitioners, and academics, to participate in congresses, as it is only there, where we have the opportunity to cover a wide range of topics that reflect the diverse spectrum of our daily practice. In addition to engaging in specialised discussions for practitioners and young dermatologists, we can anticipate some of the most esteemed figures in the field of dermatology from across Europe, USA and other continents who will share their latest insights and research.

I look forward to personally welcoming you to Berlin.

**Martin Röcken**  
President, EADV



## WELCOME FROM THE SCIENTIFIC PROGRAMMING COMMITTEE

As Chair of the Scientific Programming Committee, it is my great pleasure to welcome you to the 32<sup>nd</sup> EADV Congress in Berlin. We are thrilled to present an exceptional programme that not only showcases the remarkable advancements in our field over the past year but also provides practical insights on how to integrate these innovations into your clinical practice.

The programme will feature more than **600 speakers** from more than **50 countries**, who will deliver engaging talks across **180 sessions**.

As in previous years, these sessions will be categorized into “updates,” “training and education,” and “controversies,” encompassing a wide spectrum of topics within our speciality.

In addition, we have created **new formats** including a “Focus on session”, which will cover topics including new technologies, sclerotic skin diseases, and fragile skin, as well as a “Face-to-face” session, offering an open platform to discuss commonalities and differences in the management of skin diseases among hospital-based dermatologists and private practitioners.

We have invited **9 world-class speakers** to deliver Plenary Talks addressing hot topics of our speciality such as pruritus, melanoma, topical gene therapy, STI vaccines, mastocytosis, skin of colour and big data medicine.

This year we have received a record number of abstract submissions (over 3400) and have meticulously selected the best ones to be presented in the late-breaking news session (36), as Free Communications (72), or featured in a newly created oral e-poster presentation session (48). The remaining abstracts will be available for viewing on the Congress platform and on the dedicated e-poster area at the Congress.

Our Congress will continue to offer “hands-on workshops,” a cherished tradition. Last but not least, “subspecialty sessions” will be held for the first time on Wednesday morning and on Saturday early afternoon, starting and concluding the Congress.


Finally, for those who are unable to come to Berlin, we offer the possibility to follow the Congress virtually, as the entire educational content will be live-streamed and available on the Congress online platform.

Please join us in Berlin to make the 2023 EADV Congress a unique and unforgettable event!

### **Prof. Dr Michel Gilliet**

Chair of the EADV Scientific Programming Committee





## THE ACADEMY



Founded in 1987, the European Academy of Dermatology and Venereology is a global community with the unifying goal of advancing excellence in patient care, promoting knowledge and expertise among healthcare professionals, as well as advocating on behalf of speciality and patients.

EADV is a leading provider of education in dermatology-venereology through a unique blend of in-person and online courses, as well as digital learning tools including webinars and podcast episodes.

The Academy offers several scholarships, grants, and research funding opportunities, enriching networks and knowledge-sharing among future leaders in the specialty. EADV actively promotes better awareness of skin and venereal diseases by working closely with global and European policy-makers on public health campaigns to tackle occupational skin diseases, melanoma, sexually transmitted infections, and other maladies.

The Journal of the European Academy of Dermatology and Venereology (JEADV), publishes a wide range of articles that focus on basic science, clinical and translational research in dermatology and venereology. With an Impact Factor of 9.2, it is now ranked 4th among the international dermatology journals. The JEADV Clinical Practice is the open-access peer-reviewed publication of EADV. It features cutting-edge educational and clinically-orientated content, for aspiring researchers, to showcase the latest hands-on practices in clinics and innovative clinical and surgical skills.

Every year EADV holds a flagship Congress in the autumn and a Symposium in the spring, which attract tens of thousands of delegates from around the world, exchanging ideas, experiences and projects to improve patient care.

## FUTURE EADV MEETINGS

### 2024

**19<sup>TH</sup> EADV SPRING SYMPOSIUM**  
16-18 May 2024 | St Julian's, Malta

**33<sup>RD</sup> EADV CONGRESS**  
25-28 September 2024 | Amsterdam, The Netherlands

### 2025

**20<sup>TH</sup> EADV SPRING SYMPOSIUM**  
19-25 May 2025 | Prague, Czech Republic

**34<sup>TH</sup> EADV CONGRESS**  
17-21 September 2025 | Paris, France

## CONTINUING MEDICAL EDUCATION – CONTINUING PROFESSIONAL DEVELOPMENT (CME-CPD)

The EADV Congress 2023 in Berlin, Germany 11/10/2023 - 14/10/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 27.0 European CME credits (ECMEC®s).

### CME Credits

Each medical specialist can claim only those hours of credit actually spent in the educational activity (as recorded by the scanning process).

Here below please find the breakdown of credits per day:

Wednesday 11 October	7 credits
Thursday 12 October	7 credits
Friday 13 October	6 credits
Saturday 14 October	7 credits

The accreditation system is based on 1 ECMEC per hour.

**No credits will be guaranteed by the EADV to delegates participating in sessions organised by industry and subspecialty societies.**

### Procedure to gain your credits

**Scan your badge, complete the evaluation forms and download the CME-CPD Certificate.**

The EADV offers individual CME-CPD participation through the scanning of the bar code and the speaker/session evaluation that will be available for a period of one month after the end of the Congress (until 10 November 2023).

1. Scan your badge as you pass through the entrance of each session hall (or access the session online, live or on-demand).
2. Complete the anonymous online evaluation form for each attended session. Access the evaluation system in the “My Congress” area on the online Congress platform.
3. Download your CME-CPD certificate and retain it for your personal records.

Evaluation data is essential to our statistics and is of considerable help in the choice of future topics and speakers. Your feedback and comments are greatly appreciated.

### Conversion of credits

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

### Information regarding the conversion of EACCME®credits

Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at <https://edhub.ama-assn.org/pages/applications> to obtain the necessary paperwork and instructions. Physicians and other healthcare professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority.



## ABSTRACT REVIEWERS

EADV is grateful to the following reviewers who have given their time and expertise in reviewing the submitted abstracts:

Ashraf Badawi (Canada), Anna Balato (Italy), Zsuzsanna Bata-Csorgo (Hungary), Johann Bauer (Austria), Aslı Bilgic (Türkiye), Piergiacomo Calzavara-Pinton (Italy), Jose-Manuel Carrascosa (Spain), Pavel Chernyshov (Ukraine), Zsanett Renáta Csoma (Hungary), Clio Dessinioti (Greece), Dario Didona (Germany), Nejib Doss (Tunisia), Kossara Drenovska (Bulgaria), Andrew Finlay (United Kingdom), Carlo Gelmetti (Italy), Ana Giménez-Arnau (Spain), Claudia Heller-Vitouch (Austria), Matilde Iorizzo (Switzerland), Jana Kazandjieva (Bulgaria), Lajos Kemény (Hungary), Nicolas Kluger (Finland), Kateryna Kolyadenko (Ukraine), Dimitra Koumaki (Greece), Aikaterini Liakou (Greece), Harvey Lui (Canada), Susanna Marini (Italy), Ulrich Mrowietz (Germany), Arjen Fokko Nikkels (Belgium), Rodica Olteanu (Romania), David Pesqué (Spain), Sandra Peternel (Croatia), Asja Prohic (Bosnia and Herzegovina), Adam Reich (Poland), Mahtab Samimi (France), Luis Miguel Soares de Almeida (Portugal), Efthymia Soura (Greece), Sundaramoorthy Srinivasan (India), Philipp Tschandl (Austria), Stefano Veraldi (Italy), Christian Vestergaard (Denmark), Elke Weisshaar (Germany), Torsten Zuberbier (Germany)

## SUBSPECIALTY AND INTERNATIONAL SOCIETIES

**EHSF - European Hidradenitis Suppurativa Foundation**  
**ENS - European Nail Society**  
**ESCAD - European Society for Cosmetics and Aesthetic Dermatology**  
**ESLD - European Society for Lasers and Energy Based Devices**  
**ESMS - European Society for Micrographic Surgery**  
**ESPD - European Society for Photodermatology**  
**ETFAD - European Task Force of Atopic Dermatitis**  
**Euomelanoma**  
**EURO-PDT - European Society for Photodynamic Therapy in Dermatology**  
**EWDVS - European Women's Dermatologic and Venereologic Society**  
**GA<sup>2</sup>LEN - Global Allergy and Asthma European Network of Excellence**  
**GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis**  
**IDS - International Dermoscopy Society**  
**IEC - International Eczema Council**  
**IPC - International Psoriasis Council**  
**IPS - International Peeling Society**  
**ISD - International Society of Dermatology**  
**MEIDAM - Middle East International Dermatology and Aesthetic Medicine**  
**PALD - Pan Arab League of Dermatologists**  
**SSDDS - Saudi Society of Dermatology and Dermatologic Surgery**

WEDNESDAY 11 OCTOBER 2023

**PROGRAMME AT A GLANCE**

[CLICK TO VIEW THE INTERACTIVE PROGRAMME](#)

Room name	Hall B	Hall A8	Room 3	Room 4	Room 5	Room 6
Session type	Subspecialty session / Updates / Plenary lectures	Subspecialty session / Focus on	Subspecialty session / Updates	Subspecialty session / Updates	Subspecialty session / Updates	Subspecialty session / Updates
Track no.	1	2	3	4	5	6
08.30 - 10.00	IADV - Indian Association of Dermatologists, Venereologists & Leprologists	ETFAD - European Task Force of Atopic Dermatitis	ESCAD - European Society for Cosmetics and Aesthetic Dermatology	IDS - International Dermoscopy Society	IPC - International Psoriasis Council	EHSF - European Hidradenitis Suppurativa Foundation
10.00 - 10.15						
10.15 - 11.45						
11.45 - 12.00						
12.00 - 13.00	PL-A Plenary Lectures 1-2-3					
13.00 - 14.00		Industry sessions (Lunch satellite symposia)				
14.00 - 14.15						
14.15 - 15.45	Late breaking news	Focus on new technologies	Oral diseases	Psoriasis	Prevention and skin cancer screening	Emerging drugs
15.45 - 16.00						
16.00 - 17.30		Focus on new technologies	Pregnancy and skin diseases	Psoriasis	Actinic keratosis	Emerging drugs
17.30 - 17.45						
17.45 - 19.15	Opening ceremony with Keynote lecture					



WEDNESDAY 11 OCTOBER 2023

PROGRAMME AT A GLANCE

CLICK TO VIEW THE INTERACTIVE PROGRAMME

Room name	Hall A7	Hall A3	Hall A1	Hall A2	Hall A5	Hall A4
Session type	Subspecialty session / Updates	Subspecialty session / Updates	Subspecialty session / Updates	Subspecialty session / Updates	Subspecialty session / Training and Education	Subspecialty session / Updates
Track no.	7	8	9	10	11	12
08.30 - 10.00	Euromelanoma	ESPD - European Society for Photodermatology	ISD - International Society of Dermatology	GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis	PALD - Pan Arab League of Dermatologists	ENS - European Nail Society
10.00 - 10.15						
10.15 - 11.45						
11.45 - 12.00						
12.00 - 13.00						
13.00 - 14.00	Industry sessions (Lunch satellite symposia)					
14.00 - 14.15						
14.15 - 15.45	Dermatology in skin of color patients	Big Data and dermatology	Alopecia Areata	Microbiome and skin diseases	Acne and rosacea	Dermatopathology
15.45 - 16.00						
16.00 - 17.30	Rosacea	Tele dermatology	Vitiligo	Vasculitis and vasculopathies	Nail and hair disorders	Dermatopathology

WEDNESDAY 11 OCTOBER 2023

**PROGRAMME AT A GLANCE**

[CLICK TO VIEW THE INTERACTIVE PROGRAMME](#)

Room name	M1+2	M6+7	M4+5	M8
<b>Session type</b>	<b>Subspecialty session / Updates</b>	<b>Miscellaneous</b>	<b>Practical workshops</b>	<b>Practical workshops</b>
<b>Track no.</b>	<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>
08.30 - 10.00	CA <sup>2</sup> LEN - Global Allergy and Asthma European Network of Excellence		Use of botox in cosmetic and medical dermatology	Surgery beginners
10.00 - 10.15				
10.15 - 11.45		EADV Task Forces Highlights		
11.45 - 12.00				
12.00 - 13.00				
13.00 - 14.00	Industry sessions (Lunch satellite symposia)			
14.00 - 14.15				
14.15 - 15.45	Skin ageing and rejuvenation	Advocacy session: Advocating for better care of skin cancer patients in Europe	Use of botox in cosmetic and medical dermatology	Surgery intermediate
15.45 - 16.00				
16.00 - 17.30	JAK inhibitors	Skin diseases in Latin America		

## WEDNESDAY 11 OCTOBER 2023

## SUBSPECIALTY SESSION HALL A8

08:40 - 11:45 **ETFAD - EUROPEAN TASK FORCE OF ATOPIC DERMATITIS**

**Chairs:** Mette Sondergaard Deleuran (Aarhus, Denmark)  
Andreas Wollenberg (Munich, Germany)  
Sébastien Barbarot (Nantes, France)

**8:40 Associations of IL-35 and IL-36 with atopic dermatitis**  
Magdalena Trzeciak (Gdansk, Poland)

**8:55 Patterns of treatment, health care visits and related costs in children with controlled and uncontrolled atopic dermatitis in Sweden**  
Laura von Kobyletzki (Örebro, Sweden)

**9:10 What do atopic dermatitis patients want to know about family planning and their disease? Results from a survey among 120 adult AD patients aged 18-45**  
Christian Vestergaard (Aarhus, Denmark)

**9:25 Assessment of Quality of Life in children with atopic eczema**  
Laura von Kobyletzki (Örebro, Sweden)

**9:40 International eDelphi study to establish consensus on methotrexate dosing in patients with atopic eczema**  
Anouk Caron (Amsterdam, Netherlands)

**9:55 Comparing the treatment effectiveness and safety of dupilumab and methotrexate in paediatric and adult atopic dermatitis: results from the A-STAR register**  
Carsten Flohr (London, United Kingdom)

**10:10 Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis**  
Marjolein de Bruin-Weller (Utrecht, Netherlands)

**10:25 Effects of tralokinumab treatment on quantitative and qualitative measures of skin barrier function and biology in patients with moderate to severe atopic dermatitis**  
Stephan Weidinger (Kiel, Germany)

**10:40 Immunological characterization of dupilumab-associated ocular surface disease**  
Dagmar Simon (Bern, Switzerland)

**10:55 The TREATgermany registry: Analysis of non-responders to dupilumab**  
Annice Heratizadeh (Hannover, Germany)

**11:10 Prevalence of risk factors that may impact treatment with Oral JAK inhibitors in Danish patients with atopic dermatitis: A nationwide registry study**  
Ida Vittrup (Copenhagen, Denmark)

**11:25 Effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis: daily practice data**  
Jill Olydam (Rotterdam, Netherlands)

WEDNESDAY 11 OCTOBER 2023

SUBSPECIALTY SESSION

ROOM 3

08:30 - 11:45

**ESCAD - EUROPEAN SOCIETY FOR COSMETICS AND AESTHETIC DERMATOLOGY**

Chairs:

Peter Velthuis (Rotterdam, Netherlands)

Ashraf Badawi (Oakville, Canada)

Christopher Rowland Payne (London, United Kingdom)

8:30

**Tear trough injections, the do's and don'ts**

Miray Al-Mustafa (Oslo, Norway)

8:45

**Ethical considerations in aesthetic dermatology**

Ashraf Badawi (Oakville, Canada)

9:00

**Filler complication report 2**

Hugues Cartier (Arras, France)

9:15

**How to optimize the ultrasound image: tips and tricks**

Angeliki Koulouri (Zürich, Switzerland)

9:30

**How to approach the sad mouth with dermal fillers: a real challenge**

Nahla Hunter (Cairo, Egypt)

9:45

**Self injectors of HA filler**

Albert Wolkerstorfer (Amsterdam, Netherlands)

10:00

**New ways to increase the duration of Botulinum toxin effects**

Klaus Fritz (Landau, Germany)

10:15

**Evidence based oral supplements to improve skin quality**

Liliana Sytnyk (Kyiv, Ukraine)

10:30

**Combination treatments**

Leonardo Marini (Trieste, Italy)

10:45

**Laser for tattoos**

Keyvan Nouri (Miami, United States)

11:00

**Emotional anatomy for aesthetic facial injections – from Charles Darwin to Myomodulation**

Wolfgang Philipp-Dormston (Köln, Germany)

11:15

**Regenerative aesthetics - An evidence-based analysis**

Hema Sundaram (Rockville, United States)

11:30

**Changes in filler injection technique coming from new ultrasound research**

Peter Velthuis (Rotterdam, Netherlands)

WEDNESDAY 11 OCTOBER 2023

SUBSPECIALTY SESSION ROOM 4

08:30 - 11:45

IDS - INTERNATIONAL DERMOSCOPY SOCIETY

Chairs:

Caterina Longo (Modena, Italy)

Zoe Apalla (Thessaloniki, Greece)

John Paoli (Gothenburg, Sweden)

8:30

IDS President's corner

Aimilios Lallas (Thessaloniki, Greece)

8:45

Identification of high risk patients and digital monitoring

Elvira Moscarella (Naples, Italy)

9:00

How dermoscopy can improve surgical management of melanoma

John Paoli (Gothenburg, Sweden)

9:15

State of the art of artificial intelligence

Konstantinos Liopyris (Athens, Greece)

9:30

Super high magnification dermoscopy

Stefania Guida (Milano, Italy)

9:45

Lentigo maligna management

Philipp Tschandl (Vienna, Austria)

10:00

Dermoscopy of mucosa

Zoe Apalla (Thessaloniki, Greece)

10:15

Update on dermoscopy on skin of color

Enzo Errichetti (Udine, Italy)

10:30

Pre-surgical use of dermoscopy for basal cell carcinoma

Cristina Carrera (Barcelona, Spain)

10:45

Squamous cell carcinoma and beyond

Claudio Conforti (Trieste, Italy)

11:00

My best cases of the year

Nisa Akay Bengu (Ankara, Türkiye)

11:15

My best cases of the year

Cristian Navarrete-Dechent (Santiago, Chile)

## WEDNESDAY 11 OCTOBER 2023

**SUBSPECIALTY SESSION ROOM 5****08:30 - 11:45****IPC - INTERNATIONAL PSORIASIS COUNCIL****Chairs:**

Lluís Puig (Barcelona, Spain)  
Richard B. Warren (Manchester, United Kingdom)  
Irène Gallais Serezal (Besançon, France)  
Johann Gudjonsson (Ann Arbor, United States)

**8:30****Welcome and Introduction**

Lluís Puig (Barcelona, Spain)

**8:35****SESSION ONE: EPIGENETICS & PSORIASIS****8:35****Session Introduction: New Insights in the Pathogenesis of Psoriasis**

Johann Gudjonsson (Ann Arbor, United States)

**8:55****Panel Discussion**

Lluís Puig (Barcelona, Spain)

**9:35****SESSION TWO: DISEASE RELAPSE AND PROGRESSION****9:35****Session Introduction: New Understandings of Disease Relapse and Progression**

Irène Gallais Serezal (Besançon, France)

**9:55****The Natural Course of Psoriasis: Insights into Clinical and Genetic Markers****10:15****Panel Discussion**

Lluís Puig (Barcelona, Spain)

**10:35****Break****10:45****SESSION THREE: TREATMENT INNOVATIONS****10:45****Session Introduction: Innovations in Small Molecule Therapeutics**

Richard B. Warren (Manchester, United Kingdom)

**11:05****Panel Discussion**

Lluís Puig (Barcelona, Spain)



WEDNESDAY 11 OCTOBER 2023

SUBSPECIALTY SESSION ROOM 6

08:30 - 11:45 EHSF - EUROPEAN HIDRADENITIS SUPPURATIVA FOUNDATION

**Chairs:** Christos C. Zouboulis (Dessau, Germany)  
Gregor Borut Jemec (Roskilde, Denmark)

8:30 Introduction

Christos C. Zouboulis (Dessau, Germany)

8:35 Demographics and clinical characteristics of the HS patients in Greece: Data from the official HS registry of "Andreas Sygros" Hospital

Aikaterini Liakou (Athens, Greece)

8:45 Correlation between Clinical and Ultrasound Assessment in Hidradenitis Suppurativa: Experience from the Bulgarian HS Expert Center

Gavrail Poterov (Stara Zagora, Bulgaria)

8:55 HS in Iran

Alireza Firooz (Tehran, Iran)

9:05 Discussion

9:10 Full exome sequencing of familial Hidradenitis Suppurativa

Chiara Moltrasio (Milan, Italy)

9:20 NCSTN variation is associated with a distinct HS phenotype; results from across section-al study

Dillon Mintoff (Xemxija, Malta)

9:30 Single cell RNA sequencing reveals evolution of immune landscape during HS lesion progression

Kelsey van Straalen (Rotterdam, Netherlands)

9:40 Is HS an inborn error of immunity?

Snaigune Miskinyte (France)

9:50 Levels of IL-1 family cytokines in HS patients: more than single IL-1

Flavia Manzo Margiotta (Pisa, Italy)

10:00 Discussion

10:08 Invited lecture: Single cell RNA sequencing unveils a pivotal role of barrier defect of pilosebaceous apocrine unit in HS

Qiang Ju (Shanghai, China)

10:18 Invited lecture: Moving forward: IHS4 and IHS4-55 for severity and drug efficacy assessment in clinical trials and daily clinical

Tzellos Thrasyvoulos (Bodø, Norway)

10:28 Discussion

10:34 Three dimensional ex vivo models for pathogenesis research and preclinical HS treatment studies

Georgia Vradeli (Dessau-Roßlau, Germany)

WEDNESDAY 11 OCTOBER 2023

- 10:44 **Progression markers in hidradenitis suppurativa: results from a single center study**  
Antonella Di Cesare (Florence, Italy)
- 10:54 **Patient assessment of individual types of skin lesions in HS**  
Linnea Thorlacius (Copenhagen, Denmark)
- 11:04 **Hidradenitis suppurativa topical management: new insight in HS-TIME**  
Alessandra Michelucci (Italy)
- 11:14 **Long-term adalimumab effectiveness and safety in patients with moderate to severe hidradenitis suppurativa: a single center experience**  
Elia Rosi (Florence, Italy)
- 11:24 **Modern surgical approaches for hidradenitis suppurativa: step by STEEP**  
Peter Hollo (Budapest, Hungary)
- 11:34 **Discussion**

**SUBSPECIALTY SESSION HALL A7**

**09:30 - 11:45 EUROMELANOMA**

- Chairs:** Mariano Suppa (Brussels, Belgium)  
Sara Gandini (Milan, Italy)  
Thomas Dirschka (Wuppertal, Germany)
- 9:30 **Welcome and introduction**  
Mariano Suppa (Brussels, Belgium)
- 9:40 **Skin cancer epidemiology: what's new?**  
Sara Gandini (Milan, Italy)
- 10:00 **Cancerisation field: where the AI helps us**  
Carmen Orte Cano (Bruxelles, Belgium)
- 10:20 **Euscap: skin cancer risk platform, a first analysis**  
Katharina Wunderlicht (Brussels, Belgium)
- 10:40 **European prevalence of AK: Euromelanoma database analysis**  
Gerardo Palmisano (Rome, Italy)
- 11:00 **Euromelanoma campaign in Armenia**  
Michael Hambardzumyan (Karlsruhe, Germany)
- 11:15 **Euromelanoma 2024: A new campaign**  
Philippe Pendaries (Tunbridge Wells, United Kingdom)
- 11:30 **Final conclusions**  
Mariano Suppa (Brussels, Belgium)

WEDNESDAY 11 OCTOBER 2023

**SUBSPECIALTY SESSION HALL A3**

**08:30 - 11:45 ESPD - EUROPEAN SOCIETY FOR PHOTODERMATOLOGY**

**Chairs:** Sally Helen Ibbotson (Dundee, United Kingdom)  
Jean Krutmann (Dusseldorf, Germany)  
Lesley Rhodes (Manchester, United Kingdom)  
Marjan Garmyn (Leuven, Belgium)  
Piergiacomo Calzavara-Pinton (Brescia, Italy)  
Christophe Bedane (Limoges, France)

**8:30 Welcome**

Giovanni Leone (Roma, Italy)

**8:40 Gaining insights in Photodermatology from studying the Porphyrins and DNA repair disorders.**

Robert Sarkany (London, United Kingdom)

**9:25 Break**

**9:40 New approaches on PDT in Dermatology**

Yolanda Gilaberte (Zaragoza, Spain)

**10:10 Novel insights on chronic inducible urticarias including solar urticaria**

Marcus Maurer (Berlin, Germany)

**10:40 Short communications session**

**11:40 Concluding remarks**

Giovanni Leone (Roma, Italy)

**SUBSPECIALTY SESSION HALL A1**

**08:30 - 11:45 ISD - INTERNATIONAL SOCIETY OF DERMATOLOGY**

**Chairs:** TBC

Chairs TBC

WEDNESDAY 11 OCTOBER 2023

**SUBSPECIALTY SESSION HALL A2**

**10:00 - 11:45 GRAPPA - GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS**

**Chairs:** April W. Armstrong (Los Angeles, United States)

**10:00 Introduction**

April W. Armstrong (Los Angeles, United States)

**10:05 Immunogenetics of psoriasis**

Mona Ståhle (Solna, Sweden)

**10:20 Efficacy and safety of systemic psoriasis therapies using real-world and clinical trial data**

Alexander Egeberg (Gentofte, Denmark)

**10:35 What is hot in health services research and health economics research in psoriasis?**

Matthias Augustin (Hamburg, Germany)

**10:50 Q and A of Faculty**

**11:00 Treatment Goals**

Ulrich Mrowietz (Kiel, Germany)

**11:15 PsA**

Joseph F. Merola (Boston, United States)

**11:30 IPC collaboration and key projects**

Hervé Bachelez (Paris, France)

WEDNESDAY 11 OCTOBER 2023

SUBSPECIALTY SESSION HALL A4

08:30 - 11:45 ENS - EUROPEAN NAIL SOCIETY

**Chairs:**  
**Bertrand Richert (Brussels, Belgium)**  
**Matilde Iorizzo (Bellinzona, Switzerland)**  
**Marcel Pasch (Nijmegen, Netherlands)**

**8:30 Introduction**  
 Bertrand Richert (Brussels, Belgium)

**8:35 Onychodysplasia**  
 Bianca Maria Piraccini (Bologna, Italy)

**8:50 Clinical case**  
 Tomer Goldsmith (Tel Aviv, Israel)

**8:57 Retronychia: sometimes you have to backtrack before you can move forward**  
 Andre Lencastre (Lisboa, Portugal)

**9:12 Clinical case**  
 Asli Bilgic (Türkiye)

**9:19 What's new in Pediatric Nail Disorders**  
 Lourdes Navarro Campoamor (Madrid, Spain)

**9:34 Clinical case**  
 Kendall Billick (Montreal, Canada)

**9:41 E-Nail: Medical cases**  
 Aurora Alessandrini (Bologna, Italy)

**9:56 Break**

**10:18 E-Nail: Surgical cases**  
 Nilton Gioia Di Chiacchio (Sao Paulo, Brazil)

**10:33 Clinical case**  
 Charlotte Arnal (Brussels, Belgium)


**10:40 New tips in nail surgery**  
 Nathaniel Jellinek (East Greenwich, United States)

**10:55 Clinical case**  
 Stephano Cedirian (Bologna, Italy)

**11:02 Dressings in nail surgery**  
 Dhruvkumar Laheru (WALLINGFORD, United Kingdom)

**11:17 Clinical case**  
 Azzam Alkhalifah (Unayzah, Saudi Arabia)

**11:24 Management of myxoid cysts**  
 Fatih Göktay (Istanbul, Türkiye)



**WEDNESDAY 11 OCTOBER 2023**

<b>SUBSPECIALTY SESSION</b>	<b>M1+2</b>
<b>08:30 - 11:45</b>	<b>GA<sup>2</sup>LEN - GLOBAL ALLERGY AND ASTHMA EUROPEAN NETWORK OF EXCELLENCE</b>
<b>Chairs:</b>	<p><b>Torsten Zuberbier (Berlin, Germany)</b></p> <p><b>Carsten Bindslev-Jensen (Odense, Denmark)</b></p> <p><b>Ana Giménez-Arnau (Barcelona, Spain)</b></p>
<b>8:30</b>	<p><b>Who is GA<sup>2</sup>LEN</b></p> <p>Torsten Zuberbier (Berlin, Germany)</p>
<b>8:40</b>	<p><b>Importance of GA<sup>2</sup>LEN in EADV</b></p> <p>Torsten Zuberbier (Berlin, Germany)</p>
<b>8:50</b>	<p><b>Chronic Urticaria - where do we stand, where do we go?</b></p> <p>Marcus Maurer (Berlin, Germany)</p>
<b>9:20</b>	<p><b>Recurrent angioedema – What could be the cause and how to find it</b></p> <p>Markus Magerl (Berlin, Germany)</p>
<b>9:40</b>	<p><b>Neurosensitisation in AD: Development and persistence of itch</b></p> <p>Manuel Pereira (Berlin, Germany)</p>
<b>10:00</b>	<p><b>Guidelines for food allergy management</b></p> <p>Antonella Muraro (Padua, Italy)</p>
<b>10:20</b>	<p><b>The role of threshold values in food allergy</b></p> <p>Carsten Bindslev-Jensen (Odense, Denmark)</p>
<b>10:40</b>	<p><b>A new way to integrate real world evidence in guideline work: ARIA as an example</b></p> <p>Holger Schünemann (Milan, Italy)</p>
<b>11:00</b>	<p><b>Discussion</b></p> <p>Torsten Zuberbier (Berlin, Germany)</p>
<b>11:20</b>	<p><b>Round-up</b></p> <p>Torsten Zuberbier (Berlin, Germany)</p>



WEDNESDAY 11 OCTOBER 2023

SUBSPECIALTY SESSION HALL A5

09:45 - 11:45 PALD - PAN ARAB LEAGUE OF DERMATOLOGISTS

**Chairs:**  
**Riad Mashal (Ramallah, Palestine)**  
**Nejib Doss (Tunis, Tunisia)**  
**Ibrahim Almukahal (Benghazi, Libya)**

**9:45 Effect of biological therapies on cumulative life course impairment in Psoriasis**  
 Ibrahim Almukahal (Benghazi, Libya)

**9:55 Facial hyperpigmentation: causes & treatment**  
 Nedhal Khalifa (Manama, Bahrain)

**10:05 Dermoscopy and surgery of the nail unit: clinical cases**  
 Nouredine Litaïem (Tunis, Tunisia)

**10:15 Arteriovenous malformations: a review 15 years experience**  
 Aïcha Salhi (Algiers, Algeria)

**10:25 Onychoscopic features of various types of onychomycosis**  
 Dindar Qurtas (Erbil, Iraq)

**10:35 Dermoscopic features of cutaneous Leishmaniasis**  
 Muhsin Al Dhalimi (Najaf, Iraq)

**10:45 Psoriasis in dark skin**  
 Ibrahima Traore (Conakry, Guinea)

**10:55 Podoconiosis**  
 Aldo Morrone (Rome, Italy)

**11:05 Complications of skin-bleaching products among Sudanese**  
 Safiedin Ali (Khartoum, Sudan)

**11:15 Approach to chronic granulomatous skin infections**  
 Hadaf Aljunaiyeh (Iraq)

**11:25 Approach to hirsutism**  
 Aimen Alshami (Yemen)

**11:35 The Effect of Narrowband Ultraviolet B Phototherapy on levels of Serum Vitamin D3 in Psoriatic Patients**  
 Fouz Hassan (Latakia, Syria, Arab Rep.)

WEDNESDAY 11 OCTOBER 2023

SUBSPECIALTY SESSION HALL B

08:30 - 11:45	IADVL - INDIAN ASSOCIATION OF DERMATOLOGISTS, VENEREOLOGISTS & LEPROLOGISTS
Chairs:	<p><b>Vijay Zawar (Nashik, India)</b>  <b>Shyam Verma (Vadodara, India)</b>  <b>Dinesh Kumar Devaraj (Chennai, India)</b></p>
8:30	<p><b>Oral tranexamic acid in melasma</b>                      Kiran Vasant Godse (Navi Mumbai, India)</p>
8:42	<p><b>Approach to cutaneous vasculitis</b>                      Dinesh Kumar Devaraj (Chennai, India)</p>
8:54	<p><b>Dermoscopy in leprosy and its association with clinical spectrum and histopathology</b>                      Shivakumar Patil (Belagavi, India)</p>
9:06	<p><b>Dermoscopy in vascular lesions</b>                      Rashmi Mittal (DEHRADUN, India)</p>
9:18	<p><b>Atypical presentations of pityriasis rosea</b>                      Vijay Zawar (Nashik, India)</p>
9:30	<p><b>Tofacitinib in actinic reticuloid with dramatic response - A series of 5 cases</b>                      Anchala Parthasaradhi (HYDERABAD, India)</p>
9:42	<p><b>Is pemphigus curable? A Critical look</b>                      Ajith Kumar (Kerala, India)</p>
9:54	<p><b>Topical steroid dependent face–Demography, dermoscopy and drugs to manage it</b>                      Nidhi Sharma (Amritsar, India)</p>
10:06	<p><b>Clinical and therapeutic pearls</b>                      Dhananjay Damle (Pune, India)</p>
10:18	<p><b>Complications of cosmetic dermatology in skin of color</b>                      Rohit Batra (New Delhi, India)</p>
10:30	<p><b>Advances in treatment of lip hyperpigmentation</b>                      Leena Raveendra (Bangalore, India)</p>
10:42	<p><b>A five years retrospective analysis of the spectrum of primary cutaneous T-cell lymphoma in a tertiary care center in East India</b>                      Biswanath Behera (Bhubaneswar, India)</p>
10:54	<p><b>Combining microneedling with superficial chemical peels in Atrophic Acne Scars - Is it worthwhile in the skin of colour?</b>                      Surabhi Dayal (Rohtak, India)</p>
11:06	<p><b>Trichophyton indotineae: Fighting a new battle</b>                      Atiya Yaseen (Srinagar, India)</p>
11:18	<p><b>Drug resistance in cutaneous tuberculosis</b>                      Parul Verma (Lucknow, India)</p>
11:30	<p><b>Management of Urticaria - where we stand</b>                      Mukesh Girdhar (New Delhi, India)</p>

WEDNESDAY 11 OCTOBER 2023

PLENARY

HALL B

12:00 - 13:00

PLENARY LECTURES A

Chairs:

Branka Marinovic (Zagreb, Croatia)

Eli Sprecher (Tel Aviv, Israel)

PLA-01

12:00

Topical gene therapy for RDEB

M. Peter Marinkovich (Redwood City, United States)

PLA-02

12:20

Theranostic approach in vascular malformations

Anne Dompmartin-Blanchere (Caen, France)

PLA-03

12:40

Brain-skin axis: Itch and beyond

Sonja Ständer (Münster, Germany)

PLENARY

HALL B

17:45 - 19:15

OPENING CEREMONY WITH KEYNOTE LECTURE

Chairs:

Martin Röcken (Tübingen, Germany)

Michel Gilliet (Lausanne, Switzerland)

17:45

Introduction

Martin Röcken (Tübingen, Germany)

17:55

Welcome

Julia Welzel (Ausburg, Germany)

OPL-01

18:05

The Anthropocene. A new Earth Epoch

Bernd Scherer (Berlin, Germany)

OPL-02

18:40

Why should health professionals care about climate change - and what should they do?

Diarmid Campbell-Lendrum (Geneva, Switzerland)

WEDNESDAY 11 OCTOBER 2023

UPDATES

HALL B

DIT01.1

14:15 - 17:30

LATE BREAKING NEWS

Chairs:

Monika Arenbergerova (Prague, Czech Republic)

Paola Pasquali (Cambrils, Spain)

## WEDNESDAY 11 OCTOBER 2023

## FOCUS ON

## HALL A8

<b>DIT02.1</b>	<b>14:15 - 15:45</b>	<b>FOCUS ON NEW TECHNOLOGIES</b>
	<b>Chairs:</b>	<b>Marco Romanelli (Pisa, Italy)</b> <b>Josep Malvehy (Barcelona, Spain)</b>
<b>DIT02.1A</b>	<b>14:15</b>	<b>Applications of artificial intelligence to dermatology</b> Josep Malvehy (Barcelona, Spain)
<b>DIT02.1B</b>	<b>14:35</b>	<b>Ultra-high-frequency ultrasound in hidradenitis suppurativa and wound management</b> Marco Romanelli (Pisa, Italy)
<b>DIT02.1C</b>	<b>14:55</b>	<b>10 Years of Tele dermatology in Germany, what has changed</b> Klaus Strömer (Ahaus, Germany)
<b>DIT02.1D</b>	<b>15:15</b>	<b>New tools for self-examination</b> Javiera Perez-Anker (Barcelona, Spain)
<b>DIT02.1E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

## FOCUS ON

## HALL A8

<b>DIT02.2</b>	<b>16:00 - 17:30</b>	<b>FOCUS ON NEW TECHNOLOGIES</b>
	<b>Chairs:</b>	<b>Giovanni Pellacani (Rome, Italy)</b> <b>Mariano Suppa (Brussels, Belgium)</b>
<b>DIT02.2A</b>	<b>16:00</b>	<b>Optical coherence tomography</b> Olivier Gaide (Lausanne, Switzerland)
<b>DIT02.2B</b>	<b>16:20</b>	<b>In-vivo and ex-vivo confocal microscopy</b> Giovanni Pellacani (Rome, Italy)
<b>DIT02.2C</b>	<b>16:40</b>	<b>Line-field confocal optical coherence tomography (LC-OCT)</b> Mariano Suppa (Brussels, Belgium)
<b>DIT02.2D</b>	<b>17:00</b>	<b>Hyperspectral imaging of skin cancer</b> Vivian Lindholm (Helsinki, Finland)
<b>DIT02.2E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>

WEDNESDAY 11 OCTOBER 2023

UPDATES

ROOM 3

<b>DIT03.1</b>	<b>14:15 - 15:45</b>	<b>ORAL DISEASES</b>
	<b>Chairs:</b>	<b>Raimonds Karls (Daugmale, Latvia)</b> <b>Thomas Rustemeyer (Amsterdam, Netherlands)</b>
<b>DIT03.1A</b>	<b>14:15</b>	<b>Difficult to treat aphtous lesions in Behçet's syndrome</b> Gülen Hatemi (Istanbul, Türkiye)
<b>DIT03.1B</b>	<b>14:35</b>	<b>Mucous membrane involvement in allergic reactions</b> Thomas Rustemeyer (Amsterdam, Netherlands)
<b>DIT03.1C</b>	<b>14:55</b>	<b>Differential diagnosis and treatment of leukoplakia</b> Raimonds Karls (Daugmale, Latvia)
<b>DIT03.1D</b>	<b>15:15</b>	<b>New systemic treatment options for oral lichen planus</b> Farzan Solimani (Berlin, Germany)
	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 3

<b>DIT03.2</b>	<b>16:00 - 17:30</b>	<b>PREGNANCY AND SKIN DISEASES</b>
	<b>Chairs:</b>	<b>Selim Aractingi (Paris, France)</b> <b>Jenny Murase (San Francisco, CA, United States)</b>
<b>DIT03.2A</b>	<b>16:00</b>	<b>Skin manifestations associated with poor fetus prognosis /outcome</b> Selim Aractingi (Paris, France)
<b>DIT03.2B</b>	<b>16:20</b>	<b>Pearls from the dermatologic pregnancy clinic</b> Samantha Vaughan-Jones (Surrey, United Kingdom)
<b>DIT03.2C</b>	<b>16:40</b>	<b>Melanoma during pregnancy</b> Marek Pásek (Praha 10, Czech Republic)
<b>DIT03.2D</b>	<b>17:00</b>	<b>Biologics during pregnancy</b> Jenny Murase (San Francisco, CA, United States)
<b>DIT03.2E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>



## WEDNESDAY 11 OCTOBER 2023

## UPDATES

## ROOM 4

<b>DIT04.1</b>	<b>14:15 - 15:45</b>	<b>PSORIASIS</b>
	<b>Chairs:</b>	<b>Lluís Puig (Barcelona, Spain)</b> <b>Hervé Bachelez (Paris, France)</b>
<b>DIT04.1A</b>	<b>14:15</b>	<b>Update on pathogenesis of psoriasis subsets</b> Johann Gudjonsson (Ann Arbor, United States)
<b>DIT04.1B</b>	<b>14:35</b>	<b>New and emerging therapies for psoriasis</b> Lluís Puig (Barcelona, Spain)
<b>DIT04.1C</b>	<b>14:55</b>	<b>How to select the right treatment for your patient</b> Hervé Bachelez (Paris, France)
<b>DIT04.1D</b>	<b>15:15</b>	<b>Long-term remissions through disease modification: are we there yet?</b> Curdin Conrad (Lausanne, Switzerland)
<b>DIT04.1E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

## UPDATES

## ROOM 4

<b>DIT04.2</b>	<b>16:00 - 17:30</b>	<b>PSORIASIS</b>
	<b>Chairs:</b>	<b>Carle Paul (Toulouse, France)</b> <b>Evangelia Papadauid (Athens, Greece)</b>
<b>DIT04.2A</b>	<b>16:00</b>	<b>Early detection and prevention of psoriatic arthritis</b> Wolf-Henning Boehncke (Geneva, Switzerland)
<b>DIT04.2B</b>	<b>16:20</b>	<b>Approach to psychological burden of psoriasis</b> Carle Paul (Toulouse, France)
<b>DIT04.2C</b>	<b>16:40</b>	<b>Management of cardio-metabolic comorbidities</b> Paolo Gisondi (Verona, Italy)
<b>DIT04.2D</b>	<b>17:00</b>	<b>Management of challenging sites</b> Evangelia Papadauid (Athens, Greece)
<b>DIT04.2E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>

WEDNESDAY 11 OCTOBER 2023

UPDATES

ROOM 5

**DIT05.1 14:15 - 15:45 PREVENTION AND SKIN CANCER SCREENING**

Chairs: Veronique del Marmol (Brussels, Belgium)  
Hans Peter Soyer (Brisbane, Australia)

DIT05.1A 14:15 Risk factors for skin cancer  
Veronique del Marmol (Brussels, Belgium)

DIT05.1B 14:35 Skin cancer primary prevention  
Ana-Maria Forsea (Bucharest, Romania)

DIT05.1C 14:55 Lifestyle and cutaneous cancer risk  
Hans Peter Soyer (Brisbane, Australia)

DIT05.1D 15:15 Liquid biopsy in melanoma  
Christoffer Gebhardt (Hamburg, Germany)

DIT05.1E 15:35 Discussion, Q&A

UPDATES

ROOM 5

**DIT05.2 16:00 - 17:30 ACTINIC KERATOSIS**

Chairs: Bohdan Lytvynenko (Kyiv, Ukraine)  
Günther Hofbauer (Wetzikon, Switzerland)

DIT05.2A 16:00 Insights in epidemiology of AK  
Tamar Nijsten (Rotterdam, Netherlands)

DIT05.2B 16:20 Why treat actinic keratosis  
Bohdan Lytvynenko (Kyiv, Ukraine)

DIT05.2C 16:40 Field-treatment of actinic keratosis  
Thomas Dirschka (Wuppertal, Germany)

DIT05.2D 17:00 Treatment in immunocompromised patient  
Günther Hofbauer (Wetzikon, Switzerland)

DIT05.2E 17:20 Discussion, Q&A

## WEDNESDAY 11 OCTOBER 2023

## UPDATES

## ROOM 6

<b>DIT06.1</b>	<b>14:15 - 15:45</b>	<b>NEW AND EMERGING DRUGS</b>
	<b>Chairs:</b>	<b>Kristian Reich (Hamburg, Germany)</b> <b>Emma Guttman-Yassky (New York, United States)</b>
<b>DIT06.1</b>	<b>14:15</b>	<b>Psoriasis</b> Kristian Reich (Hamburg, Germany)
<b>DIT06.1B</b>	<b>14:35</b>	<b>Atopic dermatitis</b> Emma Guttman-Yassky (New York, United States)
<b>DIT06.1C</b>	<b>14:55</b>	<b>Alopecia areata</b> Dmitri Wall (Dublin, Ireland)
<b>DIT06.1D</b>	<b>15:15</b>	<b>Hidradenitis suppurativa</b> Errol Prens (Rotterdam, Netherlands)
<b>DIT06.1E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

## UPDATES

## ROOM 6

<b>DIT06.2</b>	<b>16:00 - 17:30</b>	<b>NEW AND EMERGING DRUGS</b>
	<b>Chairs:</b>	<b>Pascal Joly (Rouen, France)</b> <b>Victoria P. Werth (Philadelphia, United States)</b>
<b>DIT06.2A</b>	<b>16:00</b>	<b>Vitiligo</b> Reinhart Speeckaert (Ghent, Belgium)
<b>DIT06.2B</b>	<b>16:20</b>	<b>Connective tissue diseases</b> Victoria P. Werth (Philadelphia, United States)
<b>DIT06.2C</b>	<b>16:40</b>	<b>Bullous diseases</b> Pascal Joly (Rouen, France)
<b>DIT06.2D</b>	<b>17:00</b>	<b>Targeting IL-1-alpha</b> Thomas Kuendig (Zürich, Switzerland)
<b>DIT06.2D</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>

WEDNESDAY 11 OCTOBER 2023

UPDATES

HALL A7

<b>DIT07.1</b>	<b>14:15 - 15:45</b>	<b>DERMATOLOGY IN SKIN OF COLOR PATIENTS</b>
	<b>Chairs:</b>	<b>Ibrahima Traore (Conakry, Guinea)</b> <b>Andrew F. Alexis (New York, United States)</b>
<b>DIT07.1A</b>	<b>14:15</b>	<b>Hyperpigmentation disorders</b> Shyam Verma (Vadodara, India)
<b>DIT07.1B</b>	<b>14:35</b>	<b>Challenges in treating moderate-to-severe acne</b> Andrew F. Alexis (New York, United States)
<b>DIT07.1C</b>	<b>14:55</b>	<b>Inflammatory diseases: how differently do they present?</b> Nada Elbuluk (Los Angeles, United States)
<b>DIT07.1D</b>	<b>15:15</b>	<b>Challenges in detecting skin cancer in darker skin</b> Ibrahima Traore (Conakry, Guinea)
<b>DIT07.1E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A7

<b>DIT07.2</b>	<b>16:00 - 17:30</b>	<b>ROSACEA</b>
	<b>Chairs:</b>	<b>Linda Stein Gold (Michigan, United States)</b> <b>Martin Steinhoff (DOHA, Qatar)</b>
<b>DIT07.2A</b>	<b>16:00</b>	<b>New data in pathophysiology</b> Linda Stein Gold (Michigan, United States)
<b>DIT07.2B</b>	<b>16:20</b>	<b>Rosacea, not just a skin disease</b> Martin Steinhoff (DOHA, Qatar)
<b>DIT07.2C</b>	<b>16:40</b>	<b>Managing facial erythema in 2023</b> Eszter Baltas (Szeged, Hungary)
<b>DIT07.2D</b>	<b>17:00</b>	<b>Emerging therapies in rosacea</b> Lucero Noguera (Madrid, Spain)
<b>DIT07.2E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>

## WEDNESDAY 11 OCTOBER 2023

## UPDATES

## HALL A3

<b>DIT08.1</b>	<b>14:15 - 15:45</b>	<b>BIG DATA AND DERMATOLOGY</b>
	<b>Chairs:</b>	<b>Michel Gilliet (Lausanne, Switzerland)</b> <b>Nicholas Reynolds (Newcastle upon Tyne, United Kingdom)</b>
<b>DIT08.1A</b>	<b>14:15</b>	<b>What patient registries have taught us</b> Nicholas Reynolds (Newcastle upon Tyne, United Kingdom)
<b>DIT08.1B</b>	<b>14:35</b>	<b>Personal wearable devices for tracking skin health</b> Alexander Zink (Munich, Germany)
<b>DIT08.1C</b>	<b>14:55</b>	<b>New omics technologies to understand skin diseases</b> Robert Modlin (Los Angeles, United States)
<b>DIT08.1D</b>	<b>15:15</b>	<b>Precision medicine approaches in dermatology</b> Michel Gilliet (Lausanne, Switzerland)
<b>DIT08.1E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

## UPDATES

## HALL A3

	<b>16:00 - 17:30</b>	<b>TELEDERMATOLOGY</b>
	<b>Chairs:</b>	<b>Trilokraj Tejasvi (Ann Arbor, United States)</b> <b>Jonathan Shapiro (Ramat Hasharon, Israel)</b>
<b>DIT08.2A</b>	<b>16:00</b>	<b>Tele dermatology in skin cancer</b> Trilokraj Tejasvi (Ann Arbor, United States)
<b>DIT08.2B</b>	<b>16:20</b>	<b>Tele dermatology for children and adolescents</b> Tatjana Braun (Berlin, Germany)
<b>DIT08.2C</b>	<b>16:40</b>	<b>Tele dermatology in the management of chronic conditions</b> Angelo Ruggiero (Naples, Italy)
<b>DIT08.2D</b>	<b>17:00</b>	<b>Implementing store-and-forward tele dermatology consultations in general practice</b> Jonathan Shapiro (Ramat Hasharon, Israel)
<b>DIT08.2E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>

WEDNESDAY 11 OCTOBER 2023

UPDATES

HALL A1

<b>DIT09.1</b>	<b>14:15 - 15:45</b>	<b>ALOPECIA AREATA</b>
	<b>Chairs:</b>	<b>Dimitrios Ioannides (Thessaloniki, Greece)</b> <b>Maryanne M. Senna (Winchester, United States)</b>
<b>DIT09.1A</b>	<b>14:15</b>	<b>Clinical spectrum and severity of AA</b> Annika Vogt (Berlin, Germany)
<b>DIT09.1B</b>	<b>14:35</b>	<b>Trichoscopy for AA</b> Dimitrios Ioannides (Thessaloniki, Greece)
<b>DIT09.1C</b>	<b>14:55</b>	<b>AA comorbidities</b> Jovan Lalosevic (Belgrade, Serbia)
<b>DIT09.1D</b>	<b>15:15</b>	<b>Are new treatments for AA a real breakthrough?</b> Maryanne M. Senna (Winchester, United States)
<b>DIT09.1E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A1

<b>DIT09.2</b>	<b>16:00 - 17:30</b>	<b>VITILIGO</b>
	<b>Chairs:</b>	<b>Nanja van Geel (Ghent, Belgium)</b> <b>Viktorija Eleftheriadou (Wolverhampton, United Kingdom)</b>
<b>DIT09.2A</b>	<b>16:00</b>	<b>New insights into the pathogenesis of vitiligo</b> Davinder Parsad (Chandigarh, India)
<b>DIT09.2B</b>	<b>16:20</b>	<b>Assessment of disease activity and its relevance</b> Nanja van Geel (Ghent, Belgium)
<b>DIT09.2C</b>	<b>16:40</b>	<b>Advances in systemic treatment</b> Viktorija Eleftheriadou (Wolverhampton, United Kingdom)
<b>DIT09.2D</b>	<b>17:00</b>	<b>Grafting in vitiligo</b> Marcel Bekkenk (Amsterdam, Netherlands)
<b>DIT09.2E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>



WEDNESDAY 11 OCTOBER 2023

UPDATES

HALL A2

<b>DIT10.1</b>	<b>14:15 - 15:45</b>	<b>MICROBIOME AND SKIN DISEASES</b>
	<b>Chairs:</b>	<b>Brigitte Dréno (Nantes, France)</b> <b>Tilo Biedermann (Munich, Germany)</b>
DIT10.1A	14:15	<b>Microbiota and skin barrier function</b> Chris Callewaert (Ghent, Belgium)
DIT10.1B	14:35	<b>Microbiome and acne</b> Brigitte Dréno (Nantes, France)
DIT10.1C	14:55	<b>Hidradenitis suppurativa: an illness of the follicular microbiome</b> Gregor Borut Jemec (Roskilde, Denmark)
DIT10.1D	15:15	<b>How do microbiome and skin barrier interact in atopic dermatitis?</b> Tilo Biedermann (Munich, Germany)
DIT10.1E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A2

<b>DIT10.2</b>	<b>16:00 - 17:30</b>	<b>VASCULITIS AND VASCULOPATHIES</b>
	<b>Chairs:</b>	<b>Klemens Rappersberger (Vienna, Austria)</b> <b>Helmut Beltraminelli (Locarno, Switzerland)</b>
DIT10.2A	16:00	<b>Vasculitis or vasculopathy- importance of dermatopathology</b> Klemens Rappersberger (Vienna, Austria)
DIT10.2B	16:20	<b>Managing livedo reticularis</b> Helmut Beltraminelli (Locarno, Switzerland)
DIT10.2C	16:40	<b>Treatment options in livedoid vasculopathy</b> Erkan Alpsoy (Antalya, Türkiye)
DIT10.2D	17:00	<b>Urticarial vasculitis</b> Pavel Kolkhir (Berlin, Germany)
DIT10.2E	17:20	<b>Discussion, Q&amp;A</b>

WEDNESDAY 11 OCTOBER 2023

TRAINING AND  
EDUCATION

HALL A5

<b>D1T11.1</b>	<b>14:15 - 15:45</b>	<b>ACNE AND ROSACEA</b>
	Chairs:	Vincenzo Bettoli (Ferrara, Italy) Vicente Torres Lozada (ATIZAPAN, Mexico)
D1T11.1A	14:15	Pathophysiology of acne and rosacea Vincenzo Bettoli (Ferrara, Italy)
D1T11.1B	14:35	Diagnosis of inflammatory disease of the face Vicente Torres Lozada (ATIZAPAN, Mexico)
D1T11.1C	14:55	How to manage inflammatory acne in teenager Ediléia Bagatin (Sao Paulo, Brazil)
D1T11.1D	15:15	How to manage mild to severe rosacea Linda Stein Gold (Michigan, United States)
D1T11.1	15:35	Discussion, Q&A

TRAINING AND  
EDUCATION

HALL A5

<b>D1T11.2</b>	<b>16:00 - 17:30</b>	<b>NAIL AND HAIR DISORDERS</b>
	Chairs:	Ximena Wortsman (Santiago, Chile) Myrto-Georgia Trakatelli (Thessaloniki, Greece)
D1T11.2A	16:00	Benign Nail Neoplasms Ximena Wortsman (Santiago, Chile)
D1T11.2B	16:20	Malignant Nail Neoplasms Myrto-Georgia Trakatelli (Thessaloniki, Greece)
D1T11.2C	16:40	Nonsurgical treatment of alopecia Desmond Tobin (Dublin, Co. Dublin, Ireland)
D1T11.2D	17:00	Surgical treatment for alopecia Diogo Pereira Forjaz (Lisboa, Portugal)
D1T11.2D	17:20	Discussion, Q&A

WEDNESDAY 11 OCTOBER 2023

UPDATES

HALL A4

<b>DIT12.1</b>	<b>14:15 - 15:45</b>	<b>DERMATOPATHOLOGY</b>
	<b>Chairs:</b>	<b>Zlatko Marusic (Zagreb, Croatia)</b> <b>Maarten Vermeer (Leiden, Netherlands)</b>
D2T12.1A	14:15	<b>News on melanocytic lesions</b> Speaker TBC
D2T12.1B	14:35	<b>Adnexal tumours</b> Zlatko Marusic (Zagreb, Croatia)
D2T12.1C	14:55	<b>Vascular tumours</b> Speaker TBC
D2T12.1D	15:15	<b>Lymphomas</b> Maarten Vermeer (Leiden, Netherlands)
D2T12.1E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A4

<b>DIT12.2</b>	<b>16:00 - 17:30</b>	<b>DERMATOPATHOLOGY</b>
	<b>Chairs:</b>	<b>Marc-Cyriel-Marie Haspeslagh (Ghent, Belgium)</b> <b>Arianna Lamberti (Siena, Italy)</b>
DIT12.2A	16:00	<b>Vasculitis and vasculopathies</b> Marc-Cyriel-Marie Haspeslagh (Ghent, Belgium)
DIT12.2B	16:20	<b>How can dermatopathology help in connective tissues diseases</b> Arianna Lamberti (Siena, Italy)
DIT12.2C	16:40	<b>Dermatopathology in emergent infections</b> Erika Varga (Szeged, Hungary)
DIT12.2D	17:00	<b>Diagnostic benefits of new technologies</b> Linda Tognetti (Siena, Italy)
DIT12.2E	17:20	<b>Discussion, Q&amp;A</b>

WEDNESDAY 11 OCTOBER 2023

UPDATES


M1+2

<b>D1T13.1</b>	<b>14:15 - 15:45</b>	<b>SKIN AGEING AND REJUVENATION</b>
	<b>Chairs:</b>	<b>Rolf-Markus Szeimies (Recklinghausen, Germany)</b> <b>Lidiya Todorova (Plovdiv, Bulgaria)</b>
<b>D1T13.1A</b>	<b>14:15</b>	<b>Facial rejuvenation with daylight PDT</b> Rolf-Markus Szeimies (Recklinghausen, Germany)
<b>D1T13.1B</b>	<b>14:35</b>	<b>Safety and effectiveness of PRP</b> Lidiya Todorova (Plovdiv, Bulgaria)
<b>D1T13.1C</b>	<b>14:55</b>	<b>Ultrasound to improve the safety of hyaluronic acid filler treatment</b> Peter Velthuis (Rotterdam, Netherlands)
<b>D1T13.1D</b>	<b>15:15</b>	<b>Myomodulators: latest update</b> Emanuel Carneiro Marques (Prague, Czech Republic)
<b>D1T13.1E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

UPDATES

M1+2

<b>D1T13.2</b>	<b>16:00 - 17:30</b>	<b>JAK INHIBITORS</b>
	<b>Chairs:</b>	<b>Julien Seneschal (Bordeaux, France)</b> <b>Sonja Ständer (Münster, Germany)</b>
<b>D1T13.2A</b>	<b>16:00</b>	<b>TYK2 inhibitors for psoriasis</b> Richard B. Warren (Manchester, United Kingdom)
<b>D1T13.2B</b>	<b>16:20</b>	<b>JAK inhibitors for atopic dermatitis</b> Jonathan Silverberg (Washington, United States)
<b>D1T13.2C</b>	<b>16:40</b>	<b>JAK inhibitors for vitiligo and alopecia areata</b> Julien Seneschal (Bordeaux, France)
<b>D1T13.2D</b>	<b>17:00</b>	<b>JAK inhibitors for pruritus</b> Sonja Ständer (Münster, Germany)
<b>D1T13.2E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>



**WEDNESDAY 11 OCTOBER 2023**

<b>MISCELLANEOUS</b>		<b>M6+7</b>
<b>DIT14.2</b>	<b>10:15 - 11:45</b>	<b>EADV TASK FORCES HIGHLIGHTS</b>
	<b>Chairs:</b>	<b>Christa de Cuyper (Bruges, Belgium)</b>
<b>DIT14.2A</b>	<b>10:15</b>	<b>Highlights from the Dermatology for Cancer Patients</b> Azael Freites Martinez (Madrid, Spain)
<b>DIT14.2B</b>	<b>10:30</b>	<b>Highlights from the Artificial Intelligence</b> Josep Malveyh (Barcelona, Spain)
<b>DIT14.2C</b>	<b>10:45</b>	<b>Highlights from the Pruritus</b> Claudia Zeidler (Münster, Germany)
<b>DIT14.2D</b>	<b>11:00</b>	<b>Highlights from the Vasculitis and Vasculopathies</b> Cord Sunderkoetter (Halle, Germany)
<b>DIT14.2E</b>	<b>11:15</b>	<b>Highlights from the Vitiligo</b> Julien Seneschal (Bordeaux, France)
<b>DIT14.2F</b>	<b>11:30</b>	<b>Highlights from the Office Management</b> Monika Gniadecka (Herlev, Denmark)

<b>MISCELLANEOUS</b>		<b>M6+7</b>
<b>DIT14.3</b>	<b>14:15 - 15:45</b>	<b>ADVOCACY SESSION: ADVOCATING FOR BETTER CARE OF SKIN CANCER PATIENTS IN EUROPE</b>
	<b>Chairs:</b>	<b>Martin Röcken (Tübingen, Germany)</b> <b>Myrto-Georgia Trakatelli (Thessaloniki, Greece)</b>
<b>DIT14.3A</b>	<b>14:15</b>	<b>Welcome and introduction</b> Martin Röcken (Tübingen, Germany) Myrto-Georgia Trakatelli / (Thessaloniki, Greece)
<b>DIT14.3B</b>	<b>14:20</b>	<b>EADV's Advocacy programme: Putting skin cancer on the EU's agenda</b> Alexander Stratigos (Athens, Greece)
<b>DIT14.3C</b>	<b>14:30</b>	<b>Reshaping care for advanced melanoma: The role of dermato-oncology</b> Lukas Flatz (Tübingen, Germany)
<b>DIT14.3D</b>	<b>14:45</b>	<b>Patient access to systemic treatments in Europe: what can we do more as EADV?</b> Lidija Kandolf-Sekulovic (Belgrade, Serbia)
<b>DIT14.3E</b>	<b>15:00</b>	<b>EU funding opportunities for skin cancer</b> Efthymis Altsitsiadis (Frederiksberg, Denmark)
<b>DIT14.3F</b>	<b>15:20</b>	<b>Registration of melanoma and NMSC across Europe: are we making progress?</b> Ana-Maria Forsea (Bucharest, Romania)
<b>DIT14.3G</b>	<b>15:35</b>	<b>Future directions for Advocacy in dermato-venerology/ Q+A</b> Myrto-Georgia Trakatelli (Thessaloniki, Greece) Sarah Walsh / (London, United Kingdom)

WEDNESDAY 11 OCTOBER 2023

MISCELLANEOUS

M6+7


<b>DIT14.4</b>	<b>16:00 - 17:30</b>	<b>SKIN DISEASES IN LATIN AMERICA</b>
	<b>Chairs:</b>	<b>Horacio Cabo (Buenos Aires, Argentina)</b> <b>Jose Luis Lopez-Estebarez (Madrid, Spain)</b>
<b>DIT14.4A</b>	<b>16:00</b>	<b>Coccidioidomycosis in Mexico: tips for diagnosis and treatment</b> Jorge Ocampo-Candiani (Monterrey, Mexico)
<b>DIT14.4B</b>	<b>16:10</b>	<b>Leishmaniasis: Clinical manifestations</b> José Manuel Ríos-Yuil (Ciudad de Panama, Panama)
<b>DIT14.4C</b>	<b>16:20</b>	<b>Mycetoma in Caribbean countries: diagnostic and treatment approach</b> Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic)
<b>DIT14.4D</b>	<b>16:30</b>	<b>Management of acne in skin of colour</b> Jose Luis Lopez-Estebarez (Madrid, Spain)
<b>DIT14.4E</b>	<b>16:40</b>	<b>Dermoscopy of Pigmented Squamous cell carcinoma in situ</b> Horacio Cabo (Buenos Aires, Argentina)
<b>DIT14.4F</b>	<b>16:50</b>	<b>Actinic keratosis and field cancerization in skin of colour</b> Emilia Cohen Sabban (Buenos Aires, Argentina)
<b>DIT14.4G</b>	<b>17:00</b>	<b>Management of Rosacea in skin of colour</b> Patricia Troielli (Buenos Aires, Argentina)
<b>DIT14.4H</b>	<b>17:10</b>	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

PROGRAMME AT A GLANCE

CLICK TO VIEW THE INTERACTIVE PROGRAMME

Room name	Hall B	Hall A8	Room 3	Room 4	Room 5	Room 6
Session type	Focus on / Plenary Lectures / Updates	Updates	Updates	Updates	Updates	Updates
Track no.	1	2	3	4	5	6
08.30 - 10.00	Focus on Sclerotic skin diseases	Atopic dermatitis	Paediatric dermatology	Melanoma	Immediate type allergies	Dermatosurgery
10.00 - 10.15						
10.15 - 11.45	Focus on Sclerotic skin diseases	Atopic dermatitis	Paediatric dermatology	Melanoma	Contact eczema	Dermatosurgery
11.45 - 12.00						
12.00 - 13.00	PL-B Plenary Lectures 4-5-6					
13.00 - 14.00	Industry sessions (Lunch satellite symposia)					
14.00 - 14.15						
14.15 - 15.45	Late Breaking News	Hidradenitis suppurativa	Paediatric dermatology	Treating cancer in the elderly	Chronic Urticaria	Mohs sugery
15.45 - 16.00						
16.00 - 17.30		Hidradenitis suppurativa	Paediatric dermatology	Adverse events in new anti-cancer therapy	Drug eruptions	Surgery in advanced skin cancer
17.30 - 18.00						
18.00 - 19.30	Industry sessions (Evening satellite symposia)					




THURSDAY 12 OCTOBER 2023

**PROGRAMME AT A GLANCE**

[CLICK TO VIEW THE INTERACTIVE PROGRAMME](#)

Room name	Hall A7	Hall A3	Hall A1	Hall A2	Hall A5	Hall A4
Session type	Updates	Aesthetic	Training and Education	Training and Education	Controversies	Updates
Track no.	7	8	9	10	11	12
08.30 - 10.00	Hair disorders	Fillers I, Basics	Non-melanoma skin cancer	Eczemas: Atopic dermatitis	Controversies I	STIs
10.00 - 10.15						
10.15 - 11.45	Hair disorders	Botulinum Toxin I, Basics	Non-melanoma skin cancer	Non-atopic eczemas	Controversies II	HIV
11.45 - 12.00						
12.00 - 13.00						
13.00 - 14.00	Industry sessions (Lunch satellite symposia)					
14.00 - 14.15						
14.15 - 15.45	Nails disorders	Lasers and energy-based devices, Practical aspects of basics	Melanoma	Drug reactions	Controversies III	STIs
15.45 - 16.00						
16.00 - 17.30	Scalp disorders	Patient selection and practice management	Melanoma	Urticaria and vasculitis	Controversies IV	Genetics in skin diseases
17.30 - 18.00						
18.00 - 19.30	Industry sessions (Evening satellite symposia)					





THURSDAY 12 OCTOBER 2023

**PROGRAMME AT A GLANCE**

[CLICK TO VIEW THE INTERACTIVE PROGRAMME](#)

Room name	M1+2	M6+7	M4+5	M8
Session type	Free Communications	Special interest meetings	Practical workshops	Practical workshops
Track no.	13	14	15	16
08.30 - 10.00	Free Communications I	How collaboration improves access to care	Surgery advanced	Wound Healing
10.00 - 10.15				
10.15 - 11.45	Free Communications II	EADV research funding and fellowships		
11.45 - 12.00				
12.00 - 13.00				
13.00 - 14.00	Industry sessions (Lunch satellite symposia)			
14.00 - 14.15				
14.15 - 15.45	Free Communications III	Face to face: office vs hospital based therapies in Dermatology	Surgery advanced	Dermoscopy - Practical and conceptual
15.45 - 16.00				
16.00 - 17.30	Free Communications IV	Editor's Pick		
17.30 - 18.00				
18.00 - 19.30	Industry sessions (Evening satellite symposia)			

THURSDAY 12 OCTOBER 2023

PLENARY

HALL B

PLB	12:00 - 13:00	PLENARY LECTURES B
	Chairs:	Jo LW Lambert (Ghent, Belgium) Georg Stingl (Vienna, Austria)
PLB-01	12:00	<b>Immunotherapy of Melanoma: Mission accomplished?</b> Thomas Tüting (Magdeburg, Germany)
PLB-02	12:20	<b>Vaccination in STIs: What is the current state?</b> Georg Stary (Vienna, Austria)
PLB-03	12:40	<b>New insights and therapeutic approaches in Lupus Erythematosus</b> Victoria P. Werth (Philadelphia, United States)

FOCUS ON

HALL B

D2T01.1	08:30 - 10:00	FOCUS ON SCLEROTIC SKIN DISEASES
	Chairs:	Ignasi Figueras-Nart (Barcelona, Spain) Sabine Eming (Cologne, Germany)
D2T01.1A	8:30	<b>Systemic versus localized scleroderma</b> Sabine Eming (Cologne, Germany)
D2T01.1B	8:50	<b>Lichen sclerosus and its association to cancer</b> Ignasi Figueras-Nart (Barcelona, Spain)
D2T01.1C	9:10	<b>Skleromyxedema - treatment options and comorbidities</b> Hamidreza Mahmoudi (Tehran, Iran)
D2T01.1D	9:30	<b>Serological predictors of disease outcome</b> Camillo Ribi (Lausanne, Switzerland)
D2T01.1E	9:50	<b>Discussion, Q&amp;A</b>

FOCUS ON

HALL B

D2T01.2	10:15 - 11:45	FOCUS ON SCLEROTIC SKIN DISEASES
	Chairs:	Franco Rongioletti (Milan, Italy) Thomas Krieg (Cologne, Germany)
D2T01.2A	10:15	<b>Cytokine based treatments in sclerotic skin diseases</b> Franco Rongioletti (Milan, Italy)
D2T01.2B	10:35	<b>JAK-Inhibition as a treatment option in systemic sclerosis</b> Thomas Krieg (Cologne, Germany)
D2T01.2C	10:55	<b>Fibrosis and cancer: epidermolysis bullosa as a paradigm</b> Alexander Nyström (Freiburg, Germany)
D2T01.2D	11:15	<b>Fibroblast, lymphocyte, platelets: Therapeutic targets in systemic sclerosis</b> Christopher Denton (London, United Kingdom)
D2T01.2E	11:35	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

**UPDATES**

**D2T01.3**

**14:15 - 17:30**

Chairs:

**HALL B**

**LATE BREAKING NEWS**

Michel Gilliet (Lausanne, Switzerland)

Margarida Gonalo (Coimbra, Portugal)

## THURSDAY 12 OCTOBER 2023

## UPDATES

## HALL A8

<b>D2T02.1</b>	<b>08:30 - 10:00</b>	<b>ATOPIC DERMATITIS</b>
	<b>Chairs:</b>	<b>Kilian Eyerich (Freiburg, Germany)</b> <b>Patrick Brunner (New York, United States)</b>
<b>D2T02.1A</b>	<b>8:30</b>	<b>Immunopathogenesis and diseases stratification</b> Kilian Eyerich (Freiburg, Germany)
<b>D2T02.1B</b>	<b>8:50</b>	<b>Atypical manifestations and differential diagnosis</b> Patrick Brunner (New York, United States)
<b>D2T02.1C</b>	<b>9:10</b>	<b>Differences in AD of children compared to adults</b> Pedro Mendes-Bastos (Lisbon, Portugal)
<b>D2T02.1D</b>	<b>9:30</b>	<b>Head and neck AD</b> Giovanni Damiani (Milan, Italy)
<b>D2T02.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

## UPDATES

## HALL A8

<b>D2T02.2</b>	<b>10:15 - 11:45</b>	<b>ATOPIC DERMATITIS</b>
	<b>Chairs:</b>	<b>Marjolein de Bruin-Weller (Utrecht, Netherlands)</b> <b>Carsten Flohr (London, United Kingdom)</b>
<b>D2T02.2A</b>	<b>10:15</b>	<b>Early intervention to prevent atopic march?</b> Carsten Flohr (London, United Kingdom)
<b>D2T02.2B</b>	<b>10:35</b>	<b>New and emerging topical therapies for AD</b> Marjolein de Bruin-Weller (Utrecht, Netherlands)
<b>D2T02.2C</b>	<b>10:55</b>	<b>Targeting Th2 versus JAK inhibitors</b> Andreas Wollenberg (Munich, Germany)
<b>D2T02.2D</b>	<b>11:15</b>	<b>The expanding therapeutic pipeline of AD</b> Kenji Kabashima (Kyoto, Japan)
<b>D2T02.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

## THURSDAY 12 OCTOBER 2023

## UPDATES

## HALL A8

<b>D2T02.3</b>	<b>14:15 - 15:45</b>	<b>HIDRADENITIS SUPPURATIVA</b>
	Chairs:	Robert Emil Hunger (Bern, Switzerland) John R. Ingram (Cardiff, United Kingdom)
D2T02.3A	14:15	<b>Novel aspects in the pathogenesis</b> Robert Emil Hunger (Bern, Switzerland)
D2T02.3B	14:35	<b>Role of skin microbiome</b> Vincenzo Bettoli (Ferrara, Italy)
D2T02.3C	14:55	<b>Paediatric hidradenitis suppurativa</b> Simone Garcovich (Rome, Italy)
D2T02.3D	15:15	<b>How to diagnose and manage comorbidities</b> John R. Ingram (Cardiff, United Kingdom)
D2T02.3E	15:35	<b>Discussion, Q&amp;A</b>

## UPDATES

## HALL A8

<b>D2T02.4</b>	<b>16:00 - 17:30</b>	<b>HIDRADENITIS SUPPURATIVA</b>
	Chairs:	Brian Kirby (Dublin, Ireland) Petr Arenberger (Prague, Czech Republic)
D2T02.4A	16:00	<b>Endotype-directed treatment</b> Thrasylvoulos Tzellos (Bodø, Norway)
D2T02.4B	16:20	<b>New biologics and small molecules</b> Brian Kirby (Dublin, Ireland)
D2T02.4C	16:40	<b>Minimally invasive procedures in the office</b> Petr Arenberger (Prague, Czech Republic)
D2T02.4D	17:00	<b>Surgery for moderate and advanced forms</b> Antonio Martorell Calatayud (Valencia, Spain)
D2T02.4E	17:20	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

UPDATES

ROOM 3

<b>D2T03.1</b>	<b>08:30 - 10:00</b>	<b>PAEDIATRIC DERMATOLOGY</b>
	<b>Chairs:</b>	<b>Antonio Torrelo (Madrid, Spain)</b> <b>Angela Hernandez-Martin (Madrid, Spain)</b>
<b>D2T03.1A</b>	<b>8:30</b>	<b>New mosaic syndromes</b> Lihi Atzmony (Petach Tikva, Israel)
<b>D2T03.1B</b>	<b>8:50</b>	<b>The spectrum of palmoplantar keratodermas and associated diseases</b> Liisa Helena Harjama (Helsinki, Finland)
<b>D2T03.1C</b>	<b>9:10</b>	<b>The clinical chameleon of autoinflammatory diseases in children</b> Antonio Torrelo (Madrid, Spain)
<b>D2T03.1D</b>	<b>9:30</b>	<b>Neonatal erythroderma - new diagnostic aspects</b> Angela Hernandez-Martin (Madrid, Spain)
<b>D2T01.3E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 3

<b>D2T03.2</b>	<b>10:15 - 11:45</b>	<b>PAEDIATRIC DERMATOLOGY</b>
	<b>Chairs:</b>	<b>Marlies De Graaf (Utrecht, Netherlands)</b> <b>Annika Vogt (Berlin, Germany)</b>
<b>D2T03.2A</b>	<b>10:15</b>	<b>Biologics in children</b> Tiago Torres (Porto, Portugal)
<b>D2T03.2B</b>	<b>10:35</b>	<b>Fungal infections of the scalp - current treatment algorithm</b> Jacob Mashiah (Tel Aviv, Israel)
<b>D2T03.2C</b>	<b>10:55</b>	<b>Management of paediatric atopic dermatitis</b> Marlies De Graaf (Utrecht, Netherlands)
<b>D2T03.2D</b>	<b>11:15</b>	<b>Treatment of bullous diseases in children</b> Annika Vogt (Berlin, Germany)
<b>D2T03.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

UPDATES

ROOM 3

<b>D2T03.3</b>	<b>14:15 - 15:45</b>	<b>PAEDIATRIC DERMATOLOGY</b>
	Chairs:	Elodie Mendels (Den Haag, Netherlands) Michela Starace (Bologna, Italy)
D2T03.3A	14:15	<b>Lichen sclerosus in children - how to treat</b> Elodie Mendels (Den Haag, Netherlands)
D2T03.3B	14:35	<b>Nail changes: when to suspect an underlying disease</b> Michela Starace (Bologna, Italy)
D2T03.3C	14:55	<b>Alopecia areata or loose anagen syndrome?</b> Regina Fölster-Holst (Kiel, Germany)
D2T03.3D	15:15	<b>Cutaneous adverse drug reactions in childhood</b> Maja Mockenhaupt (Freiburg, Germany)
D2T03.3E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 3

<b>D2T03.4</b>	<b>16:00 - 17:30</b>	<b>PAEDIATRIC DERMATOLOGY</b>
	Chairs:	Cristina Carrera (Barcelona, Spain) Sirrku Peltonen (Göteborg, Sweden)
D2T03.4A	16:00	<b>Melanoma in congenital melanocytic naevi</b> Cristina Carrera (Barcelona, Spain)
D2T03.4B	16:20	<b>Treatment of cutaneous vascular tumours</b> Annabel Maruani (Tours, France)
D2T03.4C	16:40	<b>Work-up and follow-up of mastocytosis</b> Sigurd Broesby-Olsen (Odense, Denmark)
D2T03.4D	17:00	<b>Long-term management of neurofibromatosis type 1</b> Sirrku Peltonen (Göteborg, Sweden)
D2T03.4E	17:20	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

UPDATES

ROOM 4

<b>D2T04.1</b>	<b>08:30 - 10:00</b>	<b>MELANOMA</b>
	<b>Chairs:</b>	<b>Lieve Brochez (Ghent, Belgium)</b> <b>Marlies Wakkee (Rotterdam, Netherlands)</b>
<b>D2T04.1A</b>	<b>8:30</b>	<b>How to screen to optimise melanoma detection</b> Lieve Brochez (Ghent, Belgium)
<b>D2T04.1B</b>	<b>8:50</b>	<b>Sex/gender bias in melanoma</b> Sara Gandini (Milan, Italy)
<b>D2T04.1C</b>	<b>9:10</b>	<b>Staging systems: are they really telling us what to do?</b> Speaker TBC
<b>D2T04.1D</b>	<b>9:30</b>	<b>Role of tissue biomarkers in clinical decision making</b> Marlies Wakkee (Rotterdam, Netherlands)
<b>D2T04.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 4

<b>D2T04.2</b>	<b>10:15 - 11:45</b>	<b>MELANOMA</b>
	<b>Chairs:</b>	<b>Christian Posch (Wien, Austria)</b> <b>Martin Röcken (Tübingen, Germany)</b>
<b>D2T04.2A</b>	<b>10:15</b>	<b>Adjuvant and neoadjuvant therapies in melanoma</b> Yannick Elshot (Amsterdam, Netherlands)
<b>D2T04.2B</b>	<b>10:35</b>	<b>Targeted therapy for metastatic melanoma</b> Simone Ribero (Torino, Italy)
<b>D2T04.2C</b>	<b>10:55</b>	<b>Immunotherapy for metastatic melanoma</b> Christian Posch (Wien, Austria)
<b>D2T04.2D</b>	<b>11:15</b>	<b>Future therapies for metastatic melanoma</b> Martin Röcken (Tübingen, Germany)
<b>D2T04.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>



THURSDAY 12 OCTOBER 2023

UPDATES

ROOM 4

<b>D2T04.3</b>	<b>14:15 - 15:45</b>	<b>TREATING CANCER IN THE ELDERLY</b>
	Chairs:	Paola Pasquali (Cambrils, Spain) Lidija Kandolf-Sekulovic (Belgrade, Serbia)
D2T04.3A	14:15	<b>Observation/non-treatment</b> Caterina Longo (Modena, Italy)
D2T04.3B	14:35	<b>Minimally invasive techniques</b> Paola Pasquali (Cambrils, Spain)
D2T04.3C	14:55	<b>Surgical treatment</b> Monica Dinulescu (Rennes, France)
D2T04.3D	15:15	<b>Efficacy and safety of systemic treatment for skin cancer in the elderly</b> Lidija Kandolf-Sekulovic (Belgrade, Serbia)
D2T04.3E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 4

<b>D2T04.4</b>	<b>16:00 - 17:30</b>	<b>ADVERSE EVENTS IN NEW ANTI-CANCER THERAPY</b>
	Chairs:	Elizabeth Lazaridou (Thessaloniki, Greece) Lukas Flatz (Tübingen, Germany)
D2T04.4A	16:00	<b>Anti-cancer treatment and photosensitivity</b> Vincent Sibaud (Toulouse, France)
D2T04.4B	16:20	<b>Treatment algorithm for EGFR inhibitor induced skin side effects</b> Elizabeth Lazaridou (Thessaloniki, Greece)
D2T04.4C	16:40	<b>Common and rare skin toxicity with immune checkpoint inhibitors</b> Lukas Flatz (Tübingen, Germany)
D2T04.4D	17:00	<b>Adverse events associated with targeted treatment of melanoma</b> Dirk Tomsitz (Munich, Germany)
D2T04.4E	17:20	<b>Discussion, Q&amp;A</b>

## THURSDAY 12 OCTOBER 2023

## UPDATES

## ROOM 5

<b>D2T05.1</b>	<b>08:30 - 10:00</b>	<b>IMMEDIATE TYPE ALLERGIES</b>
	<b>Chairs:</b>	<b>Marcus Maurer (Berlin, Germany)</b> <b>Peter Schmid-Grendelmeier (Zurich, Switzerland)</b>
<b>D2T05.1A</b>	<b>8:30</b>	<b>Food allergy in childhood and adulthood</b> Charlotte G. Mortz (Odense, Denmark)
<b>D2T05.1B</b>	<b>8:50</b>	<b>Risk of anaphylaxis in urticaria patients</b> Mojca Bizjak (Golnik, Slovenia)
<b>D2T05.1C</b>	<b>9:10</b>	<b>New drugs for chronic allergic diseases</b> Peter Schmid-Grendelmeier (Zurich, Switzerland)
<b>D2T05.1D</b>	<b>9:30</b>	<b>Auto-allergy: a new concept in skin diseases</b> Marcus Maurer (Berlin, Germany)
<b>D2T05.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

## UPDATES

## ROOM 5

<b>D2T05.2</b>	<b>10:15 - 11:45</b>	<b>CONTACT ECZEMA</b>
	<b>Chairs:</b>	<b>Ana Giménez-Arnau (Barcelona, Spain)</b> <b>Andrea Bauer (Dresden, Germany)</b>
<b>D2T05.2A</b>	<b>10:15</b>	<b>New allergens during COVID-pandemic</b> Ana Giménez-Arnau (Barcelona, Spain)
<b>D2T05.2B</b>	<b>10:35</b>	<b>Rebuilding the European Baseline series</b> Thomas Rustemeyer (Amsterdam, Netherlands)
<b>D2T05.2C</b>	<b>10:55</b>	<b>Fragrance allergy revisited</b> Jeanne Duus Johansen (Hellerup, Denmark)
<b>D2T05.2D</b>	<b>11:15</b>	<b>Hand dermatitis - new treatments</b> Andrea Bauer (Dresden, Germany)
<b>D2T05.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

## THURSDAY 12 OCTOBER 2023

## UPDATES

## ROOM 5

<b>D2T05.3</b>	<b>14:15 - 15:45</b>	<b>CHRONIC URTICARIA</b>
	Chairs:	Clive Grattan (London, United Kingdom) Emek Kocatürk Göncü (Istanbul, Türkiye)
D2T05.3A	14:15	<b>News in chronic inducible urticaria</b> Mojca Bizjak (Golnik, Slovenia)
D2T05.3B	14:35	<b>Relevant biomarkers in chronic urticaria</b> Pavel Kolkhir (Berlin, Germany)
D2T05.3C	14:55	<b>Incoming treatments for chronic urticaria</b> Emek Kocatürk Göncü (Istanbul, Türkiye)
D2T05.3D	15:15	<b>Managing angioedema without urticaria</b> Clive Grattan (London, United Kingdom)
D2T05.3E	15:35	<b>Discussion, Q&amp;A</b>

## UPDATES

## ROOM 5

<b>D2T05.4</b>	<b>16:00 - 17:30</b>	<b>DRUG ERUPTIONS</b>
	Chairs:	Torsten Zuberbier (Berlin, Germany) Alexander Navarini (Basel, Switzerland)
D2T05.4A	16:00	<b>Immediate-type drug eruptions</b> Torsten Zuberbier (Berlin, Germany)
D2T05.4B	16:20	<b>What's new in DRESS?</b> Vincent Descamps (Paris, France)
D2T05.4C	16:40	<b>What's new in AGEP?</b> Alexander Navarini (Basel, Switzerland)
D2T05.4D	17:00	<b>How to manage sequelae from severe cutaneous adverse drug eruptions</b> Sarah Walsh (London, United Kingdom)
D2T05.4E	17:20	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

UPDATES

ROOM 6

<b>D2T06.1</b>	<b>08:30 - 10:00</b>	<b>DERMATOSURGERY (PART 1)</b>
	<b>Chairs:</b>	<b>Severin Läuchli (Zurich, Switzerland)</b> <b>John Paoli (Gothenburg, Sweden)</b>
<b>D2T06.1A</b>	<b>8:30</b>	<b>Curettage vs cryosurgery for low-risk basal cell carcinoma</b> Eva Johansson Backman (Gothenburg, Sweden)
<b>D2T06.1B</b>	<b>8:50</b>	<b>Surgical management of Merkel cell carcinoma</b> Stanislav Tolkachjov (Lewisville, United States)
<b>D2T06.1C</b>	<b>9:10</b>	<b>Surgical management of DFSP</b> Roland Kaufmann (Frankfurt, Germany)
<b>D2T06.1D</b>	<b>9:30</b>	<b>Do we really need wide local excisions for melanoma?</b> John Paoli (Gothenburg, Sweden)
<b>D2T06.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 6

<b>D2T06.2</b>	<b>10:15 - 11:45</b>	<b>DERMATOSURGERY (PART 2)</b>
	<b>Chairs:</b>	<b>Severin Läuchli (Zurich, Switzerland)</b> <b>John Paoli (Gothenburg, Sweden)</b>
<b>D2T06.2A</b>	<b>10:15</b>	<b>Forehead / Scalp</b> Severin Läuchli (Zurich, Switzerland) Goran van Rooijen (Haarlem, Netherlands)
<b>D2T06.2B</b>	<b>10:35</b>	<b>Nose</b> Nisith Sheth (London, United Kingdom) Aleksandar Krunic (Chicago, United States)
<b>D2T06.2C</b>	<b>10:55</b>	<b>Cheeks</b> Michael Mühlstädt (Geneva, Switzerland) Antoni Bennàssar Vicens (Palma de Mallorca, Spain)
<b>D2T06.2D</b>	<b>11:15</b>	<b>Lips</b> Joseph Alcalay (Tel Aviv, Israel) Ally-Khan Somani (Indianapolis, United States)
<b>D2T06.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

UPDATES

ROOM 6

<b>D2T06.3</b>	<b>14:15 - 15:45</b>	<b>MOHS SUGERY</b>
	Chairs:	<b>Eduardo Nagore (Valencia, Spain)</b> <b>Aleksandar Krunic (Chicago, United States)</b>
<b>D2T06.3A</b>	<b>14:15</b>	<b>Dermatofibrosarcoma protuberans</b> Renate Ruth van den Bos (Rotterdam, Netherlands)
<b>D2T06.3B</b>	<b>14:35</b>	<b>Lentigo maligna melanoma</b> Eduardo Nagore (Valencia, Spain)
<b>D2T06.3C</b>	<b>14:55</b>	<b>Keratinocytic tumors</b> Aleksandar Krunic (Chicago, United States)
<b>D2T06.3D</b>	<b>15:15</b>	<b>Role of confocal microscopy: in vivo and ex vivo</b> François Kuonen (Lausanne, Switzerland)
<b>D2T06.3E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 6

<b>D2T06.4</b>	<b>16:00 - 17:30</b>	<b>SURGERY IN ADVANCED SKIN CANCER</b>
	Chairs:	<b>Claus Garbe (Tubingen, Germany)</b> <b>Simone Ribero (Torino, Italy)</b>
<b>D2T06.4A</b>	<b>16:00</b>	<b>Surgery for cutaneous squamous cell carcinoma and its limits in advanced disease</b> Victoria Marmgren (Molndal, Sweden)
<b>D2T06.4B</b>	<b>16:20</b>	<b>Role of surgery in locally advanced basal cell carcinoma</b> Joseph Alcalay (Tel Aviv, Israel)
<b>D2T06.4C</b>	<b>16:40</b>	<b>Role of surgery in advanced melanoma under systemic treatment</b> Claus Garbe (Tubingen, Germany)
<b>D2T06.4D</b>	<b>17:00</b>	<b>The future of sentinel lymphnode biopsy</b> Simone Ribero (Torino, Italy)
<b>D2T06.4E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>

## THURSDAY 12 OCTOBER 2023

## UPDATES

## HALL A7

<b>D2T07.1</b>	<b>08:30 - 10:00</b>	<b>HAIR DISORDERS</b>
	<b>Chairs:</b>	<b>Ulrike Blume-Peytavi (Berlin, Germany)</b> <b>Sergio Vaño-Galván (Madrid, Spain)</b>
<b>D2T07.1A</b>	<b>8:30</b>	<b>Evaluation and diagnosis of scarring alopecia</b> Jerry Shapiro (New York, United States)
<b>D2T07.1B</b>	<b>8:50</b>	<b>Management of frontal fibrosing alopecia</b> Ulrike Blume-Peytavi (Berlin, Germany)
<b>D2T07.1C</b>	<b>9:10</b>	<b>Low dose oral minoxidil for androgenetic alopecia</b> Ramon Grimalt (Terrassa, Spain)
<b>D2T07.1D</b>	<b>9:30</b>	<b>Emerging therapies for androgenetic alopecia</b> Sergio Vaño-Galván (Madrid, Spain)
<b>D2T07.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

## UPDATES

## HALL A7

<b>D2T07.2</b>	<b>10:15 - 11:45</b>	<b>HAIR DISORDERS</b>
	<b>Chairs:</b>	<b>Lidia Rudnicka (Warsaw, Poland)</b> <b>Antonella Tosti (Miami, United States)</b>
<b>D2T07.2A</b>	<b>10:15</b>	<b>Telogen effluvium: evaluation and treatment</b> Anna Waskiel (Warsaw, Poland)
<b>D2T07.2B</b>	<b>10:35</b>	<b>Managing alopecia areata through trichoscopy</b> Lidia Rudnicka (Warsaw, Poland)
<b>D2T07.2C</b>	<b>10:55</b>	<b>Late onset alopecia areata</b> Antonella Tosti (Miami, United States)
<b>D2T07.2D</b>	<b>11:15</b>	<b>JAK inhibitors in alopecia areata</b> Bianca Maria Piraccini (Bologna, Italy)
<b>D2T07.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

UPDATES

HALL A7

<b>D2T07.3</b>	<b>14:15 - 15:45</b>	<b>NAILS DISORDERS</b>
	<b>Chairs:</b>	<b>Asja Prohic (Sarajevo, Bosnia and Herzegovina)</b> <b>Bertrand Richert (Brussels, Belgium)</b>
D2T07.3A	14:15	<b>Managing nail disorders through onychoscopy</b> Francesca Pampaloni (Bologna, Italy)
D2T07.3B	14:35	<b>Paediatric nail disorders</b> Matilde Iorizzo (Bellinzona, Switzerland)
D2T07.3C	14:55	<b>Update on onychomycosis treatment</b> Asja Prohic (Sarajevo, Bosnia and Herzegovina)
D2T07.3D	15:15	<b>Trachyonychia: evaluation and treatment plan</b> Bertrand Richert (Brussels, Belgium)
D2T07.3E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A7

<b>D2T07.4</b>	<b>16:00 - 17:30</b>	<b>SCALP DISORDERS</b>
	<b>Chairs:</b>	<b>Ralph Trüeb (Zürich-Wallisellen, Switzerland)</b> <b>Adriana Rakowska (Warsaw, Poland)</b>
D1T07.4A	16:00	<b>Diagnostic and therapeutic algorithm in folliculitis decalvans</b> Ralph Trüeb (Zürich-Wallisellen, Switzerland)
D2T07.4B	16:20	<b>Scalp psoriasis</b> Krisztian Gaspar (Debrecen, Hungary)
D2T07.4C	16:40	<b>Tips and tricks for scalp itch</b> Petra Dikrama (Utrecht, Netherlands)
D2T07.4D	17:00	<b>Acne, hair loss and hirsutism</b> Adriana Rakowska (Warsaw, Poland)
D2T07.4E	17:20	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A3

<b>D2T08.1</b>	<b>08:30 - 10:00</b>	<b>FILLERS I, BASICS</b>
	<b>Chairs:</b>	<b>Berthold Rzany (Vienna, Austria)</b>
D2T08.1A	8:30	<b>What is the best filler for me and my patient?</b> Berthold Rzany (Vienna, Austria)
D2T08.1B	8:50	<b>Filler treatment of the mid-face: nasolabial, cheeks and tear trough</b> Andreea Boca (Cluj-Napoca, Romania)
D2T08.1C	9:10	<b>Filler treatment of the lower face: lips, marionette lines, submental crease and chin</b> Daisy Kopera (Graz, Austria)
D2T08.1D	9:30	<b>How to inject fillers safely</b> Gregor Holzer (Vienna, Austria)
D2T08.1E	9:50	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

UPDATES

HALL A3


<b>D2T08.2</b>	<b>10:15 - 11:45</b>	<b>BOTULINUM TOXIN I, BASICS</b>
	Chairs:	Andreas Katsambas (Athens, Greece)
<b>D2T08.2A</b>	<b>10:15</b>	<b>Botulinum toxin for the periorbital area</b> Ines Verner Rashkovsky (Savyon, Israel)
<b>D2T08.2B</b>	<b>10:35</b>	<b>Tech neck, Trapezius trigger points, Temporomandibular muscle hypertrophy, Tension headaches and migraine</b> Christopher Rowland Payne (London, United Kingdom)
<b>D2T08.2C</b>	<b>10:55</b>	<b>Botulinum toxin in males</b> Leonardo Marini (Trieste, Italy)
<b>D2T08.2D</b>	<b>11:15</b>	<b>Approach of the lower face with botulinum toxin-A</b> Andreas Katsambas (Athens, Greece)
	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A3

<b>D2T08.3</b>	<b>14:15 - 15:45</b>	<b>LASERS AND ENERGY-BASED DEVICES, PRACTICAL ASPECTS OF BASICS</b>
	Chairs:	Maurice A. Adatto (Geneva, Switzerland)
<b>D2T08.3A</b>	<b>14:15</b>	<b>The laser consultation</b> Moshe Lapidoth (Ramat-Gan, Israel)
<b>D2T08.3B</b>	<b>14:35</b>	<b>Ablative and non-ablative lasers in darker skin types</b> Mukta Sachdev (Bangalore, India)
<b>D2T08.3C</b>	<b>14:55</b>	<b>Lasers for vascular lesions</b> Kristine Heidemeyer (Bern, Switzerland)
<b>D2T08.3D</b>	<b>15:15</b>	<b>Lasers for pigmented lesions and tattoos</b> Maurice A. Adatto (Geneva, Switzerland)
	<b>15:35</b>	<b>Discussion, Q&amp;A</b>






THURSDAY 12 OCTOBER 2023

UPDATES

HALL A3

D2T08.4		16:00 - 17:30	<b>PATIENT SELECTION AND PRACTICE MANAGEMENT</b>
	Chairs:		Christopher Rowland Payne (London, United Kingdom)
D2T08.4A	16:00		<b>A lot to offer! What to choose for open pores &amp; fine lines?</b> Christopher Hopper (UK)
D2T08.4B	16:20		<b>A lot to offer! What to choose for solar dermatoporosis?</b> Raphaël André (Genève, Switzerland)
D2T08.4C	16:40		<b>A lot to offer! What to choose for periorbital puffiness?</b> Susanna Marini (Trieste, Italy)
D2T08.4D	17:00		<b>My 10 top tips for success in private practice</b> Wolfgang Philip-Dormston (Köln, Germany)
D2T08.4E	17:20		<b>Discussion, Q&amp;A</b>



THURSDAY 12 OCTOBER 2023

TRAINING AND  
EDUCATION

HALL A1

<b>D2T09.1</b>	<b>08:30 - 10:00</b>	<b>NON-MELANOMA SKIN CANCER</b>
	Chairs:	Erika Varga (Szeged, Hungary) Priscila Giavedoni (Barcelona, Spain)
D2T09.1A	8:30	<b>Basal cell carcinoma and squamous cell carcinoma</b> Arjen Fokko Nikkels (Liege, Belgium)
D2T09.1B	8:50	<b>Merkel cell carcinoma</b> Erika Varga (Szeged, Hungary)
D2T09.1C	9:10	<b>Dermatofibrosarcoma protuberans</b> Zoe Apalla (Thessaloniki, Greece)
D2T09.1D	9:30	<b>Diagnosis through imaging</b> Priscila Giavedoni (Barcelona, Spain)
D2T09.1E	9:50	<b>Discussion, Q&amp;A</b>

TRAINING AND  
EDUCATION

HALL A1

<b>D2T09.2</b>	<b>10:15 - 11:45</b>	<b>NON-MELANOMA SKIN CANCER</b>
	Chairs:	Eggert Stockfleth (Bochum, Germany) Nicole Basset-Seguin (Paris, France)
D2T09.2A	10:15	<b>Non-surgical treatments</b> Eggert Stockfleth (Bochum, Germany)
D2T09.2B	10:35	<b>Management of positive margins</b> Elena Rossi (Modena, Italy)
D2T09.2C	10:55	<b>Systemic treatment for advanced skin cancer</b> Nicole Basset-Seguin (Paris, France)
D2T09.2D	11:15	<b>Tumour resistance and recurrences</b> François Kuonen (Lausanne, Switzerland)
D2T09.2E	11:35	<b>Discussion , Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

TRAINING AND  
EDUCATION

HALL A1

<b>D2T09.3</b>	<b>14:15 - 15:45</b>	<b>MELANOMA</b>
	Chairs:	Caroline Gaudy-marqueste (Marseille, France) Veronique Bataille (Hemel Hempstead, United Kingdom)
D2T09.3A	14:15	<b>Genetics and epidemiology</b> Veronique Bataille (Hemel Hempstead, United Kingdom)
D2T09.3B	14:35	<b>Imaging for diagnosis and follow up</b> Linda Tognetti (Siena, Italy)
D2T09.3C	14:55	<b>Prognostic factors of melanoma</b> Elvira Moscarella (Naples, Italy)
D2T09.3D	15:15	<b>Staging and follow up</b> Caroline Gaudy-marqueste (Marseille, France)
D2T09.3E	15:35	<b>Discussion, Q&amp;A</b>

TRAINING AND  
EDUCATION

HALL A1

<b>D2T09.4</b>	<b>16:00 - 17:30</b>	<b>MELANOMA</b>
	Chairs:	Ricardo Vieira (Coimbra, Portugal) Christian Posch (Vienna, Austria)
D2T09.4A	16:00	<b>Recommendations on sentinel lymphnode biopsy and safety margins</b> Ricardo Vieira (Coimbra, Portugal)
D2T09.4B	16:20	<b>(neo)adjuvant treatment</b> Christian Posch (Wien, Austria)
D2T09.4C	16:40	<b>Systemic treatment for advanced melanoma</b> Christian Posch (Vienna, Austria)
D2T09.4D	17:00	<b>Deciding on palliative care at the era of immunotherapy and targeted therapy</b> Speaker TBC
D2T09.4E	17:20	<b>Discussion, Q&amp;A</b>

## THURSDAY 12 OCTOBER 2023

TRAINING AND  
EDUCATION

## HALL A2

<b>D2T10.1</b>	<b>08:30 - 10:00</b>	<b>ECZEMAS: ATOPIC DERMATITIS</b>
	Chairs:	Jan Gutermuth (Brussels, Belgium) Melinda Gooderham (Peterborough, ON, Canada)
D2T10.1A	8:30	<b>Pathophysiology of atopic dermatitis</b> Jan Gutermuth (Brussels, Belgium)
D2T10.1B	8:50	<b>Phenotypes of atopic dermatitis</b> Melinda Gooderham (Peterborough, ON, Canada)
D2T10.1C	9:10	<b>Topical and conventional systemic treatment for atopic dermatitis</b> Valeria Aoki (São Paulo, Brazil)
D2T10.1D	9:30	<b>Managing atopic dermatitis with biologics and JAK inhibitors</b> Bruno Duarte (Lisbon, Portugal)
D2T10.1E	9:50	<b>Discussion, Q&amp;A</b>

TRAINING AND  
EDUCATION

## HALL A2

<b>D2T10.2</b>	<b>10:15 - 11:45</b>	<b>NON ATOPIC ECZEMAS</b>
	Chairs:	Suzana Ljubojevic (Zagreb, Croatia) Luca Stingeni (Corciano (PG), Italy)
D2T10.2A	10:15	<b>Hand eczema</b> Richard Brans (Osnabrück, Germany)
D2T10.2B	10:35	<b>Clinical spectrum of allergic contact dermatitis</b> Marie-Louise Anna Schuttelaar (Groningen, Netherlands)
D2T10.2C	10:55	<b>Most relevant allergens in 2023</b> Suzana Ljubojevic (Zagreb, Croatia)
D2T10.2D	11:15	<b>Pitfalls of patch testing</b> Luca Stingeni (Corciano (PG), Italy)
D2T10.2E	11:35	<b>Discussion, Q&amp;A</b>

## THURSDAY 12 OCTOBER 2023

TRAINING AND  
EDUCATION

## HALL A2

<b>D2T10.3</b>	<b>14:15 - 15:45</b>	<b>DRUG REACTIONS</b>
	Chairs:	Eva Remenyik (Debrecen, Hungary) Sarah Walsh (London, United Kingdom)
D2T10.3A	14:15	<b>Phenotypes of cutaneous adverse drug eruptions</b> Chia-Yu Chu (Taipei, Taiwan)
D2T10.3B	14:35	<b>Red flags in drug eruptions</b> Sarah Walsh (London, United Kingdom)
D2T10.3C	14:55	<b>AGEP and SDRIFE</b> Barbara Meier-Schiesser (Zürich, Switzerland)
D2T10.3D	15:15	<b>Drugs photosensitivity</b> Eva Remenyik (Debrecen, Hungary)
D2T10.3E	15:35	<b>Discussion, Q&amp;A</b>

TRAINING AND  
EDUCATION

## HALL A2

<b>D2T10.4</b>	<b>16:00 - 17:30</b>	<b>URTICARIA AND VASCULITIS</b>
	Chairs:	Cord Sunderkoetter (Halle, Germany) Jelena Stojkovic-Filipovic (Belgrade, Serbia)
D2T10.4A	16:00	<b>Chronic spontaneous urticaria</b> Ana Brasileiro (Lisbon, Portugal)
D2T10.4B	16:20	<b>Chronic inducible urticaria</b> Sabine Altrichter (Linz, Austria)
D2T10.4C	16:40	<b>The spectrum of cutaneous vasculitis</b> Cord Sunderkoetter (Halle, Germany)
D2T10.4D	17:00	<b>Work-up of cutaneous vasculitis</b> Jelena Stojkovic-Filipovic (Belgrade, Serbia)
D2T10.4E	17:20	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

CONTROVERSIES

HALL A5

CONTROVERSIES I	
<b>D2T11.1</b>	<b>08:30 - 10:00</b> Chairs: Michel Gilliet (Lausanne, Switzerland) Brigitte Dréno (Nantes, France)
D2T11.1A	8:30 Introduction Michel Gilliet (Lausanne, Switzerland)
D2T11.1B	8:35 Can we change the disease course of psoriasis? Yes Lars Iversen (Aarhus, Denmark)
D2T11.1C	8:50 Can we change the disease course of psoriasis? No Curdin Conrad (Lausanne, Switzerland)
D2T11.1D	9:05 Discussion, Q&A
D2T11.1E	9:15 Introduction Brigitte Dréno (Nantes, France)
D2T11.1F	9:20 Is there still a place for topical antibiotics in acne? Yes Jose Luis Lopez-Estebarez (Madrid, Spain)
D2T11.1G	9:35 Is there still a place for topical antibiotics in acne? No Vincenzo Bettoli (Ferrara, Italy)
D2T11.1H	9:50 Discussion, Q&A

CONTROVERSIES

HALL A5

CONTROVERSIES II	
<b>D2T11.2</b>	<b>10:15 - 11:45</b> Chairs: Monika Arenbergerova (Prague, Czech Republic) Phyllis Spuls (Amstelveen, Netherlands)
D2T11.2A	10:15 Introduction Monika Arenbergerova (Prague, Czech Republic)
D2T11.2B	10:20 Adjuvant vs neoadjuvant therapy in melanoma: Adjuvant Thomas Eigentler (Tubingen, Germany)
D2T11.2C	10:35 Adjuvant vs neoadjuvant therapy in melanoma: Neoadjuvant Claus Garbe (Tubingen, Germany)
D2T11.2D	10:50 Discussion, Q&A
D2T11.2E	11:00 Introduction Phyllis Spuls (Amstelveen, Netherlands)
D2T11.2F	11:05 Therapeutic drug monitoring of biologics: Yes Jo LW Lambert (Ghent, Belgium)
D2T11.2G	11:20 Therapeutic drug monitoring of biologics: No Paolo Gisondi (Verona, Italy)
D2T11.2H	11:35 Discussion, Q&A

THURSDAY 12 OCTOBER 2023

CONTROVERSIES

HALL A5

D2T11.3		14:15 - 15:50	CONTROVERSIES III
Chairs:			Salvador González Rodríguez (Madrid, Spain) Cristina Carrera (Barcelona, Spain)
D2T11.3A	14:15		<b>Introduction</b> Salvador González Rodríguez (Madrid, Spain)
D2T11.3B	14:20		<b>Dietary supplements in dermatology: Yes</b> Monika Arenbergerova (Prague, Czech Republic)
D2T11.3C	14:35		<b>Dietary supplements in dermatology: No</b> Apostolos Pappas (Branchburg, NJ, United States)
D2T11.3D	14:50		<b>Discussion, Q&amp;A</b>
D2T11.3E	15:00		<b>Introduction</b> Cristina Carrera (Barcelona, Spain)
D2T11.3F	15:05		<b>Melanocytic nevi in children: follow-up</b> Angela Hernandez-Martin (Madrid, Spain)
D2T11.3G	15:20		<b>Melanocytic nevi in children: ignore</b> Giuseppe Argenziano (Naples, Italy)
D2T11.3H	15:35		<b>Discussion, Q&amp;A</b>

CONTROVERSIES

HALL A5

D2T11.4		16:00 - 17:30	CONTROVERSIES IV
Chairs:			Jo LW Lambert (Ghent, Belgium) Paola Pasquali (Cambrils (TA), Spain)
D2T11.4A	16:00		<b>Introduction</b> Paola Pasquali (Cambrils (TA), Spain)
D2T11.4B	16:05		<b>Can teledermatology replace face to face consultation? Yes</b> Angeles Florez Menendez (Pontevedra, Spain)
D2T11.4C	16:20		<b>Can teledermatology replace face to face consultation? No</b> Lluís Puig (Barcelona, Spain)
D2T11.4D	16:35		<b>Discussion, Q&amp;A</b>
D2T11.4E	16:45		<b>Introduction</b> Jo LW Lambert (Ghent, Belgium)
D2T11.4F	16:50		<b>Are highly-potent dermo-corticoids sufficient for bullous pemphigoid? Yes</b> Enno Schmidt (Lübeck, Germany)
D2T11.4G	17:05		<b>Are highly-potent dermo-corticoids sufficient for bullous pemphigoid? No</b> Luca Borradori (Bern, Switzerland)
D2T11.4H	17:20		<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

UPDATES

HALL A4

<b>D2T12.1</b>	<b>08:30 - 10:00</b>	<b>STIS</b>
	Chairs:	Eija Hiltunen-Back (Helsinki, Finland) Clarissa Vergunst (Amsterdam, Netherlands)
D2T12.1A	8:30	<b>Revival of syphilis?</b> Eija Hiltunen-Back (Helsinki, Finland)
D2T12.1B	8:50	<b>Updates in the treatment of gonococcal infections</b> David Chromy (Vienna, Austria)
D2T12.1C	9:10	<b>Lymphogranuloma venereum, an emerging problem</b> Marco Cusini (Milan, Italy)
D2T12.1D	9:30	<b>Current trends and future visions on STIs in Europe</b> Clarissa Vergunst (Amsterdam, Netherlands)
D2T12.1E	9:50	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A4

<b>D2T12.2</b>	<b>10:15 - 11:45</b>	<b>HIV</b>
	Chairs:	Nicolas Dupin (Paris, France) Anja Potthoff (Bochum, Germany)
D2T12.2A	10:15	<b>New treatment algorithms for HIV infection</b> Speaker TBC
D2T12.2B	10:35	<b>Kaposi sarcoma</b> Nicolas Dupin (Paris, France)
D2T12.2C	10:55	<b>Use of immuno-modulators in HIV-infected patients</b> Jean-Philippe Spano (Paris, France)
D2T12.2D	11:15	<b>User profiles of HIV pre-exposure prophylaxis</b> Anja Potthoff (Bochum, Germany)
D2T12.2E	11:35	<b>Discussion, Q&amp;A</b>



THURSDAY 12 OCTOBER 2023

UPDATES

HALL A4

<b>D2T12.3</b>	<b>14:15 - 15:45</b>	<b>STIS</b>
	Chairs:	Peter Greenhouse (Bristol, United Kingdom) Esther Freeman (Boston, United States)
D2T12.3A	14:15	<b>Effects of systemic treatments on Genital HPV infections</b> Peter Greenhouse (Bristol, United Kingdom)
D2T12.3B	14:35	<b>Antibiotic landscape in genital ulcers</b> Georg Stary (Vienna, Austria)
D2T12.3C	14:55	<b>STI in times of PREP</b> Laurence Toutous-Trellu (Geneva, Switzerland)
D2T12.3D	15:15	<b>Monkeypox: Clinical findings</b> Esther Freeman (Boston, United States)
D2T12.3E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A4

<b>D2T12.4</b>	<b>16:00 - 17:30</b>	<b>GENETICS IN SKIN DISEASES</b>
	Chairs:	M. Peter Marinkovich (Redwood City, United States) Kaisa Tasanen-Maatta (Oulu, Finland)
D2T12.4A	16:00	<b>New types of inherited blistering diseases</b> M. Peter Marinkovich (Redwood City, United States)
D2T12.4B	16:20	<b>New genetic associations in atopic dermatitis</b> Kaisa Tasanen-Maatta (Oulu, Finland)
D2T12.4C	16:40	<b>Mosaic abnormalities of the skin</b> Lihi Atzmony (Petach Tikva, Israel)
D2T12.4D	17:00	<b>Rare and complex connective tissue diseases</b> Aude Beyens (Ghent, Belgium)
D2T12.4E	17:20	<b>Discussion, Q&amp;A</b>

## THURSDAY 12 OCTOBER 2023

## FREE COMMUNICATIONS M1+2

FC01	08:30 - 10:00	FREE COMMUNICATIONS I
	<b>Chairs:</b>	<b>Johann Bauer (Salzburg, Austria)</b> <b>Aikaterini I. Liakou (Athens, Greece)</b>
FC 01.1	8:30	<b>Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study</b> Christos Tziotzios (London, United Kingdom)
FC 01.2	8:40	<b>Patient Reported Outcomes for Scalp, Eyebrow and Eyelash hair loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 104 week Results from Two Phase 3 Clinical Trials</b> Brett King (New Haven, United States)
FC 01.3	8:50	<b>Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies</b> Brett King (New Haven, United States)
FC 01.4	9:00	TBC
FC 01.5	9:10	<b>Treatment of Androgenetic Alopecia via Androgen Receptor Degradation</b> Tsun-Pin Andrew Pai (Taipei, Taiwan)
FC 01.6	9:20	<b>Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse</b> Marta Bertolini (Muenster, Germany)
FC 01.7	9:30	<b>Efficacy and Safety of topical KX-826 in Adult Male Subjects with Androgenetic Alopecia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study</b>
FC 01.8	9:40	<b>Spontaneous Hair Regrowth In Patients With Severe AA Randomized To Placebo In BRAVE-AA1 And BRAVE-AA2 Trials</b> Sergio Vañó-Galván (Madrid, Spain)
FC 01.9	9:50	TBC

THURSDAY 12 OCTOBER 2023

FREE COMMUNICATIONS	M1+2	
<b>FC02</b>	<b>10:15 - 11:45</b>	<b>FREE COMMUNICATIONS II</b>
	<b>Chairs:</b>	<b>Zsuzsanna Bata-Csorgo (Szeged, Hungary)</b> <b>Thrasylvoulos Tzellos (Bodø, Norway)</b>
<b>FC 02.1</b>	<b>10:15</b>	<b>Baseline Demographic and Disease Characteristics Associated With Achieving HiSCR With Povorcitinib: Secondary Analysis From a Phase 2, Randomized, Placebo-Controlled Clinical Trial</b> Falk G. Bechara (Bochum, Germany)
<b>FC 02.2</b>	<b>10:25</b>	<b>Impact of Povorcitinib on DLQI and DLQI Subdomains in Patients With Hidradenitis Suppurativa: Results From a Randomized, Placebo-Controlled Phase 2 Study</b> Falk G. Bechara (Bochum, Germany)
<b>FC 02.3</b>	<b>10:35</b>	<b>Skin care promotes cutaneous microbiome protection and recovery in an acute stratum corneum stress model in healthy volunteers and patients with inflammatory bowel diseases</b>
<b>FC 02.4</b>	<b>10:45</b>	<b>Management of dermal filler complications using duplex ultrasound: Two case reports</b> Alba Regina Camargo Goñi (Mexico City, Mexico)
<b>FC 02.5</b>	<b>10:55</b>	<b>Botulinum toxin A intradermal injections in patients with acne</b>
<b>FC 02.6</b>	<b>11:05</b>	<b>The limited value of sentinel lymph node biopsy in lentigo maligna melanoma: results of 29 years of the nationwide Dutch Pathology Registry (PALGA)</b> Yannick Elshot (Amsterdam, Netherlands)
<b>FC 02.7</b>	<b>11:15</b>	<b>TBC</b>
<b>FC 02.8</b>	<b>11:25</b>	<b>Efficacy and Safety of Upadacitinib in a Phase 2 Randomized, Double-Blind, Dose-Ranging Study of Adults With Extensive Non-Segmental Vitiligo</b> Thierry Passeron (Nice, France)
<b>FC 02.9</b>	<b>11:35</b>	<b>ChatGPT vs. the UK Postgraduate Dermatology Exam (Specialty Certificate Examination)</b> Lauren Passby (Birmingham, United Kingdom)

## THURSDAY 12 OCTOBER 2023

## FREE COMMUNICATIONS M1+2

FC03	14:15 - 15:45	FREE COMMUNICATIONS III
	Chairs:	Ana Giménez-Arnau (Barcelona, Spain) Susanna Marini (Trieste, Italy)
FC 03.1	14:15	<b>Concordance between IHS4-55 response and HiSCR: A post hoc analysis of the SUNSHINE and SUNRISE phase 3 randomised trials of secukinumab in patients with moderate to severe hidradenitis suppurativa</b> Christos C. Zouboulis (Dessau, Germany)
FC 03.2	14:25	<b>Bimekizumab efficacy across weight and BMI based subgroups in patients with moderate to severe hidradenitis suppurativa: 48-week pooled results from the randomised, double-blind, placebo-controlled, multicentre BE HEARD I and II phase 3 trials</b> Amit Garg (New York, United States)
FC 03.3	14:35	<b>Adalimumab Treatment Failure in Hidradenitis Suppurativa: Associated Factors From a Retrospective Observational Study Using Data From the CPRD-HES Database in England</b> John R. Ingram (Cardiff, United Kingdom)
FC 03.4	14:45	<b>Bimekizumab efficacy and safety in patients with moderate to severe hidradenitis suppurativa: Analysis of pooled data from BE HEARD I and II phase 3, randomised, double-blind, placebo-controlled, multicentre studies</b> Christos C. Zouboulis (Dessau, Germany)
FC 03.5	14:55	<b>Effect of secukinumab on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Post hoc analysis of the SUNSHINE and SUNRISE Phase 3 randomised trials</b> Falk G. Bechara (Germany)
FC 03.6	15:05	<b>A 2023 snapshot of acne prevalence worldwide Data from the All Skins-All Colors-All Dermatoses: the ALL PROJECT</b>
FC 03.7	15:15	<b>IHS4 outcomes with bimekizumab in patients with moderate to severe hidradenitis suppurativa: Pooled results from the BE HEARD I and II phase 3 trials</b> Christos C. Zouboulis (Dessau, Germany)
FC 03.8	15:25	<b>Depth of the Efficacy Response to Upadacitinib Treatment in Moderate-to-Severe Hidradenitis Suppurativa (HS)</b>
FC 03.9	15:35	<b>Effects of secukinumab on hidradenitis suppurativa high-impact efficacy endpoints: A post hoc analysis of the SUNSHINE and SUNRISE phase 3 trials</b> John R. Ingram (Cardiff, United Kingdom)

THURSDAY 12 OCTOBER 2023

FREE COMMUNICATIONS	M1+2	
<b>FC04</b>	<b>16:00 - 17:30</b>	<b>FREE COMMUNICATIONS IV</b>
	<b>Chairs:</b>	<b>Zsanett Renáta Csoma (Szeged, Hungary)</b> <b>Paolo Gisondi (Verona, Italy)</b>
<b>FC 04.1</b>	<b>16:00</b>	<b>Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus</b> Victoria P. Werth (Philadelphia, United States)
<b>FC 04.2</b>	<b>16:10</b>	<b>Efficacy and safety of litifilimab in cutaneous lupus erythematosus: Phase 2/3 AME-THYST study design</b> Joseph F. Merola (Boston, United States)
<b>FC 04.3</b>	<b>16:20</b>	<b>The anti-interferon-beta neutralizing antibody PF-06823859 significantly improves molecular and histological profiles in the skin of patients with dermatomyositis in a 12-week study</b> Karen Page (Cambridge, MA, United States)
<b>FC 04.4</b>	<b>16:30</b>	<b>Identification of immunological factors predicting clinical relapse in pemphigus- a prospective bicontinental study</b> Dipankar De (Chandigarh, India)
<b>FC 04.5</b>	<b>16:40</b>	<b>Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases</b> Ivaylo Stoykov (Ghent, United States)
<b>FC 04.6</b>	<b>16:50</b>	<b>High Prevalence of Azithromycin-Resistance among Mycoplasma genitalium infections in Austria</b> David Chromy (Vienna, Austria)
<b>FC 04.7</b>	<b>17:00</b>	<b>Whole genome sequencing of Neisseria gonorrhoeae demonstrates sexual mixing throughout a spectrum of different risk groups</b> David Chromy (Vienna, Austria)
<b>FC 04.8</b>	<b>17:10</b>	<b>Trichophyton mentagrophytes genotype VII – an emerging sexually transmitted fungal infection relevant for men who have sex with men</b>
<b>FC 04.9</b>	<b>17:20</b>	<b>Avapritinib Improved Skin Findings In Patients With Indolent Systemic Mastocytosis (ISM) In the Registrational, Double-Blind, Placebo Controlled PIONEER Study</b> Marcus Maurer (Berlin, Germany)

THURSDAY 12 OCTOBER 2023

MISCELLANEOUS

M6+7

<b>D2T14.1</b>	<b>08:30 - 10:00</b>	<b>HOW COLLABORATION IMPROVES ACCESS TO CARE</b>
	<b>Chairs:</b>	<b>Visnja Zaborski-Breton (Ottawa, Canada)</b> <b>Catherine van Montfrans (Rotterdam, Netherlands)</b> <b>Aleksandra Lesiak (Lodz, Poland)</b>
<b>D2T14.1A</b>	<b>8:30</b>	<b>Welcome (state our shared community challenges)</b> Visnja Zaborski-Breton (Ottawa, Canada)
<b>D2T14.1B</b>	<b>8:35</b>	<b>Best practices in partnering with patient organizations</b> Jennifer Austin (Ottawa, Canada)
	<b>8:45</b>	<b><i>Panel Discussion: Collaborating to achieve shared objectives</i></b>
<b>D2T14.1C</b>	<b>8:45</b>	<b>Introduction of Panelists and topic</b> Aleksandra Lesiak (Lodz, Poland)
<b>D2T14.1D</b>	<b>8:50</b>	<b>Managing and working towards solutions for scabies</b> Marja Oldhoff (Paterswolde, Netherlands) Sophie Nagtegaal (Groningen, Netherlands)
<b>D2T14.1D</b>	<b>9:05</b>	<b>Exchanging best practices and challenges in Ichthyosis Management</b> Joanna Narbutt (Lodz, Poland) Antoni Gostynski (Maastricht, Netherlands) Mandy Aldwin-Easton (Karten, Germany) Karin Veldman (Assen, Netherlands)
<b>D2T14.1E</b>	<b>9:20</b>	<b>Solving a challenge together in access to care for vascular malformations</b> Lex van der Heijden (Silvolde, Netherlands) Catherine van Montfrans (Rotterdam, Netherlands)
<b>D2T14.1F</b>	<b>9:35</b>	<b>Facilitated Discussion with panelists</b> Aleksandra Lesiak (Lodz, Poland)
<b>D2T14.1G</b>	<b>9:50</b>	<b>Closing remarks</b> Visnja Zaborski-Breton (Ottawa, Canada)

THURSDAY 12 OCTOBER 2023

MISCELLANEOUS

M6+7

MISCELLANEOUS		M6+7
<b>D2T14.2</b>	<b>10:15 - 11:45</b>	<b>EADV RESEARCH FUNDING AND FELLOWSHIPS</b>
	<b>Chairs:</b>	<b>Veronique del Marmol (Brussels, Belgium)</b> <b>Cristina Has (Freiburg, Germany)</b> <b>Emmanuella Guenova (Lausanne, Switzerland)</b>
<b>D2T14.2A</b>	<b>10:15</b>	<b>Introduction</b> Veronique del Marmol (Brussels, Belgium)
<b>D2T14.2B</b>	<b>10:25</b>	<b>Complications, personological variables and satisfaction with the care received by patients undergoing nail surgery: a prospective observational study</b> Bianca Maria Piraccini (Bologna, Italy)
<b>D2T14.2C</b>	<b>10:40</b>	<b>A specific inflammatory gene signature in pityriasis rubra pilaris identifies a pathogenic role for keratinocytes</b> Curdin Conrad (Lausanne, Switzerland)
<b>D2T14.2D</b>	<b>10:55</b>	<b>Analysis of the structure and function of the epidermal barrier on patients with ichthyosis – biophysical parameters (TEWL, skin hydration), electron microscopy and microbiome examination</b> Regina Fölster-Holst (Kiel, Germany)
<b>D2T14.2E</b>	<b>11:10</b>	<b>Discussion, Q&amp;A</b>
<b>D2T14.2F</b>	<b>11:20</b>	<b>The role of microRNAs in the regulation of the generation and maintenance of skin resident memory T cells</b> Helen Vaher (Copenhagen, Denmark)
<b>D25T14.2G</b>	<b>11:30</b>	<b>Pathogenetic and clinical aspects of hidradenitis suppurativa</b> Piotr Krajewski (Wrocław, Poland)
<b>D2T14.2H</b>	<b>11:35</b>	<b>Atopic dermatitis and skin barrier function</b> Trinidad Montero-Vilchez (Granada, Spain)
<b>D2T12.2I</b>	<b>11:40</b>	<b>Discussion, Q&amp;A</b>

THURSDAY 12 OCTOBER 2023

MISCELLANEOUS

M6+7

<b>D2T14.3</b>	<b>14:15 - 15:45</b>	<b>FACE TO FACE: OFFICE VS HOSPITAL BASED THERAPIES IN DERMATOLOGY</b>
	<b>Chairs:</b>	<b>Jan Gutermuth (Brussels, Belgium)</b>
<b>D2T14.3A</b>	<b>14:15</b>	<b>Topic I Psoriasis: "Is there a place for phototherapy?"</b> Yolanda Gilaberte Calzada (Zaragoza, Spain)
<b>D2T14.3B</b>	<b>14:20</b>	<b>Topic I Psoriasis: "When to use topical therapy?"</b> Ralph von Kiedrowski (Selters, Germany)
<b>D2T14.3C</b>	<b>14:25</b>	<b>Topic I Psoriasis : "When to use 'classical' systemic therapy"</b> Jan Gutermuth (Brussels, Belgium)
<b>D2T14.3D</b>	<b>14:30</b>	<b>Discussion Topic 1</b>
<b>D2T14.3E</b>	<b>14:55</b>	<b>Topic II Skin Cancer: Limits of topical therapies</b> Menno Gaastra (Alkmaar, Netherlands)
<b>D2T14.3F</b>	<b>15:00</b>	<b>Topic II Skin cancer: Limits of office based surgery</b> Mihaela Leventer (Bucharest, Romania)
<b>D2T14.3G</b>	<b>15:05</b>	<b>Topic II Skin cancer: Limits of (neo)adjuvant treatments</b> Rolf Ostendorf (Monchengladbach, Germany)
<b>D2T14.3H</b>	<b>15:10</b>	<b>Discussion Topic II</b>

MISCELLANEOUS

M6+7

<b>D2T14.4</b>	<b>16:00 - 17:30</b>	<b>EDITORS' PICKS OF THE YEAR – A GLOBAL COMPARISON</b>
	<b>Chairs:</b>	<b>Johannes Ring (Munich, Germany)</b> <b>Dirk Elston (Charleston, United States)</b>
<b>DIT14.4A</b>	<b>16:00</b>	<b>Welcome and introduction</b> Johannes Ring (Munich, Germany)
<b>DIT14.4B</b>	<b>16:05</b>	<b>Best papers of the year from JAAD</b> Dirk Elston (Charleston, United States)
<b>DIT14.4C</b>	<b>16:20</b>	<b>Best papers of the year from JDS</b> Riichiro Abe (Niigata, Japan)
<b>DIT14.4D</b>	<b>16:40</b>	<b>Best papers of the year from BJD</b> John R. Ingram (Cardiff, United Kingdom)
<b>DIT14.4E</b>	<b>17:00</b>	<b>Best papers of the year from JEADV</b> Johannes Ring (Munich, Germany)
<b>DIT14.4F</b>	<b>17:20</b>	<b>General discussion</b>



FRIDAY 13 OCTOBER 2023

PROGRAMME AT A GLANCE

[CLICK TO VIEW THE INTERACTIVE PROGRAMME](#)

Room name	Hall B	Hall A8	Room 3	Room 4	Room 5	Room 6
Session type	Focus on / Updates	Updates	Updates	Updates	Updates	Updates
Track no.	1	2	3	4	5	6
08.30 - 10.00	Focus on fragile skin	Dermoscopy pigmented lesions	Basal cell carcinoma	Bullous diseases	Nutrition and dermatology	Top advances in 2023 presented by ESDR
10.00 - 10.15						
10.15 - 11.45	Focus on fragile skin	Dermoscopy non pigmented lesions	Squamous cell carcinoma	Bullous diseases	Photodermatology	Global dermatology (ILDS)
11.45 - 12.00						
12.00 - 13.00	<b>ANNUAL GENERAL MEETING</b>					
13.00 - 14.00	Industry sessions (Lunch satellite symposia)					
14.00 - 14.15						
14.15 - 15.45	Late breaking news	Nail and hair dermoscopy	Merkel cell carcinoma and cutaneous sarcomas	Cutaneous lupus erythematosus	Ethics, diversity and Inclusion	The best of American and European Dermatology (part 1)
15.45 - 16.00						
16.00 - 17.30		Dermoscopy in inflammatory disorders	Cutaneous lymphomas	Connective tissue diseases	Granulomatous diseases	The best of American and European Dermatology
17.30 - 18.00						
18.00 - 19.30	Industry sessions (Evening satellite symposia)					

FRIDAY 13 OCTOBER 2023

PROGRAMME AT A GLANCE

CLICK TO VIEW THE INTERACTIVE PROGRAMME

Room name	Hall A7	Hall A3	Hall A1	Hall A2	Hall A5	Hall A4
Session type	Aesthetic	Controversies	Training and Education	Training and Education	Updates	Updates
Track no.	7	8	9	10	11	12
08.30 - 10.00	Fillers II, Advanced	Controversies V	Immunology basics for dermatologist	Bullous diseases	Scars	Bacterial skin infections
10.00 - 10.15						
10.15 - 11.45	Botulinum toxin II, Advanced	Controversies VI	Translational immunology for dermatologist	Surgical therapy	Wound healing	Viral skin infections
11.45 - 12.00						
12.00 - 13.00	<b>ANNUAL GENERAL MEETING</b>					
13.00 - 14.00	Industry sessions (Lunch satellite symposia)					
14.00 - 14.15						
14.15 - 15.45	Lasers and energy-based devices II: Advanced, including complications management	Controversies VII	Psoriasis	Dermatopathology	Neutrophilic diseases	Fungal skin infections
15.45 - 16.00						
16.00 - 17.30	Energy base devices: Body contouring and tightening	Controversies VIII	Autoimmune disorders	Hidradenitis suppurativa and neutrophilic diseases	Lifestyle and skin disorders	Endo and ectoparasitic skin infections
17.30 - 18.00						
18.00 - 19.30	Industry sessions (Evening satellite symposia)					

FRIDAY 13 OCTOBER 2023

PROGRAMME AT A GLANCE

CLICK TO VIEW THE INTERACTIVE PROGRAMME

Room name	M1+2	M6+7	M4+5	M8
Session type	Free communications	Miscellaneous	Practical workshops	Practical workshops
Track no.	13	14	15	16
08.30 - 10.00	Free communications V	Tattoos and Permanent Make-up	Phlebology beginners	Laser treatment - Beginners
10.00 - 10.15				
10.15 - 11.45	Free communications VI	Skin cancer: innovations		
11.45 - 12.00				
12.00 - 13.00	<b>ANNUAL GENERAL MEETING</b>			
13.00 - 14.00	Industry sessions (Lunch satellite symposia)			
14.00 - 14.15				
14.15 - 15.45	Free Communications VII	Pediatric insights	STI Diagnosis and Treatment	Allergology - Advanced
15.45 - 16.00				
16.00 - 17.30	Free Communications VIII	Dermatological therapies		
17.30 - 18.00				
18.00 - 19.30	Industry sessions (Evening satellite symposia)			

FRIDAY 13 OCTOBER 2023

**UPDATES**

**HALL B**

**D3T01.3**

**14:15 - 17:30**

**LATE BREAKING NEWS**

Chairs:

Brigitte Dréno (Nantes, France)

Thrasylvoulos Tzellos (Bodø, Norway)

FRIDAY 13 OCTOBER 2023

UPDATES

HALL A8

<b>D3T02.1</b>	<b>08:30 - 10:00</b>	<b>DERMOSCOPY PIGMENTED LESIONS</b>
	Chairs:	Monika Arenbergerova (Prague, Czech Republic) Nisa Akay Bengu (Ankara, Türkiye)
D3T02.1A	8:30	Early diagnosis of lentigo maligna melanoma Nisa Akay Bengu (Ankara, Türkiye)
D3T02.1B	8:50	Early diagnosis of superficial spreading melanoma Danica Tiodorovic (Nis, Serbia)
D3T01.2C	9:10	Nodular melanomas - diagnostic clues Monika Arenbergerova (Prague, Czech Republic)
D3T01.2D	9:30	Digital dermoscopy and total body photography in clinical practice Caterina Longo (Modena, Italy)
D3T01.2E	9:50	Discussion, Q&A

UPDATES

HALL A8

<b>D3T02.2</b>	<b>10:15 - 11:45</b>	<b>DERMOSCOPY NON PIGMENTED LESIONS</b>
	Chairs:	Giuseppe Argenziano (Naples, Italy) Nicole Ariana Kukutsch (Leiden, Netherlands)
D3T02.2A	10:15	Early diagnosis of basal cell carcinoma Marek Pásek (Praha 10, Czech Republic)
D3T02.2B	10:35	Early diagnosis of squamous cell carcinoma Nicole Ariana Kukutsch (Leiden, Netherlands)
D3T02.2C	10:55	Rare tumors in the dermoscope Wilhelm Stolz (Munich, Germany)
D3T02.2D	11:15	Vascular lesions Giuseppe Argenziano (Naples, Italy)
D3T02.2E	11:35	Discussion, Q&A

FRIDAY 13 OCTOBER 2023

UPDATES

HALL A8

<b>D3T02.3</b>	<b>14:15 - 15:45</b>	<b>NAIL AND HAIR DERMOSCOPY</b>
	Chairs:	Luc Thomas (Pierre Bénite, France) Iris Zalaudek (Trieste, Italy)
D3T02.3A	14:15	Trichoscopy findings in alopecia Adriana Rakowska (Warsaw, Poland)
D3T02.3B	14:35	Trichoscopy-guided biopsy of the scalp Anna Waskiel (Warsaw, Poland)
D3T02.3C	14:55	Tips and tricks for onychoscopy Luc Thomas (Pierre Bénite, France)
D3T02.3D	15:15	Clinical and histopathologic features of the Hutchinson sign Iris Zalaudek (Trieste, Italy)
D3T02.3E	15:35	Discussion, Q&A

UPDATES

HALL A8

<b>D3T02.4</b>	<b>16:00 - 17:30</b>	<b>DERMOSCOPY IN INFLAMMATORY DISORDERS</b>
	Chairs:	Harald Kittler (Vienna, Austria) Aimilios Lallas (Thessaloniki, Greece)
D3T02.4A	16:00	Dermoscopy features of psoriasis and lichen planus Dimitrios Ioannides (Thessaloniki, Greece)
D3T02.4B	16:20	Infectious diseases Harald Kittler (Vienna, Austria)
D3T02.4C	16:40	Inflammoscopy of the scalp Josep Malvehy (Barcelona, Spain)
D3T02.4D	17:00	Do we need inflammoscopy? Aimilios Lallas (Thessaloniki, Greece)
D3T02.4E	17:20	Discussion, Q&A

FRIDAY 13 OCTOBER 2023

UPDATES


ROOM 3

<b>D3T03.1</b>	<b>08:30 - 10:00</b>	<b>BASAL CELL CARCINOMA</b>
	Chairs:	Alexander Stratigos (Athens, Greece) Maria Concetta Fagnoli (Aquila, Italy)
D3T03.1A	8:30	<b>Recent guidelines</b> Maria Concetta Fagnoli (Aquila, Italy)
D3T03.1B	8:50	<b>Should we treat all BCCs?</b> Isabelle Hoorens (Ghent, Belgium)
D3T03.1C	9:10	<b>Emerging treatments of advanced BCC</b> Alexander Stratigos (Athens, Greece)
D3T03.1D	9:30	<b>Non-surgical treatment of BCC</b> Lise Boussemart (Nantes, France)
D3T03.1E	9:50	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 3

<b>D3T03.2</b>	<b>10:15 - 11:45</b>	<b>SQUAMOUS CELL CARCINOMA</b>
	Chairs:	Roland Kaufmann (Frankfurt, Germany) Enrico Zelin (Trieste, Italy)
D3T03.2A	10:15	<b>Re-defining high-risk SCC</b> Michael Migden (Houston, United States)
D3T03.2B	10:35	<b>Biological markers in the management of SCC</b> Javier Canueto Alvarez (Salamanca, Spain)
D3T03.2C	10:55	<b>How to manage facial SCC</b> Roland Kaufmann (Frankfurt, Germany)
D3T03.2D	11:15	<b>Non-surgical treatment of SCC</b> Enrico Zelin (Trieste, Italy)
D3T03.2E	11:35	<b>Discussion, Q&amp;A</b>



**FRIDAY 13 OCTOBER 2023**

**UPDATES**

**ROOM 3**

**D3T03.3 14:15 - 15:45 MERKEL CELL CARCINOMA AND CUTANEOUS SARCOMAS**

**Chairs:** Mahtab Samimi (Tours, France)  
Thomas Eigentler (Tubingen, Germany)

**D3T03.3A 14:15 Recent scientific developments in Merkel cell carcinoma**  
Mahtab Samimi (Tours, France)

**D3T03.3B 14:35 Management of Merkel cell carcinoma**  
Thomas Eigentler (Tubingen, Germany)

**D1T03.3C 14:55 New approaches in angiosarcoma**  
Robin J. Young (Sheffield, United Kingdom)

**D3T03.3D 15:15 What is new in the management of soft tissue sarcoma**  
Speaker TBC

**D3T03.3E 15:35 Discussion, Q&A**

**UPDATES**

**ROOM 3**

**D3T03.4 16:00 - 17:30 CUTANEOUS LYMPHOMAS**

**Chairs:** Werner Kempf (Zürich, Switzerland)  
Maarten Vermeer (Leiden, Netherlands)

**D3T03.4A 16:00 New developments in skin-directed treatments of cutaneous T-cell lymphoma**  
Shamir Geller (New York, United States)

**D3T03.4B 16:20 Update in management of cutaneous B-cell lymphomas**  
Pablo Luis Ortiz-Romero (Madrid, Spain)

**D3T03.4C 16:40 The importance of assessing blood tumour burden in cutaneous T-cell lymphoma**  
Maarten Vermeer (Leiden, Netherlands)

**D3T03.4D 17:00 Pseudolymphomas**  
Werner Kempf (Zürich, Switzerland)

**D3T03.4E 17:20 Discussion, Q&A**



## FRIDAY 13 OCTOBER 2023

## UPDATES

## ROOM 4

<b>D3T04.1</b>	<b>08:30 - 10:00</b>	<b>BULLOUS DISEASES</b>
	Chairs:	Luca Borradori (Bern, Switzerland) Teea Salmi (Tampere, Finland)
D3T04.1A	8:30	<b>New diagnostic markers in dermatitis herpetiformis</b> Teea Salmi (Tampere, Finland)
D3T04.1B	8:50	<b>Managing bullous dermatoses in the elderly</b> Luca Borradori (Bern, Switzerland)
D3T04.1C	9:10	<b>IgA bullous dermatosis in childhood and adults</b> Emiliano Antiga (Florence, Italy)
D3T04.1D	9:30	<b>Mucous membrane pemphigoid</b> Aikaterini Patsatsi (Thessaloniki, Greece)
D3T04.1E	9:50	<b>Discussion, Q&amp;A</b>

## UPDATES

## ROOM 4

<b>D3T04.2</b>	<b>10:15 - 11:45</b>	<b>BULLOUS DISEASES</b>
	Chairs:	Michael Hertl (Marburg, Germany) Barbara Horvath (Groningen, Netherlands)
D3T04.2A	10:15	<b>Challenges of anti-PD1-induced pemphigoids</b> Dario Didona (Marburg, Germany)
D3T04.2B	10:35	<b>When to screen for malignancy</b> Barbara Horvath (Groningen, Netherlands)
D3T04.2C	10:55	<b>Rituximab in pemphigus and pemphigoid</b> Michael Hertl (Marburg, Germany)
D3T04.2D	11:15	<b>New drugs on the horizon</b> Enno Schmidt (Lübeck, Germany)
D3T04.2E	11:35	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

UPDATES

ROOM 4

<b>D3T04.3</b>	<b>14:15 - 15:45</b>	<b>CUTANEOUS LUPUS ERYTHEMATOSUS</b>
	Chairs:	Margarida Gonçalo (Coimbra, Portugal) Miloš Nikolić (Belgrade, Serbia)
D3T04.3A	14:15	<b>New insights into pathophysiology</b> Jörg Wenzel (Bonn, Germany)
D3T04.3B	14:35	<b>Challenging clinical presentations</b> Margarida Gonçalo (Coimbra, Portugal)
D3T04.3C	14:55	<b>Therapeutic algorithms</b> Miloš Nikolić (Belgrade, Serbia)
D3T04.3D	15:15	<b>New drugs</b> Joseph F. Merola (Boston, United States)
D3T04.3E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 4

<b>D3T04.4</b>	<b>16:00 - 17:30</b>	<b>CONNECTIVE TISSUE DISEASES</b>
	Chairs:	Petra De Haes (Leuven, Belgium) Bent Deleuran (Aarhus, Denmark)
D3T04.4A	16:00	<b>Diagnostic and management of dermatomyositis</b> Petra De Haes (Leuven, Belgium)
D3T04.4B	16:20	<b>Antiphospholipid syndrome</b> Ana-Luisa Stefanski (Berlin, Germany)
D3T04.4C	16:40	<b>Nail fold capillaroscopy and dermoscopy</b> Magdalena Zychowska (Rzeszów, Poland)
D3T04.4D	17:00	<b>Management of Raynaud syndrome</b> Bent Deleuran (Aarhus, Denmark)
D3T04.4E	17:20	<b>Discussion, Q&amp;A</b>

## FRIDAY 13 OCTOBER 2023

## UPDATES

## ROOM 5

<b>D3T05.1</b>	<b>08:30 - 10:00</b>	<b>NUTRITION AND DERMATOLOGY</b>
	<b>Chairs:</b>	<b>April W. Armstrong (Los Angeles, United States)</b> <b>Jan-Christoph Simon (Leipzig, Germany)</b>
<b>D3T05.1A</b>	<b>8:30</b>	<b>Which oral nutrients nourish the skin?</b> Apostolos Pappas (Branchburg, NJ, United States)
<b>D3T05.1B</b>	<b>8:50</b>	<b>Short fatty acids in skin inflammation</b> Jan-Christoph Simon (Leipzig, Germany)
<b>D3T05.1C</b>	<b>9:10</b>	<b>Nutrition and psoriasis</b> April W. Armstrong (Los Angeles, United States)
<b>D3T05.1D</b>	<b>9:30</b>	<b>Nutrition and acne</b> Christos C. Zouboulis (Dessau, Germany)
<b>D3T05.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

## UPDATES

## ROOM 5

<b>D3T05.2</b>	<b>10:15 - 11:45</b>	<b>PHOTODERMATOLOGY</b>
	<b>Chairs:</b>	<b>Yolanda Gilaberte Calzada (Zaragoza, Spain)</b> <b>Sally Helen Ibbotson (Dundee, United Kingdom)</b>
<b>D3T05.2A</b>	<b>10:15</b>	<b>Drug-induced photosensitivity</b> Sally Helen Ibbotson (Dundee, United Kingdom)
<b>D3T05.2B</b>	<b>10:35</b>	<b>From photosensitivity to skin cancer</b> Aleksandra Lesiak (Lodz, Poland)
<b>D3T05.2C</b>	<b>10:55</b>	<b>News on Solar urticaria</b> Kirsty Rutter (Manchester, United Kingdom)
<b>D3T05.2D</b>	<b>11:15</b>	<b>New sunscreens</b> Yolanda Gilaberte Calzada (Zaragoza, Spain)
<b>D3T05.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

MISCELLANEOUS

ROOM 5

<b>D3T05.3</b>	<b>14:15 - 15:45</b>	<b>ETHICS, DIVERSITY AND INCLUSION</b>
	<b>Chairs:</b>	<b>Vanda Bondare-Ansberga (Marupe, Latvia)</b> <b>Elizabeth Lazaridou (Thessaloniki, Greece)</b>
<b>D3T05.3A</b>	<b>14:15</b>	<b>Diversity in dermatology education</b> Deborah Maria Gregersen (Jena, Germany)
<b>D3T05.3B</b>	<b>14:35</b>	<b>Ethical issues in cultural diversity</b> Antoine David Petit (Paris, France)
<b>D3T05.3C</b>	<b>14:55</b>	<b>Diversity and equity in children</b> Jui Vyas (Cardiff, United Kingdom)
<b>D3T05.3D</b>	<b>15:15</b>	<b>STD and diversity issues</b> Ilona Hartmane (Riga, Latvia)
<b>D3T05.3E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

UPDATES

ROOM 5

<b>D3T05.4</b>	<b>16:00 - 17:30</b>	<b>GRANULOMATOUS DISEASES</b>
	<b>Chairs:</b>	<b>Emmanuel Laffitte (Geneva, Switzerland)</b> <b>Koenraad De Boulle (Aalst, Belgium)</b>
<b>D3T05.4A</b>	<b>16:00</b>	<b>Infectious granulomatous skin diseases</b> Emmanuel Laffitte (Geneva, Switzerland)
<b>D3T05.4B</b>	<b>16:20</b>	<b>Filler-induced granuloma</b> Koenraad De Boulle (Aalst, Belgium)
<b>D3T05.4C</b>	<b>16:40</b>	<b>Dermoscopy for granulomatous skin diseases</b> Enzo Errichetti (Udine, Italy)
<b>D3T05.4D</b>	<b>17:00</b>	<b>Interstitial granulomatous disease</b> Ramon Pujol (Barcelona, Spain)
<b>D3T05.4E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

UPDATES

ROOM 6

<b>D3T06.1</b>	<b>08:30 - 10:00</b>	<b>TOP ADVANCES IN 2023 PRESENTED BY ESDR</b>
	<b>Chairs:</b>	<b>Neil Rajan (Newcastle upon Tyne, United Kingdom)</b> <b>Eli Sprecher (Tel Aviv, Israel)</b>
D3T06.1A	8:30	<b>From GWAS to patient care – how genetic studies can help in clinical practice</b> Sara Brown (Edinburgh, United Kingdom)
D3T06.1B	8:50	<b>Non-classical monocytes in skin inflammation</b> Knut Schäkel (Heidelberg, Germany)
D3T06.1C	9:10	<b>Fine mapping of cell states in healthy human skin across anatomical sites and basal cell carcinoma</b> Clarisse Ganier (London, United Kingdom)
D3T06.1D	9:30	<b>Therapeutic approaches for genodermatoses based on CRISPR/Cas genome editing</b> Fernando Larcher (Madrid, Spain)
D3T06.1E	9:50	<b>Discussion, Q&amp;A</b>

MISCELLANEOUS

ROOM 6

<b>D3T06.2</b>	<b>10:15 - 11:45</b>	<b>GLOBAL DERMATOLOGY (ILDS)</b>
	<b>Chairs:</b>	<b>Lars E. French (Munich, Germany)</b> <b>Henry W. Lim (Detroit, United States)</b>
D3T06.2A	10:15	<b>Integrating for Impact - Opportunities for dermato-venereology to influence skin health through the WHO neglected tropical disease program</b> Jose Postigo (Geneva, Switzerland)
D3T06.2B	10:35	<b>Global Health Dermatology mentorship - collaborations in training to increase access to care globally</b> Esther Freeman (Boston, United States)
D3T06.2C	10:55	<b>Establishing effective STD care for people on the move</b> Valeska Padovese (Valletta, Malta)
D3T06.2D	11:15	<b>Preventing and reducing skin cancer amongst people with albinism in the tropics</b> Tenganawo Esther Mzumara (Lilongwe, Malawi)
D3T06.2D	11:35	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

UPDATES

ROOM 6

<b>D3T06.3</b>	<b>14:15 - 15:45</b>	<b>THE BEST OF AMERICAN AND EUROPEAN DERMATOLOGY (PART 1)</b>
	Chairs:	Michel Gilliet (Lausanne, Switzerland) Kenneth Tomecki (Cleveland, United States)
D3T06.3A	14:15	The impact of Climate Change on the skin Misha Rosenbach (Philadelphia, United States)
D3T06.3B	14:45	Basal cell carcinoma – what’s new? Alexander Stratigos (Athens, Greece)
D3T06.3C	15:15	Alopecias - diagnosis and management Natasha Mesinkovska (Irvine, United States)

UPDATES

ROOM 6

<b>D3T06.4</b>	<b>16:00 - 17:30</b>	<b>BEST OF EUROPEAN AND AMERICAN DERMATOLOGY (PART 2)</b>
	Chairs:	Michel Gilliet (Lausanne, Switzerland) Kenneth Tomecki (Cleveland, United States)
D3T06.4A	16:00	Bullous diseases – diagnosis and management Michael Hertl (Marburg, Germany)
D3T06.4B	16:30	Pyoderma Gangrenosum Jeffrey Callen (Louisville, KY, United States)
D3T06.4C	17:00	Management of sclerotic skin diseases Sabine Eming (Cologne, Germany)

UPDATES

HALL A7

<b>D3T07.1</b>	<b>08:30 - 10:00</b>	<b>FILLERS II, ADVANCED</b>
	Chairs:	Pierre Andre (Paris, France)
D3T07.1A	8:30	Anatomy of the most dangerous areas for face injections Hugues Cartier (Arras, France)
D3T07.1B	8:50	Medical rhinoplasty: how to get the best result without complication Luigi Leonardo Polla (Geneva, Switzerland)
D3T07.1C	9:10	How to manage the complications of non-permanent fillers Pierre Andre (Paris, France)
D3T07.1D	9:30	Vascular compromise: how manage it with duplex ultrasonography Peter Velthuis (Rotterdam, Netherlands)
D3T07.1E	9:50	Discussion, Q&A

FRIDAY 13 OCTOBER 2023

UPDATES

HALL A7

<b>D3T07.2</b>	<b>10:15 - 11:45</b>	<b>BOTULINUM TOXIN II, ADVANCED</b>
	Chairs:	Hans-Joachim Laubach (Geneva, Switzerland)
D3T07.2A	10:15	<b>Botulinum toxin indications in dermatology</b> Berthold Rzany (Vienna, Austria)
D3T07.2B	10:35	<b>Botulinum toxin indications in basic research and outside dermatology</b> Emanuel Carvalheiro Marques (Prague, Czech Republic)
D3T07.2C	10:55	<b>How to improve your botulinum toxin injection technique for the lower face</b> Christopher Rowland Payne (London, United Kingdom)
D3T07.2D	11:15	<b>Can botulinum toxin be used to improve wound healing?</b> Hugues Cartier (Arras, France)
	11:35	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A7

<b>D3T07.3</b>	<b>14:15 - 15:45</b>	<b>LASERS AND ENERGY-BASED DEVICES II: ADVANCED, INCLUDING COMPLICATIONS MANAGEMENT</b>
	Chairs:	Ashraf Badawi (Oakville, Canada)
D3T07.3A	14:15	<b>Dermatology Lasers updates, 2023</b> Ashraf Badawi (Oakville, Canada)
D3T07.3B	14:35	<b>Laser applications for nail disorders</b> Azzam Alkhalifah (Unayzah, Saudi Arabia)
D3T07.3C	14:55	<b>PDL for 2ry facial telangiectasia</b> Manal Bosseila (Cairo, Egypt)
D3T07.3D	15:15	<b>Combination of soft tissue fillers and lasers &amp; EBDs, from theory to practice</b> Hugues Cartier (Arras, France)
D3T07.3E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A7

<b>D3T07.4</b>	<b>16:00 - 17:30</b>	<b>ENERGY BASED-DEVICES: BODY CONTOURING AND TIGHTENING</b>
	Chairs:	Ines Verner Rashkovsky (Savyon, Israel)
D3T07.4A	16:00	<b>ACOUSTIC SUBCISION: The Latest Treatment For Cellulite</b> Martin Kassir (Dallas, United States)
D3T07.4B	16:20	<b>Integrating Radiofrequency Microneedling and Exosome Technology into an Aesthetic Practice</b> Todd Schlesinger (Charleston, SC, United States)
D3T07.4C	16:40	<b>GLP -1 analogue: challenger of EBD for body contouring</b> Hugues Cartier (Arras, France)
D3T07.4D	17:00	<b>Combining injectables and EBDs for body Contouring</b> Ines Verner Rashkovsky (Savyon, Israel)
	17:20	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

CONTROVERSIES

HALL A3

CONTROVERSIES		CONTROVERSIES V
<b>D3T08.1</b>	<b>08:30 - 10:00</b>	<b>Chairs:</b> Christine Dierickx (Luxembourg, Luxembourg) Ricardo Vieira (Coimbra, Portugal)
<b>D3T08.1A</b>	<b>8:30</b>	<b>Introduction</b> Christine Dierickx (Luxembourg, Luxembourg)
<b>D3T08.1B</b>	<b>8:35</b>	<b>Is there enough evidence for skin tightening with laser? Yes</b> Leonardo Marini (Trieste, Italy)
<b>D3T08.1C</b>	<b>8:50</b>	<b>Is there enough evidence for skin tightening with laser? No</b> Ofir Artzi (Tel Aviv, Israel)
<b>D3T08.1D</b>	<b>9:05</b>	<b>Discussion, Q&amp;A</b>
<b>D3T08.1E</b>	<b>9:15</b>	<b>Introduction</b> Ricardo Vieira (Coimbra, Portugal)
<b>D3T08.1F</b>	<b>9:20</b>	<b>Lentigo Maligna: surgery</b> Joseph Alcalay (Tel Aviv, Israel)
<b>D3T08.1G</b>	<b>9:35</b>	<b>Lentigo Maligna: no surgery</b> Roland Kaufmann (Frankfurt, Germany)
<b>D3T08.1H</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

CONTROVERSIES

HALL A3

CONTROVERSIES		CONTROVERSIES VI
<b>D3T08.2</b>	<b>10:15 - 11:45</b>	<b>Chairs:</b> Eulalia Baselga (Esplugues de Llobregat, Spain) Alexander Stratigos (Athens, Greece)
<b>D3T08.2A</b>	<b>10:15</b>	<b>Introduction</b> Eulalia Baselga (Esplugues de Llobregat, Spain)
<b>D3T08.2B</b>	<b>10:20</b>	<b>The gold standard for the diagnosis of vascular anomalies: imaging</b> Annouk Bisdorff (Paris, France)
<b>D3T08.2C</b>	<b>10:35</b>	<b>The gold standard for the diagnosis of vascular anomalies: pathology</b> Isabel Colmenero (Madrid, Spain)
<b>D3T08.2D</b>	<b>10:50</b>	<b>Discussion, Q&amp;A</b>
<b>D3T08.2E</b>	<b>11:00</b>	<b>Introduction</b> Alexander Stratigos (Athens, Greece)
<b>D3T08.2F</b>	<b>11:05</b>	<b>Do we need to treat actinic keratosis? Yes</b> Thomas Dirschka (Wuppertal, Germany)
<b>D3T08.2G</b>	<b>11:20</b>	<b>Do we need to treat actinic keratosis? No</b> Lidija Kandolf-Sekulovic (Belgrade, Serbia)
<b>D3T08.2H</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>



FRIDAY 13 OCTOBER 2023

CONTROVERSIES


HALL A3

D3T08.3		14:15 - 15:45	CONTROVERSIES VII
	Chairs:		Christos C. Zouboulis (Dessau, Germany) Martin Röcken (Tübingen, Germany)
D3T08.3A	14:15		<b>Introduction</b> Christos C. Zouboulis (Dessau, Germany)
D3T08.3B	14:20		<b>Laboratory monitoring on isotretinoin : yes</b> Clio Dessinioti (Athens, Greece)
D3T08.3C	14:35		<b>Laboratory monitoring on isotretinoin: No</b> Ruta Ganceviciene (Vilnius, Lithuania)
D3T08.3D	14:50		<b>Discussion, Q&amp;A</b>
D3T08.3E	15:00		<b>Introduction</b> Martin Röcken (Tübingen, Germany)
D3T08.3F	15:05		<b>Hidradenitis suppurativa: "biologics"</b> Robert Gniadecki (Copenhagen, Denmark)
D3T08.3G	15:20		<b>Hidradenitis suppurativa: "surgery"</b> Klemens Rappersberger (Vienna, Austria)
D3T08.3H	15:35		<b>Discussion, Q&amp;A</b>

CONTROVERSIES

HALL A3

D3T08.4		16:00 - 17:30	CONTROVERSIES VIII
	Chairs:		Margarida Gonçalo (Coimbra, Portugal) Emmanuella Guenova (Lausanne, Switzerland)
D3T08.4A	16:00		<b>Introduction</b> Emmanuella Guenova (Lausanne, Switzerland)
D3T08.4B	16:05		<b>Early Mycosis Fungoides: does treatment make the difference: Yes</b> Adele de Masson (Paris, France)
D3T08.4C	16:20		<b>Early Mycosis Fungoides: does treatment make the difference: No</b> Chalid Assaf (Krefeld, Germany)
D3T08.4D	16:35		<b>Discussion, Q&amp;A</b>
D3T08.4E	16:45		<b>Introduction</b> Margarida Gonçalo (Coimbra, Portugal)
D3T08.4F	16:50		<b>Immunosuppression for toxic epidermal necrolysis: yes</b> Michael Ardern-Jones (Southampton, United Kingdom)
D3T08.4G	17:05		<b>Immunosuppression for toxic epidermal necrolysis: no</b> Maja Mockenhaupt (Freiburg, Germany)
D3T08.4H	17:20		<b>Discussion, Q&amp;A</b>



FRIDAY 13 OCTOBER 2023

TRAINING AND  
EDUCATION

HALL A1

**D3T09.1 08:30 - 10:00 IMMUNOLOGY BASICS FOR DERMATOLOGIST**

Chairs: Jeremy Di Domizio (Lausanne, Switzerland)  
Gudrun Ratzinger (Innsbruck, Austria)

D3T09.1A 8:30 Innate immunity of the skin  
Jeremy Di Domizio (Lausanne, Switzerland)

D3T09.1B 8:50 Dendritic cells and antigen presentation  
Gudrun Ratzinger (Innsbruck, Austria)

D3T09.1C 9:10 T-cell subsets immunity  
Tiago R Matos (Amsterdam, Netherlands)

D3T09.1D 9:30 B-cell and antibody production  
Katie Lacy (London, United Kingdom)

D3T09.1E 9:50 Discussion, Q&A

TRAINING AND  
EDUCATION

HALL A1

**D3T09.2 10:15 - 11:45 TRANSLATIONAL IMMUNOLOGY FOR DERMATOLOGIST**

Chairs: Rolland Gyulai (Pécs, Hungary)  
Karoline Krause (Berlin, Germany)

D3T09.2A 10:15 Cancer immunology and basis of immunotherapy  
Sophia Karagiannis (London, United Kingdom)

D3T09.2B 10:35 Antibody-mediated skin diseases  
Rolland Gyulai (Pécs, Hungary)

D3T09.2C 10:55 Autoinflammation and neutrophilic skin diseases  
Karoline Krause (Berlin, Germany)

D3T09.2D 11:15 Chronic inflammatory T-cell mediated skin diseases  
Christoph Schlapbach (Bern, Switzerland)

D3T09.2E 11:35 Discussion, Q&A

FRIDAY 13 OCTOBER 2023

TRAINING AND  
EDUCATION


HALL A1

<b>D3T09.3</b>	<b>14:15 - 15:45</b>	<b>PSORIASIS</b>
	Chairs:	Ulrich Mrowietz (Kiel, Germany) Julia-Tatjana Maul (Zurich, Switzerland)
D3T09.3A	14:15	<b>Psoriasis as a systemic disease</b> Ulrich Mrowietz (Kiel, Germany)
D3T09.3B	14:35	<b>The challenge of psoriasis on difficult locations</b> Nejib Doss (Tunis, Tunisia)
D3T09.3C	14:55	<b>Appropriate treatment choice for particular situations</b> Julia-Tatjana Maul (Zurich, Switzerland)
D3T09.3D	15:15	<b>Evolving therapeutic landscape</b> Andreas Pinter (Frankfurt am Main, Germany)
D3T09.3E	15:35	<b>Discussion, Q&amp;A</b>

TRAINING AND  
EDUCATION

HALL A1

<b>D3T09.4</b>	<b>16:00 - 17:30</b>	<b>AUTOIMMUNE DISORDERS</b>
	Chairs:	Branka Marinovic (Zagreb, Croatia) Stefan Beissert (Dresden, Germany)
D3T09.4A	16:00	<b>Dermatomyositis</b> Branka Marinovic (Zagreb, Croatia)
D3T09.4B	16:20	<b>Lupus erythematosus</b> Stefan Beissert (Dresden, Germany)
D3T09.4C	16:40	<b>Vitiligo</b> Jaime Piquero-Casals (Barcelona, Spain)
D3T09.4D	17:00	<b>Alopecia areata</b> David Saceda Corralo (Madrid, Spain)



FRIDAY 13 OCTOBER 2023

TRAINING AND  
EDUCATION

HALL A2

D3T10.1		08:30 - 10:00	<b>BULLOUS DISEASES</b>
	Chairs:		Enno Schmidt (Lübeck, Germany) Giovanna Zambruno (Rome, Italy)
D3T10.1A	8:30		<b>Inherited blistering diseases</b> Leena K. Bruckner-Tuderman (Freiburg, Germany)
D3T10.1B	8:50		<b>Pemphigus vulgaris</b> Giovanna Zambruno (Rome, Italy)
D3T10.1C	9:10		<b>Bullous pemphigoid</b> Frederic Caux (Bobigny, France)
D3T10.1D	9:30		<b>Dermatitis herpetiformis</b> Enno Schmidt (Lübeck, Germany)
D3T10.1E	9:50		<b>Discussion, Q&amp;A</b>

TRAINING AND  
EDUCATION

HALL A2

D3T10.2		10:15 - 11:45	<b>SURGICAL THERAPY</b>
	Chairs:		Anthony Benedetto (Philadelphia, PA, United States) Severin Läuchli (Zurich, Switzerland)
D3T10.2A	10:15		<b>Suture techniques</b> Anthony Benedetto (Philadelphia, PA, United States)
D3T10.2B	10:35		<b>Grafts and flaps</b> An van Laethem (Leuven, Belgium)
D3T10.2C	10:55		<b>Nail surgery</b> Eckart Haneke (Freiburg, Germany)
D3T10.2D	11:15		<b>Pre- and post-surgery considerations</b> Severin Läuchli (Zurich, Switzerland)
D3T10.2E	11:35		<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

TRAINING AND  
EDUCATION

HALL A2

<b>D3T10.3</b>	<b>14:15 - 15:45</b>	<b>DERMATOPATHOLOGY</b>
	Chairs:	Kilian Eyerich (Freiburg, Germany) Jose Carlos Cardoso (Coimbra, Portugal)
D3T10.3A	14:15	<b>Recognising skin cancer</b> Franco Rongioletti (Milan, Italy)
D3T10.3B	14:35	<b>Patterns of inflammatory tissue reactions</b> Kilian Eyerich (Freiburg, Germany)
D3T10.3C	14:55	<b>Pattern recognition in granulomatous tissue reactions</b> Jose Carlos Cardoso (Coimbra, Portugal)
D3T10.3D	15:15	<b>Immuno-histochemistry and immunofluorescence</b> Jivko Kamarachev (Zurich, Switzerland)
D3T10.3E	15:35	<b>Discussion, Q&amp;A</b>

TRAINING AND  
EDUCATION

HALL A2

<b>D3T10.4</b>	<b>16:00 - 17:30</b>	<b>HIDRADENITIS SUPPURATIVA AND NEUTROPHILIC DISEASES</b>
	Chairs:	Antonio Martorell Calatayud (Valencia, Spain) Mariano Suppa (Brussels, Belgium)
D3T10.4A	16:00	<b>Medical management with biologics</b> Hessel van der Zee (Rotterdam, Netherlands)
D3T10.4B	16:20	<b>Surgical management of HS</b> Antonio Martorell Calatayud (Valencia, Spain)
D3T10.4C	16:40	<b>Sweet syndrome</b> Georgios Nikolakis (Dessau-Rosslau, Germany)
D3T10.4D	17:00	<b>Pyoderma gangrenosum</b> Mariano Suppa (Brussels, Belgium)
D3T10.4E	17:20	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

UPDATES

HALL A5

<b>D3T11.1</b>	<b>08:30 - 10:00</b>	<b>SCARS</b>
	Chairs:	Klaus Fritz (Landau, Germany) Alzbeta Smetanova (Prague, Czech Republic)
<b>D3T11.1A</b>	<b>8:30</b>	<b>Surgical correction of scars</b> Klaus Eisendle (Bolzano, Italy)
<b>D3T11.1B</b>	<b>8:50</b>	<b>Btx for keloids and hypertrophic scars</b> Berthold Rzany (Wien, Austria)
<b>D3T11.1C</b>	<b>9:10</b>	<b>Keloid vs. hypertrophic scars</b> Alzbeta Smetanova (Prague, Czech Republic)
<b>D3T11.1D</b>	<b>9:30</b>	<b>Which laser for which scar</b> Klaus Fritz (Landau, Germany)
<b>D3T11.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A5

<b>D3T11.2</b>	<b>10:15 - 11:45</b>	<b>WOUND HEALING</b>
	Chairs:	Kirsi Isoherranen (Helsinki, Finland) Elena Conde (Madrid, Spain)
<b>D3T11.2A</b>	<b>10:15</b>	<b>Dermatologist and the diabetic foot management</b> Malou van Zanten (Rotterdam, Netherlands)
<b>D3T11.2B</b>	<b>10:35</b>	<b>Practical pearls in the treatment of decubitus</b> Elena Conde (Madrid, Spain)
<b>D3T11.2C</b>	<b>10:55</b>	<b>Atypical ulcers</b> Kirsi Isoherranen (Helsinki, Finland)
<b>D3T11.2D</b>	<b>11:15</b>	<b>Contact dermatitis and ulcer treatment</b> Magdalena Czarnecka-Operacz (Poznan, Poland)
<b>D3T11.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

UPDATES

HALL A5

<b>D3T11.3</b>	<b>14:15 - 15:45</b>	<b>NEUTROPHILIC DISEASES</b>
	<b>Chairs:</b>	Amir Yazdi (Aachen, Germany) Emmanuella Guenova (Lausanne, Switzerland)
D3T11.3A	14:15	<b>Neutrophilic diseases and autoinflammation: what is the pathogenic link?</b> Amir Yazdi (Aachen, Germany)
D3T11.3B	14:35	<b>Cutaneous manifestations of neutrophilic diseases</b> Angelo Valerio Marzano (Milan, Italy)
D3T11.3C	14:55	<b>VEXAS-Syndrome</b> Konstantinos Krasagakis (Heraklion, Greece)
D3T11.3D	15:15	<b>Update on treatment of pyoderma gangrenosum</b> Emmanuella Guenova (Lausanne, Switzerland)
D3T11.3E	15:35	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A5

<b>D3T11.4</b>	<b>16:00 - 17:30</b>	<b>LIFESTYLE AND SKIN DISORDERS</b>
	<b>Chairs:</b>	Brian Kirby (Dublin, Ireland)
D3T11.4A	16:00	<b>Alcohol, smoking and psoriasis</b> Brian Kirby (Dublin, Ireland)
D3T11.4B	16:20	<b>Very-low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity</b> Ludovica Verde (Naples, Italy)
D3T11.4C	16:40	<b>Exercise in skin health</b> Marcus Schmitt-Egenolf (Umeå, Sweden)
D3T11.4D	17:00	<b>Dietary supplements for photoprotection and skin cancer prevention</b> Giovanni Pellacani (Rome, Italy)
D3T11.4E	17:20	<b>Discussion, Q&amp;A</b>

## FRIDAY 13 OCTOBER 2023

## UPDATES

## HALL A4

<b>D3T12.1</b>	<b>08:30 - 10:00</b>	<b>BACTERIAL SKIN INFECTIONS</b>
	Chairs:	Omar Lupi (Rio De Janeiro, Brazil) Mateja Dolenc Voljc (Ljubljana, Slovenia)
D3T12.1A	8:30	Managing recurrent cellulitis and skin abscesses Omar Lupi (Rio De Janeiro, Brazil)
D3T12.1B	8:50	Is TB testing for the newer biologicals still necessary? Mateja Dolenc Voljc (Ljubljana, Slovenia)
D3T12.1C	9:10	Borreliosis and Lyme disease Speaker TBC
D3T12.1D	9:30	Surgical site infections prevention and management Veronica Ruiz Salas (Barcelona, Spain)
D3T12.1E	9:50	Discussion, Q&A

## UPDATES

## HALL A4

<b>D3T12.2</b>	<b>10:15 - 11:45</b>	<b>VIRAL SKIN INFECTIONS</b>
	Chairs:	Mihael Skerlev (Zagreb, Croatia) TBC
D3T12.2A	10:15	Should we worry about Monkeypox? Why or why not? José Riera Monroig (Barcelona, Spain)
D3T12.2B	10:35	A future outlook on COVID-19 Angelo Valerio Marzano (Milan, Italy)
D3T12.2C	10:55	The advantages of HPV vaccination Mihael Skerlev (Zagreb, Croatia)
D3T12.2D	11:15	Herpes zoster vaccination Arjen Fokko Nikkels (Liege, Belgium)
D3T12.2E	11:35	Discussion, Q&A



## FRIDAY 13 OCTOBER 2023

## UPDATES

## HALL A4

<b>D3T12.3</b>	<b>14:15 - 15:45</b>	<b>FUNGAL SKIN INFECTIONS</b>
	Chairs:	Roderick James Hay (London, United Kingdom) Ditte Marie Saunte (Virum, Denmark)
D3T12.3A	14:15	<b>The spread of resistant tinea</b> Roderick James Hay (London, United Kingdom)
D3T12.3B	14:35	<b>Malassezia-related skin diseases</b> Ditte Marie Saunte (Virum, Denmark)
D3T12.3C	14:55	<b>Onychomycosis by non-dermatophytes</b> Stamatis Gregoriou (Athens, Greece)
D3T12.3D	15:15	<b>Deep fungal infections</b> Omar Lupi (Rio De Janeiro, Brazil)
D3T12.3E	15:35	<b>Discussion, Q&amp;A</b>

## UPDATES

## HALL A4

<b>D3T12.4</b>	<b>16:00 - 17:30</b>	<b>ENDO AND ECTOPARASITIC SKIN INFECTIONS</b>
	Chairs:	Olivier Chosidow (Créteil, France) Carmen Maria Salavastru (Bucharest, Romania)
D3T12.4A	16:00	<b>Got the travel bug? Diagnostic and management approach</b> Kenneth Tomecki (Cleveland, United States)
D3T12.4B	16:20	<b>Scabies goes evidence-based</b> Olivier Chosidow (Créteil, France)
D3T12.4C	16:40	<b>Challenges in diagnosis and management of Leishmaniasis</b> Clea Melenotte (Paris, France)
D3T12.4D	17:00	<b>Management of resistant pediculosis</b> Carmen Maria Salavastru (Bucharest, Romania)
D3T12.4E	17:20	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

FREE COMMUNICATIONS M1+2

FC05	08:30 - 10:00	FREE COMMUNICATIONS V
	Chairs:	Mahtab Samimi (Tours, France) Piergiacomo Calzavara-Pinton (Brescia, Italy)
FC 05.1	8:30	<b>ANB032, a novel BTLA agonist monoclonal antibody, inhibits T cell proliferation, reduces inflammatory cytokines, and down modulates BTLA expression on circulating T and B cells: Results from a first-in-human Phase 1 study</b> Bruce Randazzo (San Diego, United States)
FC 05.2	8:40	<b>Effect of high-dose subcutaneous spesolimab on skin manifestations: Results from the pivotal Effisayil 2 trial of flare prevention in generalized pustular psoriasis</b> Matthias Augustin (Hamburg, Germany)
FC 05.3	8:50	<b>Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study</b> Laura Loman (Groningen, Netherlands)
FC 05.4	9:00	<b>Bimekizumab efficacy and safety in patients with active psoriatic arthritis and psoriasis: 52-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies</b> Diamant Thaçi (Luebeck, Germany)
FC 05.5	9:10	<b>Deucravacitinib significantly improves symptoms and signs of psoriasis in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials</b>
FC 05.6	9:20	<b>Deucravacitinib, an oral selective tyrosine kinase 2 inhibitor, vs placebo and apremilast in moderate to severe plaque psoriasis: Subgroup analyses of phase 3 studies examining Psoriasis Symptom and Sign Diary and Dermatology Life Quality Index scores</b>
FC 05.7	9:30	<b>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, improves outcomes in plaque, generalized pustular, and erythrodermic psoriasis in Japan: results from the POETYK PSO-4 study</b>
FC 05.8	9:40	<b>Checkpoint inhibitor associated bullous cutaneous immune related adverse events: a multi-centre observational study</b> Anusuya Kawsar (London, United Kingdom)
FC 05.9	9:50	<b>Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials</b> Kristian Reich (Hamburg, Germany)

## FRIDAY 13 OCTOBER 2023

## FREE COMMUNICATIONS M1+2

10:15 - 11:45

## FREE COMMUNICATIONS VI

Chairs:

Clio Dessinioti (Athens, Greece)

Matilde Iorizzo (Lugano, Switzerland)

FC 06.1	10:15	<b>Long-term clinical effectiveness and reasons for discontinuation of dupilumab treatment in patients with atopic dermatitis; 5-year results from the BioDay registry</b> Celeste Boesjes (Utrecht, Netherlands)
FC 06.2	10:25	<b>Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control</b>
FC 06.3	10:35	<b>Downstream effects of IL-13R alpha 1 blockade on Th2-driven inflammation and Th1 immune axis activation in atopic dermatitis</b> Ferda Cevikbas (Menlo Park CA, United States)
FC 06.4	10:45	<b>Senile atopic dermatitis - epidemiology and features of the clinical picture</b>
FC 06.5	10:55	<b>Dupilumab provides sustained effectiveness in patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice Bioday Registry</b> Marie-Louise Anna Schuttelaar (Groningen, Netherlands)
FC 06.6	11:05	<b>Raising the Bar of Efficacy in Atopic Dermatitis: Lebrikizumab Provides Sustained Deep Skin and Itch Relief Up to 52 Weeks</b> Eric Simpson (Portland, United States)
FC 06.7	11:15	<b>Efficacy and safety of lebrikizumab in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvan tage)</b> Richard B. Warren (Manchester, United Kingdom)
FC 06.8	11:25	<b>Sensitive areas in atopic dermatitis: is Dupilumab less effective on head and neck? A single-centre retrospective study.</b> Gabriele Perego (Castello di Brianza, Italy) Silvia Ferrucci (Milano, Italy)
FC 06.9	11:35	<b>The impact of molecular diagnostics in hand dermatoses</b> Philipp Bentz (Heidelberg, Germany)

FRIDAY 13 OCTOBER 2023

FREE COMMUNICATIONS M1+2

14:15 - 15:45

FREE COMMUNICATIONS VII

Chairs:

Nicolas Kluger (Helsinki, Finland)

Alexander Katoulis (Athens, Greece)

FC 07.1	14:15	Overview of the impact of skin diseases in the world in 2023 Data from the “All Skin, All Colour, All Dermatoses” study: the ALL PROJECT
FC 07.2	14:25	Stigma in patients with pigmentary disorders: results of an international study
FC 07.3	14:35	Dupilumab is Efficacious in Patients with Prurigo Nodularis Regardless of Stable Use of Topical Corticosteroids and Topical Calcineurin Inhibitors: Pooled Results from Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2)
FC 07.4	14:45	Oral Nalbuphine Extended-Release Was Well Tolerated Over 52 Weeks of Treatment During the Open-Label Extension of the PRISM Study Elke Weisshaar (Heidelberg, Germany)
FC 07.5	14:55	Symptoms of Neuropathic Itch: A Report From the Neuropathic Itch Patient Survey (NIRVE) Brian S. Kim (New York, United States)
FC 07.6	15:05	Dupilumab is Efficacious in Patients with Prurigo Nodularis Regardless of Baseline Lesion Severity: Pooled Results from Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2) Sonja Ständer (Münster, Germany)
FC 07.7	15:15	Remibrutinib provides fast and clinically important improvement of CSU disease activity: Post-hoc analysis from the Phase 2b study
FC 07.8	15:25	Remibrutinib (LOU064) treatment decreases disease activity in patients with chronic spontaneous urticaria: Post hoc analysis from the Phase 2b study
FC 07.9	15:35	Remibrutinib, an oral, highly selective BTKi in development for CSU: Analysis of safety data from the completed Phase 2 studies in inflammatory immune-mediated diseases

## FRIDAY 13 OCTOBER 2023

## FREE COMMUNICATIONS M1+2

16:00 - 17:30

## FREE COMMUNICATIONS VIII

Chairs:

Mihaela Leventer (Bucharest, Romania)

Lajos Kemény (Szeged, Hungary)

FC 08.1	16:00	<b>Early intervention with secukinumab may affect the establishment of tissue memory in psoriasis: Results from a DNA methylation analysis</b> Curdin Conrad (Lausanne, Switzerland)
FC 08.2	16:10	<b>JNJ-77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients With Plaque Psoriasis: Results From the Phase 2, FRONTIER 1 Study</b> Andreas Pinter (Frankfurt am Main, Germany)
FC 08.3	16:20	<b>Flare frequency and duration in patients with generalized pustular psoriasis (GPP)</b>
FC 08.4	16:30	<b>Effects of Apremilast on Quality of Life and Skin Clearance in Men and Women With Genital Psoriasis: Subgroup Analysis From the Phase 3 DISCREET Study</b> Joseph F. Merola (Boston, United States)
FC 08.5	16:40	<b>Treatment-free period of more than 1 year in guselkumab super responders with short disease duration of psoriasis: withdrawal data from the GUIDE trial</b> Knut Schäkel (Heidelberg, Germany)
FC 08.6	16:50	<b>Ixekizumab Trough Concentrations in Psoriasis: Paving the Way towards Personalized Therapy - A Cohort Study</b> Lisa Schots (Ghent, Belgium)
FC 08.7	17:00	<b>Roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARREC-TOR trial: Efficacy, patient-reported outcomes, and safety</b> Melinda Gooderham (Peterborough, Canada)
FC 08.8	17:10	<b>Risk of Developing Inflammatory Arthritis in Psoriasis Patients Initiating Treatment with Biologics: A Population Based Analysis</b>
FC 08.9	17:20	<b>A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: Efficacy of Overall and Scalp Psoriasis Responses from FRONTIER 1</b> Robert Bissonnette (Montreal, Canada)

FRIDAY 13 OCTOBER 2023

MISCELLANEOUS

M6+7

<b>D3T14.1</b>	<b>08:30 - 10:00</b>	<b>TATTOOS AND PERMANENT MAKE-UP</b>
	<b>Chairs:</b>	<b>Christa de Cuyper (Bruges, Belgium)</b>
<b>D3T14.1A</b>	<b>8:30</b>	<b>Permanent Make-Up, indications and complications</b> Christa de Cuyper (Bruges, Belgium)
<b>D3T14.1B</b>	<b>8:50</b>	<b>What about Tattoos and Moles?</b> Nicolas Kluger (Helsinki, Finland)
<b>D3T14.1C</b>	<b>9:10</b>	<b>Body art: how to avoid infections?</b> Aneta Szczerkowska-Dobosz (Gdansk, Poland)
<b>D3T14.1D</b>	<b>9:30</b>	<b>Tattoos and sun; the BEACH study</b> Katrina Hutton Carlsen (Copenhagen, Denmark)
<b>D3T14.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

MISCELLANEOUS

M6+7

<b>D3T14.2</b>	<b>10:15 - 11:45</b>	<b>SKIN CANCER: INNOVATIONS</b>
	<b>Chairs:</b>	<b>Marlies Wakkee (Rotterdam, Netherlands)</b> <b>Sheila Ryan (Co Limerick, Ireland)</b>
<b>D3T14.2A</b>	<b>10:15</b>	<b>The impact of an AI-based App for skin detection: a clinical practice evaluation</b> Marlies Wakkee (Rotterdam, Netherlands)
<b>D3T14.2B</b>	<b>10:35</b>	<b>Overview of skin cancers</b> Arjen Fokko Nikkels (Liege, Belgium)
<b>D3T14.2C</b>	<b>10:55</b>	<b>Lesion directed screening</b> Amber Shen (Ghent, Belgium)
<b>D3T14.2D</b>	<b>11:15</b>	<b>Health Care Workers ... a hidden resource in sun-awareness</b> Evelyn Dooley Power (Limerick, Ireland)
<b>D3T14.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

MISCELLANEOUS

M6+7


<b>D3T14.3</b>	<b>14:15 - 15:45</b>	<b>PEDIATRIC INSIGHTS</b>
	<b>Chairs:</b>	<b>Kathrin Thormann (Bern, Switzerland)</b>
<b>D3T14.3A</b>	<b>14:15</b>	<b>Alopecia Areata in children</b> Ulrike Blume-Peytavi (Berlin, Germany)
<b>D3T14.3B</b>	<b>14:35</b>	<b>Non-pharmacological interventions for eczema to distract children from itch -</b> Heidi Singleton (Bournemouth, United Kingdom)
<b>D3T14.3C</b>	<b>14:55</b>	<b>Diaper dermatitis</b> Kathrin Thormann (Bern, Switzerland)
<b>D3T14.3D</b>	<b>15:15</b>	<b>AD in young adults</b> Susanne Lundin (Stockholm, Sweden)
<b>D3T14.3E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

FRIDAY 13 OCTOBER 2023

MISCELLANEOUS

M6+7

MISCELLANEOUS		M6+7
<b>D3T14.4</b>	<b>16:00 - 17:30</b>	<b>DERMATOLOGICAL THERAPIES</b>
	<b>Chairs:</b>	<b>Sheila Ryan (Co Limerick, Ireland)</b>
<b>D3T14.4A</b>	<b>16:00</b>	<b>Patient's Experiences of Conventional PDT and Simulated Daylight PDT</b> Alexandra Sjöholm (Mölndal, Sweden)
<b>D3T14.4B</b>	<b>16:20</b>	<b>JAK inhibitors</b> Luis Dias (Lisboa, Portugal)
<b>D3T14.4C</b>	<b>16:40</b>	<b>Atopic dermatitis in children and topical treatment. Same procedures and patient information at all treatment sites in Norway</b> Teresa Løvold Berents (Oslo, Norway)
<b>D3T14.4D</b>	<b>17:00</b>	<b>Nursing care of patients with Steven Johnson syndrome</b> Sheila Ryan (Co Limerick, Ireland)
	<b>17:20</b>	<b>Discussion, Q&amp;A</b>



SATURDAY 14 OCTOBER 2023

**PROGRAMME AT A GLANCE**

[CLICK TO VIEW THE INTERACTIVE PROGRAMME](#)

Room name	Hall A8	Hall A1	Hall A2	Hall A3	Hall A4	Hall A5
Session type	Updates / Plenary Lectures / Subspecialty sessions	Updates/ Subspecialty sessions	Updates/ Subspecialty sessions	Updates/ Subspecialty sessions	Updates / Subspecialty sessions	Aesthetic
Track no.	1	2	3	4	5	6
08.30 - 10.00	Acne	Pruritus and Prurigo	Hypopigmentation	Varicose veins	Visual literacy in Dermatology	Peeling
10.00 - 10.15						
10.15 - 11.45	Acne	Pruritus and Prurigo	Hyperpigmentation	Chronic leg ulcers	Hot topics in Dermatology selected by the EADV President	Aesthetic dermatology for medical indications
11.45 - 12.00						
12.00 - 13.00	PL-C Plenary Lectures 7-8-9					
13.00 - 14.00	Industry sessions (Lunch satellite symposia)					
14.00 - 14.15						
14.15 - 15.45	ESLD	IEC - International Eczema Council	EURO-PDT	MEIDAM - Middle East International Dermatology and Aesthetic Medicine	IPS - International Peeling Society	Scars treatments
15.45 - 16.00						
16.00 - 17.30						Combination treatments in aesthetic medicine



SATURDAY 14 OCTOBER 2023

PROGRAMME AT A GLANCE

CLICK TO VIEW THE INTERACTIVE PROGRAMME

Room name	Hall A7	M1+2	M6+7
Session type	Training and Education / Subspecialty sessions	Training and Education / Subspecialty sessions	Updates/ Subspecialty sessions
Track no.	7	8	9
08.30 - 10.00	Infectious diseases	Paediatric dermatology	Red flags and emergencies in dermatology
10.00 - 10.15			
10.15 - 11.45	STIs	Paediatric dermatology	Psychodermatology
11.45 - 12.00			
12.00 - 13.00			
13.00 - 14.00	Industry sessions (Lunch satellite symposia)		
14.00 - 14.15			
14.15 - 15.45	ESMS - European Society for Micrographic Surgery	EWDVS - European Women's Dermatologic and Venereologic Society	SSDDS - Saudi Society of Dermatology and Dermatologic Surgery
15.45 - 16.00			
16.00 - 17.30			

SATURDAY 14 OCTOBER 2023

PLENARY

HALL A8

PLC	12:00 - 13:00	PLENARY LECTURES C
	Chairs:	Michel Gilliet (Lausanne, Switzerland) Carmen Maria Salavastru (Bucharest, Romania)
PLC-01	12:00	ESDR plenary lecture: 'Decoding healthy and inflammatory skin disease at single cell resolution' Muzlifah Haniffa (Cambridge, United Kingdom)
PLC-02	12:20	René Touraine plenary lecture: "Paediatric mastocytoses" Christine Bodemer (Paris, France)
PLC-03	12:40	Diagnostic and therapeutic pitfalls in skin of colour Andrew F. Alexis (New York, United States)

UPDATES

HALL A8

D4T01.1	08:30 - 10:00	ACNE
	Chairs:	Alberto Mota (Porto, Portugal) Falk Ochsendorf (Frankfurt, Germany)
D4T01.1A	8:30	Prepubertal acne Ediléia Bagatin (Sao Paulo, Brazil)
D4T01.1B	8:50	How to manage acne during pregnancy Falk Ochsendorf (Frankfurt, Germany)
D4T01.1C	9:10	Truncal acne: from the diagnosis to the treatment Alberto Mota (Porto, Portugal)
D4T01.1D	9:30	Prevention and treatment of atrophic scars? Hassan Galadari (Dubai, United Arab Emirates)
D4T01.1E	9:50	Discussion, Q&A

UPDATES

HALL A8

D4T01.2	10:15 - 11:45	ACNE
	Chairs:	Clio Dessinioti (Athens, Greece) Brigitte Dréno (Nantes, France)
D4T01.2A	10:15	Is there still a place for antibiotics in acne? Clio Dessinioti (Athens, Greece)
D4T01.2B	10:35	Dietary supplementation: an alternative treatment in acne Dae Hun Suh (Seoul, Korea, Rep. of South)
D4T01.2C	10:55	Can microbiome manipulation control inflammatory acne? Brigitte Dréno (Nantes, France)
D4T01.2D	11:15	Which patient benefits from low doses of isotretinoin Jose Luis Lopez-Estebarez (Madrid, Spain)
D4T01.2E	11:35	Discussion, Q&A

## SATURDAY 14 OCTOBER 2023

## UPDATES

## HALL A1

<b>D4T02.1</b>	<b>08:30 - 10:00</b>	<b>PRURITUS AND PRURIGO</b>
	<b>Chairs:</b>	<b>Martin Metz (Berlin, Germany)</b> <b>Elke Weisshaar (Heidelberg, Germany)</b>
<b>D4T02.1A</b>	<b>8:30</b>	<b>Defining Chronic Pruritus and Prurigo and their subtypes</b> Laurent Misery (Brest, France)
<b>D4T02.1B</b>	<b>8:50</b>	<b>New insights into the pathophysiology of itch</b> Martin Metz (Berlin, Germany)
<b>D4T02.1C</b>	<b>9:10</b>	<b>The burden of chronic pruritis/chronic prurigo</b> Elke Weisshaar (Heidelberg, Germany)
<b>D4T02.1D</b>	<b>9:30</b>	<b>New treatments for chronic pruritus</b> Brian S. Kim (New York, United States)
<b>D4T02.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

## UPDATES

## HALL A1

<b>D4T02.2</b>	<b>10:15 - 11:45</b>	<b>PRURITUS AND PRURIGO</b>
	<b>Chairs:</b>	<b>Thomas Luger (Münster, Germany)</b> <b>Jacek Szepietowski (Wroclaw, Poland)</b>
<b>D4T02.2A</b>	<b>10:15</b>	<b>Pediatric pruritus</b> Andreas Wollenberg (Munich, Germany)
<b>D4T02.2B</b>	<b>10:35</b>	<b>Neuroimmune circuits in pruritus</b> Jacek Szepietowski (Wroclaw, Poland)
<b>D4T02.2C</b>	<b>10:55</b>	<b>Systemic diseases underlying pruritic disorders</b> Adam Reich (Rzeszów, Poland)
<b>D4T02.2D</b>	<b>11:15</b>	<b>New treatments for Chronic Prurigo</b> Thomas Luger (Münster, Germany)
<b>D4T02.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

SATURDAY 14 OCTOBER 2023

UPDATES

HALL A2

<b>D4T03.1</b>	<b>08:30 - 10:00</b>	<b>HYPOPIGMENTATION</b>
	<b>Chairs:</b>	<b>Robert Artur Dahmen (Zürich, Switzerland)</b> <b>Mauro Picardo (Rome, Italy)</b>
D4T03.1A	8:30	<b>Diagnostic algorithm in hypopigmentation</b> Robert Artur Dahmen (Zürich, Switzerland)
D4T03.1B	8:50	<b>Tips and tricks for hypomelanosis guttata</b> Beata Bergler-Czop (Katowice, Poland)
D4T03.1C	9:10	<b>Post-inflammatory hypopigmentation</b> Mauro Picardo (Rome, Italy)
D4T03.1D	9:30	<b>Difficult to manage Pityriasis versicolor</b> Lorena Guadalupe Moreno Ordaz (Tlalpan, Mexico)
D4T03.1E	9:50	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A2

<b>D4T03.2</b>	<b>10:15 - 11:45</b>	<b>HYPERPIGMENTATION</b>
	<b>Chairs:</b>	<b>Jean Krutmann (Dusseldorf, Germany)</b> <b>Thierry Passeron (Nice, France)</b>
D4T03.2A	10:15	<b>Pathogenesis of melasma</b> Jean Krutmann (Dusseldorf, Germany)
D4T03.2B	10:35	<b>Topical and procedural therapies for melasma</b> Thierry Passeron (Nice, France)
D4T03.2C	10:55	<b>The challenges of hyperpigmented mycosis fungoides</b> Chalid Assaf (Krefeld, Germany)
D4T03.2D	11:15	<b>Insuline resistance in Acanthosis nigricans</b> Steven Feldman (Winston-Salem, North Carolina, United States)
D4T03.2E	11:35	<b>Discussion, Q&amp;A</b>

SATURDAY 14 OCTOBER 2023

UPDATES

HALL A3

<b>D4T04.1</b>	<b>08:30 - 10:00</b>	<b>VARICOSE VEINS</b>
	Chairs:	Felizitas Pannier (Bonn, Germany) Catherine van Montfrans (Rotterdam, Netherlands)
D4T04.1A	8:30	<b>How to properly evaluate a patient with varicose veins</b> Kees-Peter de Roos (Uden, Netherlands)
D4T04.1B	8:50	<b>2022 varicose vein guidelines</b> Felizitas Pannier (Bonn, Germany)
D4T04.1C	9:10	<b>Phlebectomy or foam?</b> Birgit Kahle (Luebeck, Germany)
D4T04.1D	9:30	<b>Spider teleangiectasias</b> Michael Kocakert (Zurich, Switzerland)
D4T04.1E	9:50	<b>Discussion, Q&amp;A</b>

UPDATES

HALL A3


<b>D4T04.2</b>	<b>10:15 - 11:45</b>	<b>CHRONIC LEG ULCERS</b>
	Chairs:	Jürg Hafner (Zurich, Switzerland) Marco Romanelli (Pisa, Italy)
D4T04.2A	10:15	<b>Epidemiology and etiopathogenesis</b> Matthias Augustin (Hamburg, Germany)
D4T04.2B	10:35	<b>Appropriate use of dressings</b> Anne Domp martin-Blanchere (Caen, France)
D4T04.2C	10:55	<b>Martorell's ulcer: the therapeutic challenge</b> Jürg Hafner (Zurich, Switzerland)
D4T04.2D	11:15	<b>Negative pressure and grafting</b> Marco Romanelli (Pisa, Italy)
D4T04.2E	11:35	<b>Discussion, Q&amp;A</b>

SATURDAY 14 OCTOBER 2023

MISCELLANEOUS

HALL A4

<b>D4T05.1</b>	<b>08:30 - 10:00</b>	<b>VISUAL LITERACY IN DERMATOLOGY</b>
	<b>Chairs:</b>	<b>Sarah Walsh (London, United Kingdom)</b> <b>Carle Paul (Toulouse, France)</b>
<b>D4T05.1A</b>	<b>8:30</b>	<b>The Origins of Visual Literacy– translating concept to training</b> Christopher Griffiths (Manchester, United Kingdom)
<b>D4T05.1B</b>	<b>8:50</b>	<b>Visual literacy: A Dermatologist's perspective</b> Sarah Walsh (London, United Kingdom)
<b>D4T05.1C</b>	<b>9:10</b>	<b>Visual literacy: an art historian's perspective</b> Anne-Elisabeth Puetz (London, United Kingdom)
<b>D4T05.1D</b>	<b>9:30</b>	<b>Interactive analysis of French painting with the Dermatologist eye</b> Carle Paul (Toulouse, France)
<b>D4T05.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>



**SATURDAY 14 OCTOBER 2023**

**UPDATES**

**HALL A4**

<b>D4T05.2</b>	<b>10:15 - 11:45</b>	<b>HOT TOPICS IN DERMATOLOGY SELECTED BY THE EADV PRESIDENT</b>
	<b>Chairs:</b>	<b>Martin Röcken (Tübingen, Germany)</b> <b>Branka Marinovic (Zagreb, Croatia)</b> <b>Alexander Stratigos (Athens, Greece)</b>
<b>D4T05.2A</b>	<b>10:15</b>	<b>From genetics to clinical care in dermatology: time to bring down the walls</b> Eli Sprecher (Tel Aviv, Israel)
<b>D4T05.2B</b>	<b>10:40</b>	<b>Leveraging the Impact and Influence of Dermatology in the International Health Arena?</b> Lucinda Claire Fuller (London, United Kingdom)
<b>D4T05.2C</b>	<b>11:05</b>	<b>Immune checkpoint inhibition in skin cancer: a Nobel price-winning innovation!</b> Axel Hauschild (Kiel, Germany)
<b>D4T05.2D</b>	<b>11:30</b>	<b>Discussion, Q&amp;A</b>

**UPDATES**


**HALL A5**

<b>D4T06.1</b>	<b>08:30 - 10:00</b>	<b>PEELING</b>
	<b>Chairs:</b>	<b>Carlos Wambier</b>
<b>D4T06.1A</b>	<b>8:30</b>	<b>Peeling for darker skin types</b> Manal Bosseila (Cairo, Egypt)
<b>D4T06.1B</b>	<b>8:50</b>	<b>Superficial peeling</b> Foteini Bageorgou (Athens, Greece)
<b>D4T06.1C</b>	<b>9:10</b>	<b>Blepharopeeling with phenol-croton oil</b> Carlos Wambier
<b>D4T06.1D</b>	<b>9:30</b>	<b>Phenol peeling</b> Felipe Ribeiro (São Paulo, Brazil)
	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

**UPDATES**

**HALL A5**

<b>D4T06.2</b>	<b>10:15 - 11:45</b>	<b>AESTHETIC DERMATOLOGY FOR MEDICAL INDICATIONS</b>
	<b>Chairs:</b>	<b>Klaus Fritz (Landau, Germany)</b>
<b>D4T06.2A</b>	<b>10:15</b>	<b>Microneedling and microneedle RF for medical indications</b> Klaus Fritz (Landau, Germany)
<b>D4T06.2B</b>	<b>10:35</b>	<b>Lasers for Psoriasis</b> H.A. Martino Neumann (Banholt, Netherlands)
<b>D4T06.2C</b>	<b>10:55</b>	<b>Dermatologist's guide on the uses of botulinum toxin for medical indications</b> Hassan Galadari (Dubai, United Arab Emirates)
<b>D4T06.2D</b>	<b>11:15</b>	<b>Fillers for medical indications</b> Peter Velthuis (Rotterdam, Netherlands)
<b>D4T06.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>



**SATURDAY 14 OCTOBER 2023**

**UPDATES**

**HALL A5**


<b>D4T06.3</b>	<b>14:15 - 15:45</b>	<b>SCARS TREATMENTS</b>
	Chairs:	Keyvan Nouri (Miami, United States)
<b>D4T06.3A</b>	<b>14:15</b>	<b>Lasers for Treatment of Scars Overview</b> Keyvan Nouri (Miami, United States)
<b>D4T06.3B</b>	<b>14:35</b>	<b>Treatment of Scars in Skin of Colour</b> Mukta Sachdev (Bangalore, India)
<b>D4T06.3C</b>	<b>14:55</b>	<b>Fractional Laser/ Drug Delivery for Treatment of Scars</b> Christine Dierickx (Luxembourg)
<b>D4T06.3D</b>	<b>15:15</b>	<b>What's New for Treatment of Scars</b> Brian Berman (Miami Beach, FL, United States)
<b>D4T06.3E</b>	<b>15:35</b>	<b>Discussion, Q&amp;A</b>

**UPDATES**

**HALL A5**

<b>D4T06.4</b>	<b>16:00 - 17:30</b>	<b>COMBINATION TREATMENTS IN AESTHETIC MEDICINE</b>
	Chairs:	Leonardo Marini (Trieste, Italy)
<b>D4T06.4A</b>	<b>16:00</b>	<b>Combination treatments for vascular targets</b> Leonardo Marini (Trieste, Italy)
<b>D4T06.4B</b>	<b>16:20</b>	<b>Combination treatments for photo- and chrono-aging</b> Ashraf Badawi (Oakville, Canada)
<b>D4T06.4C</b>	<b>16:40</b>	<b>Combination treatments for pigmentary skin alterations</b> Martin Kassir (Dallas, United States)
<b>D4T06.4D</b>	<b>17:00</b>	<b>Combination treatments for skin structural and functional remodelling</b> Ahmed Sadek (Cairo, Egypt)
<b>D4T06.4E</b>	<b>17:20</b>	<b>Discussion, Q&amp;A</b>





**SATURDAY 14 OCTOBER 2023**

**TRAINING AND  
EDUCATION**

**HALL A7**

<b>D4T07.1</b>	<b>08:30 - 10:00</b>	<b>INFECTIOUS DISEASES</b>
	<b>Chairs:</b>	<b>Markus Vincent Starink (Amstelveen, Netherlands)</b> <b>Ditte Marie Saunte (Virum, Denmark)</b>
<b>D4T07.1A</b>	<b>8:30</b>	<b>Bacterial skin infections : clinics and treatment</b> Markus Vincent Starink (Amstelveen, Netherlands)
<b>D4T07.1B</b>	<b>8:50</b>	<b>Viral skin infections : recognizing localized and generalized disease</b> George Sorin Tiplica (Bucharest, Romania)
<b>D4T07.1C</b>	<b>9:10</b>	<b>Fungal nail infections: how to treat best?</b> Ditte Marie Saunte (Virum, Denmark)
<b>D4T07.1D</b>	<b>9:30</b>	<b>Mycobacterial skin infections</b> Mario Fabri (Koln, Germany)
<b>D4T07.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

**TRAINING AND  
EDUCATION**

**HALL A7**

<b>D4T07.2</b>	<b>10:15 - 11:45</b>	<b>STIS</b>
	<b>Chairs:</b>	<b>Marco Cusini (Milan, Italy)</b> <b>Laurence Toutous-Trellu (Geneva, Switzerland)</b>
<b>D4T07.2A</b>	<b>10:15</b>	<b>The syphilis revival</b> Valeska Padovese (Valletta, Malta)
<b>D4T07.2B</b>	<b>10:35</b>	<b>Treatment of gonococcal infections</b> Marco Cusini (Milan, Italy)
<b>D4T07.2C</b>	<b>10:55</b>	<b>Lymphogranuloma venereum</b> Claudia Heller-Vitouch (Vienna, Austria)
<b>D4T07.2D</b>	<b>11:15</b>	<b>Epidemiology and trends in STI</b> Laurence Toutous-Trellu (Geneva, Switzerland)
<b>D4T07.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

SATURDAY 14 OCTOBER 2023

TRAINING AND  
EDUCATION

M1+2

<b>D4T08.1</b>	<b>08:30 - 10:00</b>	<b>PAEDIATRIC DERMATOLOGY</b>
	<b>Chairs:</b>	<b>Mario Cutrone (Venice, Italy)</b> <b>Marie-Anne Morren (Lausanne, Switzerland)</b>
<b>D4T08.1A</b>	<b>8:30</b>	<b>Neonatal disease</b> Mario Cutrone (Venice, Italy)
<b>D4T08.1B</b>	<b>8:50</b>	<b>Autoimmune blistering diseases in childhood</b> Marie-Anne Morren (Lausanne, Switzerland)
<b>D4T08.1C</b>	<b>9:10</b>	<b>Vascular anomalies in children</b> Andrea Diociaiuti (Roma, Italy)
<b>D4T08.1D</b>	<b>9:30</b>	<b>Scleroderma in children</b> Speaker TBC
<b>D4T08.1E</b>	<b>9:50</b>	<b>Discussion, Q&amp;A</b>

TRAINING AND  
EDUCATION

M1+2

<b>D4T08.2</b>	<b>10:15 - 11:45</b>	<b>PAEDIATRIC DERMATOLOGY</b>
	<b>Chairs:</b>	<b>Regina Betz (Bonn, Germany)</b> <b>Sébastien Barbarot (Nantes, France)</b>
<b>D4T08.2A</b>	<b>10:15</b>	<b>Atopic Dermatitis in children</b> Sébastien Barbarot (Nantes, France)
<b>D4T08.2B</b>	<b>10:35</b>	<b>Nail diseases</b> Bianca Maria Piraccini (Bologna, Italy)
<b>D4T08.2C</b>	<b>10:55</b>	<b>Hair diseases</b> Regina Betz (Bonn, Germany)
<b>D4T08.2D</b>	<b>11:15</b>	<b>Tumors in children</b> Antonio Torrelo (Madrid, Spain)
<b>D4T08.2E</b>	<b>11:35</b>	<b>Discussion, Q&amp;A</b>

## SATURDAY 14 OCTOBER 2023

## UPDATES

## M6+7

**D4T09.1 08:30 - 10:00 RED FLAGS AND EMERGENCIES IN DERMATOLOGY**

Chairs: Lars E. French (Munich, Germany)  
Tu-Anh Duong (Boulogne-Billancourt, France)

D4T09.1A 8:30 Acute retiform purpura  
Robert Micheletti (Philadelphia, USA)

D4T09.1B 8:50 Toxic epidermal necrolysis  
Lars E. French (Munich, Germany)

D4T09.1C 9:10 Erythroderma  
Katharina Shaw (Philadelphia, United States)

D4T09.1D 9:30 Clinical pitfalls: what not to miss  
Tu-Anh Duong (Boulogne-Billancourt, France)

D4T09.1E 9:50 Discussion, Q&A

## UPDATES

## M6+7

**D4T09.2 10:15 - 11:45 PSYCHODERMATOLOGY**

Chairs: Anthony Bewley (London, United Kingdom)  
John Koo (San Francisco, United States)

D4T09.2A 10:15 Psychodermatology in clinical practice: main principles  
Anthony Bewley (London, United Kingdom)

D4T09.2B 10:35 Psychiatric and psychological aspects of chronic skin diseases  
Mohammad Jafferany (Saginaw, United States)

D4T09.2C 10:55 Management of delusions of parasitosis  
John Koo (San Francisco, United States)

D4T09.2D 11:15 Trichotillomania and skin picking disorder  
Carmen Rodríguez Cerdeira (Vigo, Spain)

D4T09.2E 11:35 Discussion, Q&A

## SATURDAY 14 OCTOBER 2023

## SUBSPECIALTY SESSION HALL A1

14:15 - 17:30

## IEC - INTERNATIONAL ECZEMA COUNCIL

Chairs:

Sonja Ständer (Münster, Germany)

Gil Yosipovitch (Miami, United States)

14:15

**Welcome from the IEC**

Robert Bissonnette (Montreal, Canada)

14:25

**Program introduction**

Sonja Ständer (Münster, Germany)

14:30

**How interleukins start the game: Pathophysiology of atopic inflammation**

Mette Sondergaard Deleuran (Aarhus, Denmark)

15:00

**Itch and scratch: A tap dance on nerve fibers**

Sonja Ständer (Münster, Germany)

15:30

**Break**

15:45

**From skin to brain and back: How the central nervous system modifies atopic itch**

Gil Yosipovitch (United States)

16:15

**Antipruritic effects of biologics, small molecules and topical treatments in AD**

Robert Bissonnette (Montreal, Canada)

16:45

**Influence of itch on quality of life and happiness in atopic dermatitis**

Alexander Zink (Munich, Germany)

17:15

**Complications of skin-bleaching products among Sudanese**

Sonja Ständer (Münster, Germany)

SATURDAY 14 OCTOBER 2023

**SUBSPECIALTY SESSION HALL A4**

**14:15 - 17:30 IPS - INTERNATIONAL PEELING SOCIETY: "CHEMICAL PEELINGS - PAST, PRESENT AND FUTURE"**

**Chairs:** Foteini Bageorgou (Athens, Greece)

**14:15 Introduction**

**14:20 Rosacea, is chemical peeling relevant?**

Foteini Bageorgou (Athens, Greece)

**14:35 Chemical Peeling vs Laser treatment Pros and Cons**

Claudia Borelli (Tübingen, Germany)

**14:50 Nails and Chemical Peelings**

Ioanna Triantafillopoulou (Greece)

**15:05 Frontal Fibrotic Alopecia and Chemical peeling**

Ioannis Venetsanos (Greece)

**15:20 Combining Chemical peeling with micro needling for optimal results**

Amin Amer (Cairo, Egypt)

**15:35 Treatment strategies to control melasma topically**

Sabine Zenker (Munich, Germany)

**15:50 Q&A**

**16:00 Peels in skin of colour / Advanced / Pigmentation / Newer peels etc.**

Mukta Sachdev (Bangalore, India)

**16:15 Complications of Chemical Peels**

Felipe Ribeiro (São Paulo, Brazil)

**16:30 Maximize the use of TCA 35% peels**

Maria Garcia Baldovi (Sueca, Spain)

**16:45 The role of chemical peels in the treatment of precancerous skin lesions**

Christina Fotiadou (Thessaloniki, Greece)

**17:00 A modification of Jessner's peel for acne cases**

Manal Bosseila (Cairo, Egypt)

**17:15 Q&A**

SATURDAY 14 OCTOBER 2023

SUBSPECIALTY SESSION

M1+2

14:15 - 17:30

**EWDVS - EUROPEAN WOMEN'S DERMATOLOGIC AND VENEREOLOGIC SOCIETY**

Chairs:

**Carmen Rodríguez Cerdeira (Vigo, Spain)**

**Brunilda Bardhi (Tiran, Albania)**

**May Elsamahy (Cairo, Egypt)**

14:15

**Introduction and objectives**

Carmen Rodríguez Cerdeira (Vigo, Spain)

14:27

**Emergency in dermatology- what we should know?**

Monika Fida (Tirana, Albania)

14:39

**Skin microbiome in wound healing: A crucial player**

May Elsamahy (Cairo, Egypt)

14:51

**Acne and rosacea, new update treatments**

Brunilda Bardhi (Tirana, Albania)

15:03

**Stress and sleep disturbances in patients with hidradenitis suppurativa**

Marta García Bustínduy (Tenerife, Spain)

15:15

**Role of estrogens in fungal infections in women. An allied or an enemy?**

José Guillermo Pereira-Brunelli (Asunción, Paraguay)

15:27

**Neonatal dermatological emergencies: what should we know?**

Nayera Mofteh (Cairo, Egypt)

15:39

**Chromomycosis and rhinoconidiobolomycosis. Caribbean experience**

Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic)

15:51

**Cutaneous tuberculosis: A great imitator**

Clara Emilia Mázquez-Palencia (Ciudad de México, Mexico)

16:03

**Chromoblastomycosis: Prevalence, clinical and epidemiological features in Colombia**

Cristhian David Castillo-Sánchez (Bogota, Colombia)

16:15

**Prof. Gabriella Fabbrocini and the EWDVS: In memory of her**

Carmen Rodríguez Cerdeira (Vigo, Spain)

## SATURDAY 14 OCTOBER 2023

**SUBSPECIALTY SESSION HALL A2****14:15 - 17:30 EURO-PDT - EUROPEAN SOCIETY FOR PHOTODYNAMIC THERAPY IN DERMATOLOGY**

- Chairs:** Lasse R. Braathen (Oberhofen, Switzerland)  
Rolf-Markus Szeimies (Recklinghausen, Germany)
- 14:15 Welcome and Introduction**  
Lasse R. Braathen (Oberhofen, Switzerland)
- 14:25 New insights in actinic keratosis pathology**  
Thomas Dirschka (Wuppertal, Germany)
- 14:45 Field Cancerization - a reappraisal**  
Lasse R. Braathen (Oberhofen, Switzerland)
- 15:05 5-FU pretreatment for PDT**  
Stine Regin Wiegell (Copenhagen NV, Denmark)
- 15:25 PDT for acne and rosacea**  
Eleni Sotiriou (Thessaloniki, Greece)
- 15:45 Artificial daylight vs. daylight PDT for actinic keratosis**  
Rolf-Markus Szeimies (Recklinghausen, Germany)
- 16:05 The term "keratinocyte cancer" - A European Consensus**  
Wolfgang Philipp-Dormston (Köln, Germany)
- 16:25 Counteracting PDT side effects**  
Hans Christian Wulf (Vedbæk, Denmark)
- 16:45 PDT as anti-infective therapy**  
Yolanda Gilaberte (Zaragoza, Spain)
- 17:05 Q&A and Summary of Session**  
Lasse R. Braathen (Oberhofen, Switzerland)

SATURDAY 14 OCTOBER 2023

SUBSPECIALTY SESSION HALL A3

14:15 - 17:30	MEIDAM - MIDDLE EAST INTERNATIONAL DERMATOLOGY AND AESTHETIC MEDICINE
<b>Chairs:</b>	<b>Khaled AlNuaimi (Dubai, United Arab Emirates)</b> <b>Saad AlSogair (Riyadh, Saudi Arabia)</b> <b>Ruaa Alharithy (Riyadh, Saudi Arabia)</b>
<b>14:15</b>	<b>Cellulite and a new technique</b> Martin Kassir (Dallas, United States)
<b>14:30</b>	<b>Collagen biostimulators: review and comparison of the available options</b> Ahmad AlEisa (Riyadh, Saudi Arabia)
<b>14:45</b>	<b>The Wonderful World of Dermatology: The journey continues</b> Ameen Alwadhi (Manama, Bahrain)
<b>15:00</b>	<b>Between past and present how our aesthetics techniques changed (cases from my clinic)</b> Amera Bayumi (Muscat, Oman)
<b>15:15</b>	<b>Integrated facial anti-aging non surgical approach</b> Yasser Hamed (Cairo, Egypt)
<b>15:30</b>	<b>Medical blepharoplasty: my seven years experience</b> Faten Ishak El Kateb (Tunis, Tunisia)
<b>15:45</b>	<b>Combined treatment of facial scars</b> Siham Dikhaye (Onjoha, Morocco)
<b>16:00</b>	<b>New horizons in management of generalized pustular psoriasis</b> May Elsamahy (Cairo, Egypt)
<b>16:15</b>	<b>Clinical cases in dermatology paediatric</b> Hocar Ouafa (Marrakech, Morocco)
<b>16:30</b>	<b>Effectiveness of autoinoculation therapy in cutaneous warts</b> Nazim Khaled Benmehidi (Algiers, Algeria)
<b>16:45</b>	<b>Trichoscopy in dissecting cellulitis</b> Ismahene Souissi (Ghazela Ariana, Tunisia)
<b>17:00</b>	<b>Hair care practices and their association with scalp and hair disorders: clinical cases and an update</b> Awatef Kelati (Casablanca, Morocco)
<b>17:15</b>	<b>Vitiligo and its mimickers: contribution of confocal microscopy</b> Meryem Soughi (Fes, Morocco)



SATURDAY 14 OCTOBER 2023

**SUBSPECIALTY SESSION HALL A7**

**14:15 - 17:30 ESMS - EUROPEAN SOCIETY FOR MICROGRAPHIC SURGERY**

**Chairs:** Severin Läubli (Zurich, Switzerland)

**14:15 Welcome**

**14:20 What are the advantages of being organised in the ESMS?**  
Severin Läubli (Zurich, Switzerland)

**14:35 Dutch Mohs Registry**  
Marcus Muche (Hoorn, Netherlands)

**15:05 How to assure quality in an emerging country?**  
Noureddine Litaïem (Tunis, Tunisia)  
Meriem Jones (Tunis, Tunisia)

**15:20 Break**

**15:35 AI in Mohs**  
Daniela Hartmann (Munich, Germany)

**16:20 Setting up a safe sedation centre in dermatological surgery**  
Sweta Rai (London, United Kingdom)

**16:40 Case presentations**  
Mariana Zamir (Gedera, Israel)

**17:00 Honorary Lecture**  
Birger Konz (Munich, Germany)

SATURDAY 14 OCTOBER 2023

**SUBSPECIALTY SESSION M6+7**

**14:15 - 17:30 SSDDS - SAUDI SOCIETY OF DERMATOLOGY AND DERMATOLOGIC SURGERY**

**Chairs:** Ruaa Alharithy (Riyadh, Saudi Arabia)  
Abdullah Alakeel (Riyadh, Saudi Arabia)

**14:15 Visible Light and Dark Skin**

Ahmed Alissa (Riyadh, Saudi Arabia)

**14:35 Golden Rules in Dermatology**

Sultan Al-Khenaizan (Riyadh, Saudi Arabia)

**14:50 Hidradenitis Suppurativa: an Overview and Update on Management**

Abdulhadi Jfri (Jeddah, Saudi Arabia)

**15:05 Hair Supplements in 15 Minutes**

Abdullah Alkhalifah (Riyadh, Saudi Arabia)

**15:20 Laser Treatment of Skin of Color: How to Get Best Results and Avoid Complications**

Louai Salah (Jeddah, Saudi Arabia)

**15:35 Annual Full Skin Examination: Who's in charge?**

Nadya Al-Faraidy (Riyadh, Saudi Arabia)

**15:50 Achieving the Ultimate Biostimulation**

Fatima AlRasheed (Riyadh, Saudi Arabia)

**16:05 Nail Colors: Approach to Diagnosis and Management**

Azzam Alkhalifah (Unayzah, Saudi Arabia)

**16:20 Laser Treatment for Acne and Acne Scars: An Update**

Bader Zimmo (Jeddah, Saudi Arabia)

**16:35 New surgical approaches for vitiligo**

Saad Altalhab (Riyadh, Saudi Arabia)

SATURDAY 14 OCTOBER 2023

SUBSPECIALTY SESSION HALL A8

14:15 - 17:30	ESLD - EUROPEAN SOCIETY FOR LASERS AND ENERGY BASED DEVICES
Chairs:	Ashraf Badawi (Oakville, Canada) Albert Wolkerstorfer (Amsterdam, Netherlands) Johan Snauwaert (Brussels, Belgium)
14:15	<b>Zoom dysmorphia</b> Cemre Turk (Boston, United States)
14:28	<b>Practical evidence based tips about the use of CO2 laser in the daily practice in Dermatology</b> Albert Wolkerstorfer (Amsterdam, Netherlands)
14:41	<b>Fractional CO2 laser, a lot beyond rejuvenation</b> Samia Esmat (Cairo, Egypt)
14:54	<b>Dermatology Laser updates, 2023</b> Ashraf Badawi (Oakville, Canada)
15:07	<b>Q SW laser assisted photodynamic preventive rejuvenation</b> Leonardo Marini (Trieste, Italy)
15:20	<b>A review of home-use devices as 'companion products' for professional treatments</b> Natallia Uzunbajakava (Eindhoven, Netherlands)
15:33	<b>Employing various laser modalities to improve aesthetic and functionality in gender-matoses patients</b> Alia Galadari (Paris, France)
15:46	<b>When things go wrong with laser treatment</b> Azzam Alkhalifah (Unayzah, Saudi Arabia)
15:59	<b>10 years experience in BCC and Bowen treatment with i-PDT.</b> Johan Snauwaert (Brussels, Belgium)
16:12	<b>Carbon wave: The newest technology for cellulite treatment</b> Martin Kassir (Dallas, United States)
16:25	<b>PDT, 2023 Updates</b> Peter Bjerring (Aalborg, Denmark)
16:38	<b>Devices that failed, why not each innovation is a success</b> Klaus Fritz (Landau, Germany)
16:51	<b>Laser assisted hair growth stimulation</b> Keyvan Nouri (Miami, United States)
17:04	<b>Psoriatic skin optics, diagnostic and therapeutic implications</b> Ahmed Sadek (Cairo, Egypt)
17:17	<b>Reversing fibroblast senescence with Lasers and EBDs</b> Hans-Joachim Laubach (Geneva, Switzerland)

## PRACTICAL WORKSHOPS

WEDNESDAY 11 OCTOBER 2023

**DIT15.1** **M4+5****08:30 - 11:45** **USE OF BOTOX IN COSMETIC AND MEDICAL DERMATOLOGY - MORNING SESSION**

**Chairs:** Samira Baharlou (Brussels, Belgium)  
Sanjay Rajpara (Aberdeen, United Kingdom)  
Armanda Onderdijk (The Hague, Netherlands)

The workshop will focus on the practice of use of botulinum toxin in a dermatologist office.

This workshop gives theory behind the use of botulinum toxin for aesthetic and medical dermatological indications. The hands-on part to study the practical use of toxins and to learn where to place the injections points for successful treatment outcomes.

**DIT15.2** **M4+5****14:15 - 17:30** **USE OF BOTOX IN COSMETIC AND MEDICAL DERMATOLOGY - AFTERNOON SESSION**

**Chairs:** Samira Baharlou (Brussels, Belgium)  
Sanjay Rajpara (Aberdeen, United Kingdom)  
Armanda Onderdijk (The Hague, Netherlands)

The workshop will focus on the practice of use of botulinum toxin in a dermatologist office.

This workshop gives theory behind the use of botulinum toxin for aesthetic and medical dermatological indications. The hands-on part to study the practical use of toxins and to learn where to place the injections points for successful treatment outcomes.

**DIT16.1** **M8****08:30 - 11:45** **SURGERY - BEGINNERS**

**Chairs:** Marcus Muche (Hoorn, Netherlands)  
Victoria Marmgren (Molndal, Sweden)  
Frida Appelqvist (Gothenburg, Sweden)  
Stephanie Steeman (Haarlem, Netherlands)

In the first part of the workshop, we will introduce the theory of preparation of surgical procedures, (facial) anatomy, anaesthesia, instruments and suturing. The second part will focus on exercising punch biopsy, ellipse excision and different suture techniques. At the end, basic principles of flaps and grafts will be reviewed shortly. All aspects will be discussed and illustrated with lots of pictures, followed by hands-on training in groups. During the training, live video will be used to visualize anaesthetic procedures, use of instruments and suturing.

**DIT16.2** **M8****14:15 - 17:45** **SURGERY - INTERMEDIATE**

**Chairs:** Marcus Muche (Hoorn, Netherlands)  
Victoria Marmgren (Molndal, Sweden)  
Frida Appelqvist (Gothenburg, Sweden)  
Stephanie Steeman (Haarlem, Netherlands)

In the first part of the workshop, we will interactively discuss details and pitfalls in preparation of surgical procedures, (facial) anatomy, anesthesia, instruments and suturing. This will be followed by hands-on training of some special aspects of suturing and biopsing. The second part will focus on the principles of flaps and grafts. The different techniques will be discussed and illustrated with lots of pictures, followed by hands-on training in groups.

During the training, live video will be used to visualize the procedures.

## PRACTICAL WORKSHOPS

THURSDAY 12 OCTOBER 2023

**D2T15.1** **M4+5****08:30 - 11:45** **SURGERY ADVANCED - MORNING SESSION****Chairs:** **Robert Gniadecki (Copenhagen, Denmark)**  
**Annik Van Rengen (Dordrecht, Netherlands)**  
**Stijn Kouwenhoven (Dordrecht, Netherlands)**

The aim of this interactive session is to review the principles of closures of surgical wounds in the face, commonly encountered in the practice of dermatological surgery. We will provide practical experience and training with the advanced reconstruction of skin defects after cancer excisions in different regions of the face. The target audience will comprise of dermatologists who have basic experience with surgery and would like to improve their skills with surgical excisions of the face. After short introductory talks the participants will be divided into groups and will be presented a series of challenging cases of facial tumours or surgical defects for reconstruction. The proposals will be discussed within the groups and selected cases will also be brought for comments and discussion by all participants. The session will end with a self-assessment test

**D2T15.2** **M4+5****14:15 - 17:30** **SURGERY ADVANCED - AFTERNOON SESSION****Chairs:** **Robert Gniadecki (Copenhagen, Denmark)**  
**Annik Van Rengen (Dordrecht, Netherlands)**  
**Stijn Kouwenhoven (Dordrecht, Netherlands)**

The aim of this interactive session is to review the principles of closures of surgical wounds in the face, commonly encountered in the practice of dermatological surgery. We will provide practical experience and training with the advanced reconstruction of skin defects after cancer excisions in different regions of the face. The target audience will comprise of dermatologists who have basic experience with surgery and would like to improve their skills with surgical excisions of the face. After short introductory talks the participants will be divided into groups and will be presented a series of challenging cases of facial tumours or surgical defects for reconstruction. The proposals will be discussed within the groups and selected cases will also be brought for comments and discussion by all participants. The session will end with a self-assessment test

**D2T16.1** **M8****08:30 - 11:45** **WOUND HEALING****Chairs:** **Elena Conde (Madrid, Spain)**  
**Kirsi Isoherranen (Helsinki, Finland)**  
**George Sorin Tiplica (Bucharest, Romania)**  
**Justin Schlager (Germany)**

After an introduction that will explain the main principles of diagnosis and treatment of leg ulcers, participants will be divided in groups that will rotate in different stations. Wound assessment will be explained following an holistic framework, considering not only the wound, but also perilesional skin and patient comorbidities. Different diagnostic tools to establish the vascular status of the patient will be discussed. Ankle-brachial index measurement will be performed by the participants themselves. Practical tips to get to a systematic and efficient differential diagnosis pathway will be suggested. The variety of possible aetiologies of leg ulcers will be explained through rich iconography. A theoretical and practical approach to compression therapy will be based not only on its benefits for venous ulcers but also on its usefulness in any leg ulcer, when no contraindications exist. The range of wound dressings and other products, such as negative pressure devices, that are commercially available will be explained, focusing on their components and indications. Autologous skin grafting and cutaneous substitutes will be suggested as interesting options to promote epithelialisation.

## PRACTICAL WORKSHOPS

THURSDAY 12 OCTOBER 2023

D2T16.2

M8

14:15 - 17:30

## DERMOSCOPY - PRACTICAL AND CONCEPTUAL

Chairs:

Harald Kittler (Vienna, Austria)  
Giuseppe Argenziano (Naples, Italy)  
Aimilios Lallas (Thessaloniki, Greece)  
Lidia Rudnicka (Warsaw, Poland)  
Iris Zalaudek (Trieste, Italy)

Dermoscopy is commonly used to improve the diagnosis of neoplastic and non-neoplastic disease. This interactive workshop will discuss practical problems of dermoscopy, including applications beyond its traditional use in pigmented neoplastic lesions.

FRIDAY 13 OCTOBER 2023

D3T15.1

M4+5

08:30 - 11:45

## PHLEBOLOGY BEGINNERS

Chairs:

Felizitas Pannier (Bonn, Germany)  
George Sorin Tiplica (Bucharest, Romania)  
Eberhard Rabe (Bonn, Germany)  
Laura Fischer (Hürth, Germany)

The participants will be introduced to the main principles of phlebology.

- To start the following will be explained and discussed:
- the anatomy and physiology of the lower limbs,
- the diagnostics and investigations used by phlebologists,
- the therapy of varicose veins according to the newest guidelines, including sclerotherapy.

Afterwards, participants will be divided in 3 rotating groups for hand-on learning of

- production of sclerosing foam,
- injection of spider veins,
- duplex guided injection techniques.

Injection models are used to practice injection techniques and foam production will be demonstrated and performed by the participants themselves.

In addition, there will be time to discuss questions around indications, techniques, side effects and results of sclerotherapy.

D3T15.2

M4+5

14:15 - 17:30

## STI DIAGNOSIS AND TREATMENT

Chairs:

Clarissa Vergunst (Amsterdam, Netherlands)  
Marja Oldhoff (Paterswolde, Netherlands)

In this interactive workshop, our aim is to let both residents and dermatologists walk away with fresh knowledge and inspiration with regard to the approach of STI. The workshop will consist of presentations with up-to-date knowledge on STI diagnosis and treatment options. Topics include syphilis, other ulcerative STI, and HIV-indicator diseases.

Management of infectious diseases more and more calls for knowledge on mechanisms of antimicrobial resistance (AMR) and how to detect AMR in pathogens. Background information on mechanisms of AMR and (molecular) techniques for detection of AMR for practical use will be discussed.

Participants are encouraged to share local guidelines and experience, and individual cases for discussion.

## PRACTICAL WORKSHOPS

FRIDAY 13 OCTOBER 2023

**D3T16.1** **M8****08:30 - 11:45** **LASER TREATMENT- BEGINNERS**


**Chairs:** **Albert Wolkerstorfer (Amsterdam, Netherlands)**  
**Keyvan Nouri (Miami, United States)**  
**Pablo Boixeda (Madrid, Spain)**

The main goal of the workshop is to gain insight into the essentials of laser dermatology and improve outcomes in laser therapy. It will focus on vascular lesions, pigmented lesions, laser endpoints, how to avoid complications, laser assisted drug delivery and ablative and fractional lasers. Each of these topics will be systematically approached by an expert through 1) a short introduction, 2) an overview of available devices, 3) a review of indications, 4) an interactive panel discussion with tips, tricks and pitfalls. Questions from the audience are welcome throughout the whole workshop.

**D3T16.2** **M8****14:15 - 17:30** **ALLERGOLOGY - ADVANCED**

**Chairs:** **Ana Giménez-Arnau (Barcelona, Spain)**  
**Sabine Altrichter (Linz, Austria)**  
**Mette Sommerlund (Aarhus, Denmark)**

The workshop will focus on theoretical and practical aspects to correctly diagnose etiologically immunologic cutaneous disorders. These conditions include, dermatitis / eczema (contact or atopic) and urticaria (acute or chronic) trigger by environmental stimuli and agents. Its clinical identification would need some specialized complementary tests in order to typify the responsible agent, assess severity, implement correct treatment and also preventive measures. For this is essential a training. How to identify and demonstrate type I and type IV hypersensitivity in cutaneous Immunol allergic diseases and how to made a correct differential diagnosis of inducible chronic urticarias is the main goal of this workshop.



## GENERAL INFORMATION

### ADDRESS AND CONTACT

#### European Academy of Dermatology and Venereology

EADV Headquarters  
Via S.Balestra 22B - 6900 Lugano  
Switzerland  
Tel: +41 91 973 45 20  
Website: [eadv.org](http://eadv.org)

#### Congress venue

Messe Berlin (Berlin ExpoCenter City)  
Eingang Süd / Entrance South  
Jafféstraße  
14055 Berlin  
Website: [messe-berlin.de/](http://messe-berlin.de/)

#### Destination management company

Congrex Switzerland Ltd  
Reinacherstrasse 131  
CH-4053 Basel  
Phone: +41 61 686 77 94  
Website: [eadvcongress2023.org/accommodation/](http://eadvcongress2023.org/accommodation/)  
Email: [hotel.eadv@congrex.com](mailto:hotel.eadv@congrex.com)

### ONSITE FACILITIES

#### Venue opening hours

<b>Wednesday 11 October</b>	<b>07:30 – 23:00</b>
<b>Thursday 12 October</b>	<b>07:30 – 20:30</b>
<b>Friday 13 October</b>	<b>07:30 – 20:30</b>
<b>Saturday 14 October</b>	<b>07:30 – 18:30</b>

#### Registration desks

The registration desks are located in the Hall 2.1, once passed the main entrance.

The registration area will be open during the following days:

<b>Wednesday 11 October</b>	<b>07:30 – 18:30</b>
<b>Thursday 12 October</b>	<b>07:30 – 16:30</b>
<b>Friday 13 October</b>	<b>07:30 – 16:30</b>
<b>Saturday 14 October</b>	<b>07:30 – 15:00</b>

#### Exhibitors desks

The Exhibitors desks are located in the Hall 2.1 – Registration Area, and will be open during the following days:

<b>Wednesday 11 October</b>	<b>07:30 – 18:30</b>
<b>Thursday 12 October</b>	<b>07:30 – 18:30</b>
<b>Friday 13 October</b>	<b>07:30 – 18:30</b>
<b>Saturday 14 October</b>	<b>07:30 – 11:00</b>



## GENERAL INFORMATION

### Exhibition area

The Congress will host three exhibition halls of more than 15.000sqm, located in Halls 2.2 – 4.2 – 6.2, Floor 2 of the Messe Berlin.

The exhibition halls can be accessed from the corridors in between of Halls 2.1-4.1 and 2.2-4.2. Products, techniques and equipment will be displayed for exchange between industry partners and dermatology professionals participating in the event.

Please note that the exhibition halls are open to Healthcare Professionals (HCPs) only, as prescription medical products will be advertised.

According to the European Union Directive 2001/83 /EC (and amended version 2010/84/EU), the promotion of prescription-only medicines should be directed solely at Healthcare Professionals or any person who is authorised to prescribe or handle them.

The following National German laws, codes and regulations will be in full force and effect during the 32nd EADV Congress in Berlin. Therefore, access to the Exhibition Halls, Satellite Symposia and Industry HUB sessions dealing with development, research or other related to prescription medicine will be restricted to Healthcare Professionals only.

The exhibition halls will be open during the following hours:

<b>Wednesday 11 October</b>	<b>12:00* – 17:30*</b>
<b>Thursday 12 October</b>	<b>09:00* – 17:30*</b>
<b>Friday 13 October</b>	<b>09:00* – 17:30*</b>
<b>Saturday 14 October</b>	<b>09:00* – 12:00</b>

\*Exhibitors can enter the exhibition halls 1 hour before and after the opening hours

### Speaker preview room

All session rooms are equipped with LCD projection for PowerPoint presentation. Speakers are asked to hand in their presentation at least 3 hours before the lecture if not already uploaded earlier. Speakers with a presentation during the first time slot of the morning are kindly asked to hand in their PowerPoint presentation the day before.

The speaker preview room is located in Hall 2.1 – Lev. 1 and will be open during the following hours:

<b>Tuesday 10 October</b>	<b>15:00 – 18:00</b>
<b>Wednesday 11 October</b>	<b>07:30 – 18:00</b>
<b>Thursday 12 October</b>	<b>07:30 – 17:00</b>
<b>Friday 13 October</b>	<b>07:30 – 17:00</b>
<b>Saturday 14 October</b>	<b>07:30 – 17:00</b>

All presentations must be in English. Speakers should also verify in the Final Programme that the name of the room and time of the session have not changed.

## GENERAL INFORMATION

### Abstract and e-Poster

Accepted abstracts will be made available on a dedicated section of the EADV website, [eadv.org/scientific/abstract-books/](https://eadv.org/scientific/abstract-books/)

Abstracts selected for e-Posters will be published as electronic posters during the Congress and will be available for viewing in the e-Poster area which is located in Hall 2.1. Forty big screens are provided and configured exclusively to display the e-Posters. The e-Posters can be viewed sequentially by number, submission topic or searched individually by title, keyword or author.

The e-poster area will be open during the following days:

<b>Wednesday 11 October</b>	<b>08:00 – 17:30</b>
<b>Thursday 12 October</b>	<b>08:00 – 17:30</b>
<b>Friday 13 October</b>	<b>08:00 – 17:30</b>
<b>Saturday 14 October</b>	<b>08:00 – 17:30</b>

### Accommodation and Information Desk

The information desk where delegates can get details on accommodation, taxi transfers and the city of Berlin is located in the EADV Registration Area, in Hall 2.1.

### Cloakroom

The Cloakroom is located in Hall 2.1 and will be open during the following days:

<b>Wednesday 11 October</b>	<b>07:30 – 22:30</b>
<b>Thursday 12 October</b>	<b>07:30 – 20:30</b>
<b>Friday 13 October</b>	<b>07:30 – 20:30</b>
<b>Saturday 14 October</b>	<b>07:30 – 18:30</b>

### Lost & found

Please hand in all found items and ask for lost items at the cloakroom in Hall 2.1 - Registration Area.

### Catering facilities

Lunches and coffee breaks are NOT included in the registration fees. Meals and snacks can be purchased within the Congress venue during the opening hours in various catering areas located in the following areas:

Messe Berlin:

- South Entrance
- Foyers in between Halls 2.1-4.1 and Halls 2.2-4.2

CityCube:

- Service Centre (from/to CityCube Lev. 2 from/to Hall 7)
- Cube Café – Lev. 2
- East Lobby – Lev. 1

## GENERAL INFORMATION

### First aid room and emergency numbers

In case of need please visit the Medical Centre, located in the lobby area of Hall 2.1. Further emergency numbers are:

- **112** for ambulance
- **+49 30 3038-2222** Emergency Red Cross Paramedics
- **+49 30 3038-4444** for any emergency at Messe Berlin – CityCube

### MY EADV CENTRE

MyEADV is located in Hall 2.1. It is the information point for the upcoming events, membership queries, EADV courses and publications.

### INTERACTION ON SOCIAL MEDIA

You are invited to follow EADV on the following social media channels to stay up to date with our activities and announcements. Follow us on your favourite platforms to stay connected and interact with other professionals in the field. If you need help with social media interactions, please visit the Resource Centre in Hall 2.1. Join the conversation using **#EADVCongress**.



### INTERNET ACCESS/WI-FI

Free Wi-Fi access will be available in the common areas of the venue and in the session rooms. Please select the following network name and password to start your navigation:

Network name: **EADVCongress2023**

Password: **EADV2023**

### MOBILE PHONE APPLICATION (EVENTS APP)

The EADV Events App will bring the 32nd EADV Congress to your smart phone or tablet. The application offers a tailor-made mobile overview of this scientific event. You will get instant access to the full scientific programme, abstracts, e-posters, session surveys, industry sessions, and the latest news before, during and after the meeting! Interactions during sessions will be facilitated by the App, allowing you to send questions, vote and evaluate.

A few days before the event you will receive further information via email about how to download the App. For support, visit the Help & Info section on the EADV Events App.

### MOBILE PHONES, PHOTOGRAPHY, AUDIO AND VIDEO RECORDING

The use of mobile phones, as well as audio and video recording devices, is strictly prohibited within the scientific session rooms. Please ensure that you have your mobile phone switched off when attending a session.

Photography is also not permitted.

## GENERAL INFORMATION

### OFFICIAL LANGUAGE

English is the official language of the Congress. No simultaneous translation will be provided at any EADV scientific session.

### PATIENT ORGANISATION AREA

EADV actively works to develop a synergic action between the patient community and key healthcare providers.

We invite all Congress attendees to visit the Patient Organisation Area taking place from 11-14 October 2023. In this dedicated area you have the opportunity to meet with leaders of the represented patient organisations, discuss activities of common interest, explore different perspectives, needs and roles and how to fit them into the larger world of European dermatology.

The Patient Organisation Area will take place from the 11-14 October 2023 in Hall 2.1 of the Messe Berlin.

We acknowledge and thank the below patient organisations for their commitment and involvement during this year's Congress:

#### **Action for XP**

**Center For Ichthyosis Related Members**

**CMTC-OVM**

**DEBRA South Africa**

**Deutscher Psoriasis Bund e.V. (DPB)**

**European Network for Ichthyosis**

**FRANCE ACNE ADOS ADULTES**

**Global Albinism Alliance**

**Hidradenitis Patienten Vereniging**

**International Alliance of Dermatology Patient Organizations (IADPO)**

**International Federation of Psoriasis Association (IFPA)**

**International Pemphigus & Pemphigoid Foundation**

**Lichen Sclerosus Foreningen**

**Nävus Netzwerk Deutschland e.V.**


**Nevus Outreach**

**Prurigo Nodularis International**

**The Collaborative Group for Psychodermatology in Canada**

**The Irish Skin Foundation**

**The Rare Diseases Foundation of Iran**



## GENERAL INFORMATION

### SCIENTIFIC SESSIONS

Sessions of different formats will cover important fields of dermatology and venereology. Subjects will be treated with different approaches and from different perspectives. The following session types will be scheduled throughout the duration of the Congress and are available to all registered participants: Plenary lectures, Subspecialties, Focus on, Updates, Training and Education, Controversies, Free Communications, Miscellaneous meetings and Late Breaking news.

The scientific programme has been organised on full or half-day tracks; each track has a specific topic and a structured programme.

#### Session Halls

The Scientific Session rooms for the 32nd EADV Congress are located within the Messe Berlin and CityCube. Please refer to the floor plan for orientation. Seating is regulated on a first-come, first-served basis. We recommend you go to the session room well in advance of the session to ensure your place. Due to safety regulations, the organisers will close access to the session if all seats are occupied. Delegates are not permitted to stand in the aisles of the session rooms.

# Navigate the Congress with ease: download our App and stay informed

## Scientific programme

Access the full programme and create your own agenda

## Abstracts and e-Posters

Access the latest research from your device

## Session evaluations

Evaluate all sessions and gain your CME-CPD credits

## Interactivity

Participate to the sessions by answering the polls and ask your questions

**The EADV Events App will bring the EADV Congress to your iPhone or Android phone!**



Download on the  
**App Store**



GET IT ON  
**Google Play**

Search for "EADV 2023" to  
download the app (available from  
29 September 2023)

**Find out more  
about the event on  
[eadvcongress2023.org](https://eadvcongress2023.org)**

Free WiFi is available in all areas

## GENERAL INFORMATION

### CERTIFICATES AND ACCREDITATION

All registered participants will be able to download their certificates online based on their level of engagement:

- A **Certificate of Attendance** is available for all registered participants who have a valid registration badge and attended at least 1 session.
- A **CME-CPD Certificate** is available for all participants who actively attended scientific sessions, have their badge scanned and completed the online evaluation forms.
- An **e-Poster Certificate** is available for all leading e-Poster authors.
- A **Free Communications Certificate** is available for all presenters in the “Free Communications” sessions.
- A **Workshop Certificate** is available for all for all Workshop participants.
- A **Scholarship Certificate** is available for all HCP Scholarship recipients


The certificates are not sent out automatically to the attendees.

You can download them directly from the following link by entering the email address and password used during the registration process OR the EADV member log-in details (if a EADV member):

<https://eadv.m-anage.com/Home/Index/Event/eadvcongress2023>



**VENUE FLOORPLANS**




**LEGEND**

- |   |   |
|---|---|
|  <b>South Entrance</b>         |  <b>Registration Area</b>            |
|  <b>Session Rooms</b>          |  <b>MyEADV Area</b>                  |
|  <b>Industry Meeting Rooms</b> |  <b>e-Poster Area</b>                |
|  <b>Exhibition Halls</b>       |  <b>Patient Organisation Area</b>    |
|  <b>Marshall House</b>         |  <b>National Societies</b>           |
|   |  <b>Speaker Preview Room</b>         |
|   |  <b>Connections Messe - CityCube</b> |
|   |  <b>Helsinki Meeting Room</b>        |
|   |  <b>Budapest</b>                     |







VENUE FLOORPLANS

# Level 1




**LEGEND**





-  Escalators
-  Lifts
-  Stairs
-  Toilets

VENUE FLOORPLANS

Level 2




LEGEND

-  Escalators
-  Lifts
-  Stairs
-  Toilets

VENUE FLOORPLANS

# Level 3

## CityCube




**LEGEND**

- EADV Meeting Rooms
- Press Rooms
- Session Rooms
- Industry Meeting Rooms
- Task Forces
- Workshops

VENUE FLOORPLANS

Hall 2.2 Level 2




Exhibitor list

	BOOTH
Almirall	C03
Amgen Inc.	B08
BIODERMA (NAOS)	D08
BIOGENED SA	A03
Bristol Myers Squibb	B09
Canfield Scientific Inc.	A08
Cantabria Labs	B04
CeraVe	B10A
DermLite	D02
ETAT PUR (NAOS)	D06
FotoFinder Systems GmbH	D01
General Topics s.r.l.	A01
Genové Dermatologies	B01
Incyte	D03
INSTITUT ESTHEDERM (NAOS)	D09
Istituto Canassini S.p.A. di Ricerche Biochimiche / Rilastil	A05
Janssen Pharmaceutica NV	B06
LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE	B10B
LABORATOIRE DERMATOLOGIQUE ACM	B03
LABORATOIRE SVR	D04
Laboratoires Dermatologiques D'Uriage	A04
LDB.com	B10C
LEO Pharma A/S	C05
L'Oréal Dermatological Beauty	A03A
medac GmbH	C06
MESOESTETIC PHARMA GROUP	D05
NAOS	D07
NOREVA LED	B02
Novartis	B05
Novartis	B07
Pierre Fabre SA	A06
Regeneron	B11
UCB	C01
UCB	C02
VICHY LABORATOIRES	B10
VivaScope GmbH	A07

VENUE FLOORPLANS

Hall 4.2 Level 2




Exhibitor list

	BOOTH
A.D.O. MEDICAL S.R.L.	H08
AbbVie	G02
AbbVie	G03
AbbVie Medical	G01
Adamo Srl	E10
Amryt Pharma	H12
BODERM S.A.	E12
Boehringer Ingelheim International GmbH	E01
Boehringer Ingelheim International GmbH	E02
BRYMILL CRYOGENIC SYSTEMS	H07
CATALYSIS, S. L.	E04
CoolHealth	H10
CosmeRNA	H01
Daavlin	H02
Damae Medical	H05
Dermagnostix GmbH	E05
DermapenWorld	H03
DermapenWorld	H04
Eli Lilly and Company	F03
Galderma SA	G06
GME German Medical Engineering	F05
HEINE Optotechnik	H09
ISISPHARMA	H11
Isocell Nutra	E06
Laboratorios Viñas	E09
Lutronic Medical Systems Germany GmbH	G07
Nia Health	F06
Novartis	G04
Pertemps Medical	E08
Pfizer inc	F04
Quantificare	E11
Sanofi	G05
Sanofi Regeneron	F01
Sanofi Regeneron	F02
Symbio Research	E03
TKL Research	H06
Viomed Medical GmbH	F05A
Wasserman Medic	E07

VENUE FLOORPLANS

Hall 6.2

Level 2



Exhibitor list

	BOOTH
ACELYRIN, Inc.	K39
Advalight	K37
Aerolase	J05
Allergika Pharma GmbH	I09
Altruist	I20
APS SRL	K01
Aslan Pharmaceuticals	I07
ASTERASYS CO., LTD	I26
BeautyTECH	J04A
Bio Cosmetics International	I25
BIONNEX	J07
Casio Europe GmbH	K08
Clarteis	K28
Cortex Technology ApS	I05
Cosmed Cosmeceuticals	I02

	BOOTH
Courage+Khazaka electronic GmbH	K38
Dermaceutic Laboratoire	K32
DERMALINE CO., LTD	K30
Dermus Kft.	I06
Dr. Hönle Medizintechnik GmbH	I03
DUBAI DERMA 2024	J32
Emblation	K21
Eucerin by Beiersdorf	I22
Eucerin by Beiersdorf	I23
Eurofins bioskin GmbH	K29
EUROIMMUN Medizinische Labordiagnostika AG	I18
Fagron Genomics, S.L.U.	J14
Fotona d.o.o.	J24
Fotona d.o.o.	J25
GCT GmbH	K11

	BOOTH
HO equipments	K22
ibita gmbh	I32
ILOODA Co., Ltd	J20
Innovaderm Research Inc.	J33
JBP Korea Co., Ltd.	I21
Jiangsu Medomics Medical Technology Co.,Ltd	I08
JMBIOTECH Corporation Limited	J28
Karger Publishers	I01
KERNEL MEDICAL EQUIPMENT CO.LTD	J10
KMS Srls	I19A
KREUSSLER PHARMA	J02
LASEROPTEK Co., Ltd.	K24
LASERVISION GmbH & Co. KG	J03A
MartiDerm	K26
Medicines Evaluation Unit	K12

	BOOTH
Medabs Service GmbH	I28
MGC Derma	K07
MM MEDICAL s.r.o.	J07A
NeoStrata Company, Inc.	I27
NoIR Laser Co. L.L.C.	K35
OCULO-PLASTIK, INC.	J27
OPATRA LONDON	K09
OXFORD UNIVERSITY PRESS	I11
Peninsula Medical	J35
Pharmacaris	J06
PROTECT-Laserschutz GmbH	K06
Recordati Rare Diseases Germany GmbH	J03
Retix-C Professional	K04
SamanTree Medical SA	J01
Scibase	I12


	BOOTH
Sebapharma GmbH & Co. KG	I24
Softwave Medical Ltd	J04
siHealth Ltd	K13
SKIN TECH PHARMA GROUP SL	K23
Specilipse Europe GmbH	J26
Sun Pharma Advanced Research Company (SPARC)	J15
Techderma	K20
TFS HealthScience	I33
Tuenda	J31
Universal Skin Technology BvBA	K02
VYDENCE MEDICAL	I19
WINTHER	K14
Wisepress Medical Bookshop	J29
Zero Gravity skin	J08
zhengzhou bestview laser co ltd	K31
Zimmer MedizinSysteme GmbH	J22

VENUE FLOORPLANS

# Hall 1.1


## Industry Meeting Rooms

## Industry Lounges



## Company list

		ROOM			ROOM
AbbVie		Room 12	Innovaderm Research Inc.		Room 10
Almirall		Rooms 15, 17, 18	Janssen Pharmaceutica NV		Rooms 04, 05, 06, 08
Amgen Inc.		Rooms 26, 34, 36, 39	LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE		Room 22
Apogee Therapeutics		Room 09	LEO Pharma A/S		Room 03
argenx		Room 02	Merck Sharp & Dohme LLC		Room 41
Boehringer Ingelheim International GmbH		Room 28	NAOS		Room 26
Bristol Myers Squibb		Room 38	Novartis		Room 19, 35
Canfield Scientific Inc.		Room 26	Pfizer inc		Room 37
CeraVe		Room 20	Pierre Fabre SA		Room 13 (12 October)
Damae Medical		Room 13 (11 October)	RAPT Therapeutics		Room 46
Eli Lilly and Company		Rooms 13 (13 October), 27, 29, 30, 31, 32	Regeneron		Room 42, 44
Eucerin by Beiersdorf		Room 01	Sanofi		Room 16
Galderma SA		Room 11, 13 (11 October)	Sanofi Regeneron		Room 25, 33
Globalskin		Room 24	SkinAlliance		Room 21
GSK		Room 23	Takeda Pharmaceuticals		Room 40
Incyte		Room 14	UCB		Room 07



## GENERAL INFORMATION

### USE OF PRIVATE DATA

The data made available through the Registration Portal for Congresses and Symposia are gathered and treated by the EADV in compliance with the Swiss regulation on data protection and the General Data Protection Regulation. We advise you to read the full EADV Privacy Policy on [www.eadv.org/privacy-policy](http://www.eadv.org/privacy-policy).

### TRANSFERRING THE DATA TO THE INDUSTRY SESSION ORGANISER

During the EADV Congress, you have the right to transfer the data collected by EADV to another controller (“the industry session organiser”, “Industry”). It might happen through scanning a badge, QR code or other means.

Each participant shall consider that by accepting any scanning of the badge, QR code or other means at any industry session at the Congress, the participant gives authorization to EADV to transfer the data of the participant to the Industry.

EADV is obliged to make this process possible but does not take any responsibility for what happens with the data after it is being transferred to the Industry session organiser. We advise you to make sure that Industry presents its Privacy Policy and read it carefully. It might occur that purposes described by the Industry might include the promotion of pharmaceutical products and similar.

Transfer of the data from EADV to the Exhibitor does not mean the removal of original data from EADV. If you wish the data to be removed or have any requests or questions, please contact us at any time by writing to [communication@eadv.org](mailto:communication@eadv.org).

### THIRD-PARTY REGISTRATION

EADV does not officially support or authorize any third-party organization that creates registrations for individuals or groups. We strongly advise you to register according to the official fees and only on EADV’s official websites.

### LIABILITY DISCLAIMER

The Organisers cannot be held liable for any hindrance or disruption to the EADV Congress arising from political, social or economic events or any other unforeseen incidents beyond their control. The Organisers will accept no liability for any personal injuries sustained or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress or during tours and events. Registration of a participant entails acceptance of these conditions.



## GENERAL INFORMATION

### REGISTRATION

#### General Information

Any person who wishes to make a registration for the EADV Congress can proceed either online on the registration system platform or directly on-site at the Self-registration stations. In order to avoid queuing on-site, we recommend that you register for the event online, prior to the event.

Registrations are possible during the Congress until Saturday 14 October 2023.

Self-registration counters will be open during the entire event and within the official registration opening hours that will be available on the [EADV Congress website](#).

#### Additional Notes

- EADV active Members benefit from a preferential rate. In order to qualify for this rate, it is possible to sign up for an EADV membership and pay the related dues at the latest by 6 October 2023. To find out more about the membership benefits, please click [here](#).

The Membership process might take up to 10 working days. Please allow sufficient time to review and process your application to be able to benefit from the member rates for the Congress.

- Trainees (under 35 years old), Students (under 35 years old) and Nurses & Medical Assistants are requested to provide a "Proof of status" which fulfils the published requirements. Registration to these special categories is possible only by Wednesday, 27 September 2023. After this date, the Non Member category applies.
- In order to access the event, payment of the registration fee must be settled before the beginning of the event.

*On-site registrations:* Payment is accepted by Credit Card (VISA and Mastercard only) or Debit Card. Cash payment cannot be accepted.

*Online registrations:* Payments made via Bank Transfer are possible until Wednesday, 27 September 2023. After this date, only Credit Card payments (VISA or Mastercard) are possible.

- **Cancellation, refunds, name changes policies and other important information are published online [here](#).**

## GENERAL INFORMATION

The EADV Full Ticket includes:

- Admission to the live Congress Scientific Sessions
- Access to the EADV Virtual Congress Platform
- Admission to the Networking Symposium on Wednesday, 11 October 2023
- Access to Subspecialty Society Meetings
- Access to the e-poster area, MyEADV booth and Patient Advocacy Booth
- Access to the Exhibition Hall (for Healthcare Professionals and Industry Participants only)
- Access to Satellite Symposia Sessions and Industry Expert Hub sessions\*
- Eligibility to claim ECMEC Credits for participating in the live Scientific Sessions
- Transportation pass

Along with all the benefits of the virtual registration

- Access to the EADV Virtual Congress Platform with live-streamed scientific sessions
- Access to all on-demand content until 31 December 2023
- Access to the streaming of Subspecialty Society Meetings
- Access to the online library of e-posters and abstracts
- Access to the online EADV area and Patient Organisation Hub
- Access to the exhibiting company profiles (for Healthcare Professionals and Industry Participants only)
- Live-streaming of selected Satellite Symposia Sessions and Industry Expert Hub\*
- Eligibility to claim ECMEC Credits for participating in the live-streamed Scientific Sessions

*\*IMPORTANT: Industry Session organisers could limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the industry session. The organising company reserves the right to refuse single categories, if not adequately related to the objective and purpose of the session.*

*A 1-Day Ticket is only valid for 1 of the 4 days of the Congress and is limited to one ticket per participant.*

*The 1-Day Ticket **does not include** access to the Virtual Congress Platform. Participants with a 1-Day Ticket who wish to access the Virtual Platform need to purchase a Full Ticket.*


### Registration Name Badge

Registered participants are invited to print out their badge at the self-printing machines on arrival to the Registration area. The name badge is the official EADV Congress identification document and should be worn at all times in order to gain entry to the various Congress areas.

The name badge is your ticket for booked activities and sessions. Admission to other areas of the venue is not permitted without badge identification.

### Special Note

- Participants are asked to check the registration documents immediately after receiving them by email or on-site at the self-registration stations. Once issued, invoices cannot be amended at a later stage.
- The badge includes a QR-code containing your full address and email. It is the participant's decision to disclose these details to the Industry Session's organisers with a scanner.




## GENERAL INFORMATION

### PRESS INFORMATION FOR JOURNALISTS AND MEDIA REPRESENTATIVES

Journalists who are working for and representing recognised news organisations are encouraged to attend the Congress as Press. To register, journalists must complete the online application, upload a valid press card, and confirm adherence to the Embargo policy.

All registered Press members must adhere to the EADV Press & Media Guidelines, Embargo Policy and Filming/Photography/Recording Policy for Professionals. Registered Press can access all scientific sessions, but not the Exhibition Area, Satellite Symposia or Meet-the-Expert sessions. Only HCP Press representatives can access the Exhibition area.

For further information about registration, the EADV Press and Media Guidelines and the Embargo Policy, please visit the [press page on our website](#).



## OPENING PLENARY SESSION AND NETWORKING SYMPOSIUM

### DATE

**Wednesday, 11th October 2023**

### START TIME

**17:45**


### LOCATION

**Hall B (CityCube - Lev.2)**

Join us in Hall B (CityCube – Lev. 2) on Wednesday, October 11th, at 17:45 as we celebrate the commencement of the 32nd EADV Congress. The evening will begin with the EADV's Opening Plenary Lecture, featuring a welcome address from EADV President Prof. Martin Röcken, officially inaugurating the Congress.

After Prof. Röcken's address, Prof. Bernd Scherer will delve into the topic of "The Anthropocene: A New Earth Epoch," and Prof. Diarmid Campbell-Lendrum will enlighten us on "Why Health Professionals Should Care About Climate Change – and What They Should Do."

Following the enriching session, starting at 18:30, we invite you to join us for a networking reception at the Messe Berlin – South Entrance. Let's celebrate the beginning of an incredible congress together.



## HEALTHCARE PROFESSIONAL DEFINITION

### Important Note to Healthcare and Non-Healthcare Professionals

Access to the different areas and sessions of the Congress depends on the delegate's status as a Healthcare Professional or a Non-Healthcare Professional. Carefully read the description below to ensure you comply with Germany's regulations.

EADV Members are not designated as Healthcare Professionals by default. Please define the correct status (HCP or Non-HCP) during registration.

### Definition

According to the European Union Directive 2001/83 /EC (and amended version 2010/84/EU), the promotion of prescription-only medicines should be directed solely at Healthcare Professionals or any person who is authorised to prescribe them.

As a multidisciplinary audience will be attending the EADV Congress, the EADV will assign different classes to Healthcare Professionals (HCP) and Non-Healthcare Professionals (Non-HCP) to ensure compliance with these regulations.

The German Code Of Conduct (amended on 14 November 2019 (announced in the German Federal Gazette on 30 March 2020, German Federal Gazette AT 30.03. 2020) states the following:


"Healthcare Professionals" or "HCPs" are European-based and full-time physicians and pharmacists, as well as any member of the medical, dental, pharmaceutical or other nursing professions who in the course of their professional activities are authorised to prescribe, recommend or lawfully trade in medicinal products for human use. This also includes employees of public authorities or employees of the funders responsible at that body for prescribing, procuring, supplying, administering or deciding on the reimbursement of medicines, as well as employees of the member companies who, in addition to working for the company, practise full-time as physicians, pharmacists or other HCPs. It excludes, however, all other employees of a member company, wholesaler or other person trading with medicinal products.

### Industry Sessions and Advertising

Satellite Symposia and Industry Hub Sessions presenting data on the development, research or other issues related to prescription medicine can be restricted to Healthcare Professionals and Industry Participants upon indication provided by the Industry Session Organizer. All promotional material and marketing aids related to these industry sessions should be strictly limited to HCPs.

Industry Session organisers could limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry session. The organising company reserves the right to refuse single categories, in particular, if not adequately related to the objective and purpose of the session.

The industry session organizer is responsible for the compliance of the session.



## HEALTHCARE PROFESSIONAL DEFINITION

### Other categories

**STUDENTS** are NOT considered Healthcare Professionals under the current guidelines and will be automatically classified as **Non-Healthcare Professionals**.

**PATIENT ASSOCIATION REPRESENTATIVES** must indicate whether they are Healthcare Professionals or not at registration.

The full EADV Scientific Programme, e-Poster Area and Industry sessions organised by companies producing over-the-counter (OTC) products and similar will be open to all participants.



INDUSTRY  
SESSIONS  
AND  
EXHIBITION

## INDUSTRY SESSIONS

The EADV Industry Partners organize several sessions as an adjunct to the EADV Scientific Sessions. The sessions are organized by the companies and feature presentations by experts in the field, panel discussions and other type of sessions.

The industry sessions are a valuable way to learn about new research, techniques or treatments in the field of dermatology and venereology. In addition, some sessions will focus on sharing information about new products, services and/or technologies available.

**At the EADV Congress, 2 different types of industry sessions are organized:**

### Satellite symposia

Satellite Symposia are organized in the main session rooms and take place during the lunch breaks and after the last session of the day. These sessions last between 60 and 90 minutes and offer a wider education on the presented topic to remain updated on any progression in the field.

### Industry expert hubs

Industry Expert hubs are organized in the exhibition area, in Hall 4.2. These sessions last 45 minutes and are focused on bringing together a smaller group of experts to discuss more in-depth or to focus on a specific topic.

## INDUSTRY SESSIONS PROGRAMME

The industry session organiser is solely responsible for keeping any of its industry sessions activities compliant with all relevant laws and regulations. EADV is not involved with in or has any control over the content, quality, organization, operation, scientific integrity of the activity and materials. EADV will not be involved in the selection of speakers, moderators and other faculty.

[VIEW THE INDUSTRY SESSIONS PROGRAMME](#)

## ACCESS TO INDUSTRY SESSIONS

As a multidisciplinary audience will be attending the EADV Congress 2023, please make sure to select the right category, Healthcare Professionals (HCPs) and Non-Healthcare Professionals (NON-HCPs), during the registration process.

Access to any industry sessions where data or research of prescription medicines is presented will be exclusively limited to Healthcare Professionals (HCPs) and industry participants.

Industry Session organisers may limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry session.





Inspired by **patients.**  
Driven by **science.**

# No. 1 Platinum Sponsor

Meet us at **Hall 2.2!**

## INDUSTRY SESSIONS

### SATELLITE SYMPOSIA PROGRAMMES AT A GLANCE – WEDNESDAY 11 OCTOBER 2023

WEDNESDAY 11 OCTOBER 2023											
Room name		Room 3		Room 5	Room 6		Hall A3		Hall A2	Hall A1	Hall A4
Level		Level 1		Level 1	Level 1		Level 1		Level 1	Level 1	Level 1
Capacity		500		500	500		476		439	439	397
Lunch	Session Code	SAT 01		SAT 03	SAT 04		SAT 05		SAT 06	SAT 07	SAT 08
		Presentation: 13:00-14:00	<b>Procter &amp; Gamble</b>  SK-II: Skin Research via Spatial Biology		<b>Eucerin</b>  Thiamidol	<b>Galderma</b>  Acne		<b>Eli Lilly</b>  Inflammatory Skin Diseases - Plaque Psoriasis, Atopic Dermatitis and Alopecia Areata		<b>Janssen Pharmaceutica NV</b>  Inflammatory skin disease	<b>Sanofi and Regeneron</b>  AD Pediatrics

- Access restricted to Health Care Professionals Only
- Access Open to All

INDUSTRY SESSIONS

SATELLITE SYMPOSIA PROGRAMMES AT A GLANCE – THURSDAY 12 OCTOBER 2023

THURSDAY 12 OCTOBER 2023											
Room name	Room 3	Room 4	Room 5	Room 6	Hall A7	Hall A3	Hall A5	Hall A2	Hall A1	Hall A4	
Level	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	
Capacity	500	500	500	500	476	476	439	439	439	397	
Lunch	Session Code	SAT 09	SAT 10	SAT 11	SAT 12		SAT 13		SAT 14	SAT 15	SAT 16
	Presentation: 13:00-14:00	<b>Eli Lilly</b>  Personalized treatment approach in Atopic dermatitis and Alopecia Areata	<b>L'Oréal Dermatological Beauty</b>  To be announced	<b>Bristol Myers Squibb</b>  To be announced	<b>Galderma</b>  AD and PN		<b>UCB</b>  Psoriasis and Psoriatic Arthritis		<b>Janssen Pharmaceutica NV</b>  PSO	<b>Pfizer</b>  AD/AA	<b>Sanofi and Regeneron</b>  AD
Evening	Session Code	SAT 17	SAT 18	SAT 19	SAT 20	SAT 21	SAT 22	SAT 23	SAT 24	SAT 25	SAT 26
	Presentation: 18:00-19:30	<b>Medthority</b>  Urticaria	<b>Bristol Myers Squibb</b>  Women Leaders in Dermatology	<b>AbbVie</b>  PSO	<b>LEO Pharma A/S</b>  Chronic Hand Eczema	<b>Sanofi and Regeneron</b>  Cross Derm	<b>Sanofi and Regeneron</b>  PN	<b>Organized by Medscape Education Global – Supported by an independent educational grant from UCB Biopharma SRL</b>  Psoriatic Disease	<b>Janssen Pharmaceutica NV</b>  PSO	<b>Pfizer</b>  AD	<b>Almirall S.A.</b>  PSO

Access restricted to Health Care Professionals Only  
 Access Open to All

# JOIN US AT OUR EDUCATIONAL EVENTS AT EADV 2023 IN BERLIN

and visit the DUPIXENT booth to learn more about  
**Atopic Dermatitis and Prurigo Nodularis**

## ITCH IS ONLY THE BEGINNING: ACHIEVING DISEASE CONTROL IN ATOPIC DERMATITIS AND PRURIGO NODULARIS

Thursday 12 October 13:00 - 14:00  
Messe Berlin Congress Centre (Hall A4 - Level 1)

### SPEAKERS



Prof. Martin Metz



Dr. Raj Chovatiya  
CHAIR



Dr. Andreas Pinter

## THE REVOLUTION CONTINUES: EXPANDING BIOLOGIC THERAPY IN ATOPIC DERMATITIS

Thursday 12 October 18:00 - 19:30  
Messe Berlin Congress Centre (Hall A3 - Level 1)

### SPEAKERS



Prof. Adam Friedman



Prof. Stephan Weidinger  
CHAIR



Prof. Emma Guttman

sanofi | REGENERON®


This session is restricted to Healthcare Professionals only.

## INDUSTRY SESSIONS

### SATELLITE SYMPOSIA PROGRAMMES AT A GLANCE – FRIDAY 13 OCTOBER 2023

FRIDAY 13 OCTOBER 2023											
Room name	Room 3	Room 4	Room 5	Room 6	Hall A7	Hall A3	Hall A5	Hall A2	Hall A1	Hall A4	
Level	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	
Capacity	500	500	500	500	476	476	439	439	439	397	
Lunch	Session Code	SAT 27	SAT 28	SAT 29	SAT 30		SAT 31		SAT 32	SAT 33	SAT 34
	Presentation: 13:00-14:00	Novartis  HS	Pierre Fabre Dermo-Cosmetic  Rosacea	AbbVie  AD	Incyte  Vitiligo		Almirall S.A.  AD		Institut Esthederm (NAOS)  Aging management	Boehringer Ingelheim International GmbH  GPP	LEO Pharma A/S  AD
Evening	Session Code			SAT 37			SAT 40		SAT 42		SAT 44
	Presentation: 18:00-19:30			AbbVie  AD			UCB  Hidradenitis suppurativa		Sanofi and Regeneron  PN		Pfizer  AA

Access restricted to Health Care Professionals Only  
 Access Open to All



## INDUSTRY SESSIONS

### SATELLITE SYMPOSIA PROGRAMMES AT A GLANCE – SATURDAY 14 OCTOBER 2023

SATURDAY 14 OCTOBER 2023										
Room name	Room 3	Room 4	Room 5	Room 6	Hall A7	Hall A3	Hall A5	Hall A2	Hall A1	Hall A4
Level	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1	Level 1
Capacity	500	500	500	500	476	476	439	439	439	397
Lunch	Session Code									SAT 48
	Presentation: 13:00-14:00									Sanofi  AD


Access restricted to Health Care Professionals Only  
 Access Open to All





LEARN MORE  
at  
BOOTH #B09

Messe Berlin  
Congress Center



## INDUSTRY SESSIONS

### INDUSTRY EXPERT HUB PROGRAMMES AT A GLANCE – THURSDAY 12 OCTOBER 2023

THURSDAY 12 OCTOBER 2023				
Room Name	Industry Experts Hub 1	Industry Experts Hub 2	Industry Experts Hub 3	Industry Experts Hub 4
Level	Level 2	Level 2	Level 2	Level 2
Capacity	70	70	50	50
09:15-10:00		Hub 2.05		Hub 4.05
		Pfizer AA <i>On Invitation Only</i>		L'Oréal Dermatological Beauty Xerosis cutis
10:15-11:00	Hub 1.06	Hub 2.06	Hub 3.06	Hub 4.06 *
	LEO Pharma A/S AD	Incyte Vitiligo <i>On Invitation Only</i>	Janssen Pharmaceutica NV PSO	Argenx Autoimmune Blistering Diseases <i>No Industry Participants and exhibitor tickets</i>
11:15-12:00	Hub 1.07	Hub 2.07	Hub 3.07	Hub 4.07
	Fotona Laser non-invasive facial rejuvenation and pigment treatments	UCARE Urticaria	Pierre Fabre Dermo-Cosmetic Microbiome	Boehringer Ingelheim International GmbH GPP
12:15-13:00	Hub 1.08			
	Pierre Fabre Dermo-Cosmetic Scalp Seborrheic Dermatitis			
14:15-15:00	Hub 1.09	Hub 2.09		Hub 4.09
	LEO Pharma A/S AD	Amryt Pharma Epidermolysis Bullosa		Lutronic Vascular and Pigmented lesions
15:15-16:00		Hub 2.10		
		Amryt Pharma Epidermolysis Bullosa		
16:15-17:00				

Access restricted to Health Care Professionals Only  
 Access Open to All\*

*\* Industry Experts Hubs are located inside the Exhibition Hall which grants access to HCPs delegates only.  
 Industry Experts Hubs marked as "Open to All" are available to all delegates on the platform (live stream and on-demand).*



## INDUSTRY SESSIONS

### INDUSTRY EXPERT HUB PROGRAMMES AT A GLANCE – FRIDAY 13 OCTOBER 2023

FRIDAY 13 OCTOBER 2023				
Room Name	Industry Experts Hub 1	Industry Experts Hub 2	Industry Experts Hub 3	Industry Experts Hub 4
Level				
Capacity	70	70	50	50
	<b>Hub 1.12</b>			
09:15-10:00	<b>UCB</b>			
	Psoriasis			
10:15-11:00			<b>Hub 3.13</b>	<b>Hub 4.13</b>
			Janssen Pharmaceutica NV PSO	L'Oréal Dermatological Beauty To be announced
11:15-12:00	<b>Hub 1.14</b>		<b>Hub 3.14</b>	<b>Hub 4.14</b>
	<b>LEO Pharma A/S</b>		<b>General Topics S.r.l.</b>	<b>L'Oréal Dermatological Beauty</b>
	AD		Rosacea On Invitation Only	Pigmentary disorders
12:15-13:00	<b>Hub 1.15 *</b>	<b>Hub 2.15</b>		
	<b>Eucerin</b> Sun protection	<b>ISTITUTO GANASSINI SPA - RILASTIL</b> AD		
14:15-15:00	<b>Hub 1.16</b>			<b>Hub 4.16</b>
	<b>LEO Pharma A/S</b> AD			<b>Lutronic</b> Vascular and Pigmented lesions
15:15-16:00				
16:15-17:00				

Access restricted to Health Care Professionals Only  
Access Open to All

\* Industry Experts Hubs are located inside the Exhibition Hall which grants access to HCPs delegates only.  
Industry Experts Hubs marked as "Open to All" are available to all delegates on the platform (live stream and on-demand).

## EXHIBITOR LIST

EXHIBITOR	BOOTH NUMBER	HALL
A.D.O. MEDICAL S.R.L.	H08	4.2
AbbVie	G02	4.2
AbbVie	G03	4.2
AbbVie Medical	G01	4.2
ACELYRIN, Inc.	K39	6.2
Adamo Srl	E10	4.2
Advalight	K37	6.2
Aerolase	J05	6.2
Allergika Pharma GmbH	I09	6.2
Almirall	C03	2.2
Altruist	I20	6.2
Amgen Inc.	B08	2.2
Amryt Pharma	H12	4.2
APS SRL	K01	6.2
Aslan Pharmaceuticals	I07	6.2
ASTERASYS CO., LTD	I26	6.2
BeautyTECH	J04A	6.2
Bio Cosmetics International	I25	6.2
BIODERMA (NAOS)	D08	2.2
BIOGENED SA	A03	2.2
BIONNEX	J07	6.2
BODERM S.A.	E12	4.2
Boehringer Ingelheim International GmbH	E01	4.2
Boehringer Ingelheim International GmbH	E02	4.2
Bristol Myers Squibb	B09	2.2
BRYMILL CRYOGENIC SYSTEMS	H07	4.2
Canfield Scientific Inc.	A08	2.2
Cantabria Labs	B04	2.2
Casio Europe GmbH	K08	6.2
CATALYSIS, S. L.	E04	4.2
CeraVe	B10A	2.2
Clarteis	K28	6.2
CoolHealth	H10	4.2
Cortex Technology ApS	I05	6.2
Cosmed Cosmeceuticals	I02	6.2
CosmeRNA	H01	4.2
Courage+Khazaka electronic GmbH	K38	6.2
Daavlin	H02	4.2

## EXHIBITOR LIST

EXHIBITOR	BOOTH NUMBER	HALL
Damae Medical	H05	4.2
Dermaceutic Laboratoire	K32	6.2
Dermagnostix GmbH	E05	4.2
DERMALINE CO., LTD	K30	6.2
DermapenWorld	H03	4.2
DermapenWorld	H04	4.2
DermLite	D02	2.2
Dermus Kft.	I06	6.2
Dr. Hönle Medizintechnik GmbH	I03	6.2
DUBAI DERMA 2024	J32	6.2
Eli Lilly and Company	F03	4.2
ETAT PUR (NAOS)	D06	2.2
Eucerin by Beiersdorf	I22	6.2
Eucerin by Beiersdorf	I23	6.2
Eurofins bioskin GmbH	K29	6.2

Please join us for a Sanofi-sponsored symposium at the 2023 Meeting of the European Academy of Dermatology and Venereology

# *A Balancing Act:* Exploring the Pivotal Role of OX40-OX40L Signaling Axis in Atopic Dermatitis

*Saturday, October 14, 2023 | 13:00-14:00 PM | City Cube, Level 1, Hall A4*



**Presented by Professor Stephan Weidinger**

Professor and Chair for Dermatology, Christian-Albrechts-University and Director of the Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Germany

This medical educational symposium is intended for healthcare professionals only. The speaker will receive compensation for their participation in this event.

**Visit us at *Booth #G05* or [click here](#) to access our virtual presence**

**Access to the exhibition area is restricted to Healthcare Professionals only**

**Eucerin**<sup>®</sup>

LIFE-CHANGING POWER OF  
DERMATOLOGICAL SKINCARE

# SYMPOSIUM - SAT03 -



PATENTED  
THIAMIDOL

## THIAMIDOL, AN INNOVATION IN HYPERPIGMENTATION: THERAPEUTIC BENEFITS



DR MARISA  
TAYLOR,  
UK



PROF THIERRY  
PASSERON,  
FRANCE



DR LUDGER  
KOLBE,  
GERMANY



DR WOLFGANG  
PHILIPP-DORMSTON,  
GERMANY

**MESSE BERLIN,**  
LEVEL 1 · HALL 4.1 · ROOM 5  
MESSEDAMM 22 · 14055 BERLIN, GERMANY  
OCT 11 2023 | 13:00- 14:00 H  
LUNCH BOX WILL BE PROVIDED



## EXHIBITOR LIST

EXHIBITOR	BOOTH NUMBER	HALL
EUROIMMUN Medizinische Labordiagnostika AG	I18	6.2
Fagron Genomics, S.L.U.	J14	6.2
FotoFinder Systems GmbH	D01	2.2
Fotona d.o.o.	J24	6.2
Fotona d.o.o.	J25	6.2
Galderma SA	G06	4.2
GCT GmbH	K11	6.2
General Topics s.r.l.	A01	2.2
Genové Dermatologics	B01	2.2
GME German Medical Engineering	F05	4.2
HEINE Optotechnik	H09	4.2
HO equipments	K22	6.2
ibita gmbh	I32	6.2
ILOODA Co., Ltd	J20	6.2
Incyte	D03	2.2
Innovaderm Research Inc.	J33	6.2
INSTITUT ESTHEDERM (NAOS)	D09	2.2
ISISPHARMA	H11	4.2
Isocell Nutra	E06	4.2
Istituto Ganassini S.p.A. di Ricerche Biochimiche / Rilastil	A05	2.2
Janssen Pharmaceutica NV	B06	2.2
JBP Korea Co., Ltd.	I21	6.2
Jiangsu Medomics Medical Technology Co.,Ltd	I08	6.2
JM BIOTECH Corporation Limited	J28	6.2
Karger Publishers	I01	6.2
KERNEL MEDICAL EQUIPMENT CO.LTD	J10	6.2
KMS Srls	I19A	6.2
KREUSSLER PHARMA	J02	6.2
LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE	B10B	2.2
LABORATOIRE DERMATOLOGIQUE ACM	B03	2.2
LABORATOIRE SVR	D04	2.2
Laboratoires Dermatologiques D'Uriage	A04	2.2
Laboratorios Viñas	E09	4.2
LASEROPTEK Co., Ltd.	K24	6.2
LASERVISION GmbH & Co. KG	J03A	6.2
LDB.com	B10C	2.2
LEO Pharma A/S	C05	2.2
L'Oréal	A03A	2.2





# Science-driven medical dermatology

Almirall, proud sponsor of the

**EA  
DV** CONGRESS  
BERLIN  
11-14 OCTOBER 2023

Don't miss these two remarkable Symposia on **psoriasis** and **atopic dermatitis** and keep on building the future of medical dermatology with Almirall.

Thursday,  
October  
**12<sup>th</sup>**  
18:00

## New Landmark on Psoriasis treatment: the P<sup>o</sup>SITIVE study



Co-Chair, Prof. Dr. Matthias Augustin  
Co-Chair, Prof. Dr. Ulrich Mrowietz

Friday,  
October  
**13<sup>th</sup>**  
13:00

## Targeting what is clinically meaningful in AD



Chair, Prof. Alan Irvine  
Prof. Dr. Stephan Weidinger  
Prof. Christian Vestergaard

LUNCH BOX  
PROVIDED

Visit [www.almiralldermatologycongress.com](http://www.almiralldermatologycongress.com) or scan the QR code to learn more about the speakers and download the calendar invite



These sessions are organized and funded by Almirall S.A. and may include promotional contents. Almirall event, stand and website are intended for HCP holding a Congress registration.

## EXHIBITOR LIST

EXHIBITOR	BOOTH NUMBER	HALL
Lutronic Medical Systems Germany GmbH	G07	4.2
MartiDerm	K26	6.2
medac GmbH	C06	2.2
Medicines Evaluation Unit	K12	6.2
Medsab Service GmbH	I28	6.2
MESOESTETIC PHARMA GROUP	D05	2.2
MGC Derma	K07	6.2
MM MEDICAL s.r.o.	J07A	6.2
NAOS	D07	2.2
NeoStrata Company, Inc.	I27	6.2
Nia Health	F06	4.2
NoIR Laser Co. L.L.C.	K35	6.2
NOREVA LED	B02	2.2
Novartis	B05	2.2
Novartis	B07	2.2
Novartis	G04	4.2

## Breakthrough Androgenetic Alopecia Solution For All

# CosmeRNA

“Safely Achieve Results”

Precision Targeting of Androgen Receptor mRNA in Human Hair Follicles



- Androgen Receptor mRNA suppressor
- Safe for both of men and women



## EXHIBITOR LIST

EXHIBITOR	BOOTH NUMBER	HALL
OCULO-PLASTIK, INC.	J27	6.2
OPATRA LONDON	K09	6.2
OXFORD UNIVERSITY PRESS	I11	6.2
Peninsula Medical	J35	6.2
Pertemps Medical	E08	4.2
Pfizer inc	F04	4.2
Pharmaceris	J06	6.2
Pierre Fabre SA	A06	2.2
PROTECT-Laserschutz GmbH	K06	6.2
Quantificare	E11	4.2
Recordati Rare Diseases Germany GmbH	J03	6.2
Regeneron	B11	2.2
Retix.C Professional	K04	6.2
SamanTree Medical SA	J01	6.2
Sanofi	G05	4.2
Sanofi Regeneron	F01	4.2
Sanofi Regeneron	F02	4.2
Scibase	I12	6.2
Sebapharma GmbH & Co. KG	I24	6.2
siHealth Ltd	K13	6.2
SKIN TECH PHARMA GROUP SL	K23	6.2
Sofwave Medical Ltd	J04	6.2
Speclipse Europe GmbH	J26	6.2
Sun Pharma Advanced Research Company (SPARC)	J15	6.2
Swift by Emblation	K21	6.2
Symbio Research	E03	4.2
Techderma	K20	6.2
TFS HealthScience	I33	6.2
TKL Research	H06	4.2
Tuenda	J31	6.2
UCB	C01	2.2
UCB	C02	2.2
Universal Skin Technology BvbA	K02	6.2
VICHY LABORATOIRES	B10	2.2
Viromed Medical GmbH	F05A	4.2
VivaScope GmbH	A07	2.2
VYDENCE MEDICAL	I19	6.2
Wasserman Medic	E07	4.2



# SK-II

Satellite Symposium

## Novel Approaches of Spatial Biology:

A Comprehensive Evaluation of  
Galactomyces Ferment Filtrate (PITERA™) Benefits,  
From Cellular Activities to In-Vivo Skin Imaging

13:00 – 14:00 October 11 (Wed.) 2023



### CHAIR

**Kenji Kabashima, M.D., Ph.D.**

*Professor and Chairman, Department of Dermatology,  
Graduate School of Medicine, Kyoto University*

### TOPIC 1

**Analysis via Novel Approach of Spatial Biology: The  
Efficacy of Galactomyces Ferment Filtrate (PITERA™)  
on the Human Epidermis**

### PRESENTER

Xianghong Yan, Ph.D.

*P&G Innovation Godo Kaisha, Japan*

### TOPIC 2

**Novel Skin Imaging Methodology to Quantify Spatial  
Dimension of Skin Radiance Appearance and  
Treatment Benefit of Skin Care Formula containing  
Galactomyces Ferment Filtrate (PITERA™)**

### PRESENTER

Kukizo Miyamoto, Ph.D.

*P&G Innovation Godo Kaisha, Japan*

**EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY CONGRESS 2023**

## EXHIBITOR LIST

EXHIBITOR	BOOTH NUMBER	HALL
WINTHER	K14	6.2
Wisepress Medical Bookshop	J29	6.2
Zero Gravity skin	J08	6.2
zhengzhou bestview laser co ltd	K31	6.2
Zimmer MedizinSysteme GmbH	J22	6.2

For the Exhibition floorplan please consult the EADV Virtual Platform on the [Industry Section](#) or the [Interactive Exhibition Floorplan](#) available on the EADV Congress Website.

Scan here to  
start building  
your success



# THE FUTURE OF ADDRESSING PIGMENTARY DISORDERS

## ACHIEVE RESULTS WITH AEROLASE

aerolase®

Hyperpigmentation, including melasma, post-inflammatory hyperpigmentation, and dyschromia, is the leading skin concern among all patient populations. Melasma is a commonly acquired hyperpigmentation disorder frequently occurring in women, most commonly in Fitzpatrick skin types III-VI, which includes Hispanic, Asian, and patients of African descent.<sup>1</sup> While many treatment options are available for melasma, none have effectively addressed the condition's symptoms and causative factors.

Melasma typically presents as hyperpigmented patches on the forehead, cheeks, upper lip, and nose.<sup>1,4</sup> It is a multifactorial condition with a genetic component. While the pathogenesis is not fully understood, it involves UV radiation exposure and inflammatory processes signaling multiple pathways to stimulate melanogenesis. The histological features of melasma include epidermal and dermal melanin with an increase in the number of melanosomes and dermal blood vessels with increased vascularity in melasma patches.<sup>1</sup>

It is essential to understand that a comprehensive treatment plan is required for clearing melasma. Topicals, chemical peels, and lasers in the microsecond, nanosecond, and picosecond domains can address epidermal melanin. It is vital that when using light-based devices, no excess heat or inflammation occurs, as this can exacerbate the condition and cause further melanogenesis, which has been well-documented in picosecond and nanosecond lasers.<sup>2</sup>



After 4 Treatments

Photo courtesy of Jason Emer, MD

Aerolase® uses a novel, short 650-microsecond pulse with high energy to address melasma. Since Aerolase's high energy coagulates melasma's excess melanin and vasculature without creating heat in the surrounding tissue, it addresses the symptoms of melasma and causative factors leading to melasma for a comprehensive treatment.<sup>3</sup>

Aerolase is the first device to address melasma effectively, comprehensively, and safely. Aerolase is the first 1064nm laser to deliver energy into the skin using 650 Microsecond Technology®. For melasma, it creates a unique treatment.<sup>3</sup>

**1) Pigment:** Aerolase targets melanin in the dermis by safely bypassing epidermal melanin. By bypassing the epidermal pigment, it enables the laser energy to penetrate to greater depths, increasing efficacy and safety for all Fitzpatrick skin types.

**2) Vascular Components:** Aerolase targets hemoglobin to break down hyper-vasculature in melasma. Measurements using optical coherence tomography revealed a 52% reduction in vessel diameter and a 22% reduction in vessel density after a single Neo Elite treatment.<sup>5</sup>

**3) Skin Tone & Texture:** Aerolase targets water to superheat the dermal tissue and stimulate neocollagenases, enhancing overall skin tone & texture

Aerolase is a new laser treatment that has proven effective in treating melasma, and it's the first and only device to combine the benefits of comprehensively addressing melasma.

1. Grimes PE, Ijaz S, Nashawati R, et al. New oral and topical approaches for the treatment of melasma. *Int J Womens Dermatol* 2019;5:30-36.
2. Zhou Y, Hamblin MR, Wen X. An update on fractional picosecond laser treatment: histology and clinical applications. *Lasers Med Sci*. 2023 Jan 20;38(1):45.
3. Burgess C, Chilukuri S, Campbell-Chambers DA, Henry M, Saedi N, Roberts WE. Practical Applications for Medical and Aesthetic Treatment of Skin of Color With a New 650-Microsecond Laser. *J Drugs Dermatol*. 2019 Apr 1;18(4):s138 - 143. PMID: 31026130.
4. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. *J Am Acad Dermatol* 2011;65:689-97.
5. Aerolase clinical data on file.

### TRADITIONAL TREATMENTS:

- Increased risk of pigmentary changes induced by inflammation
- Commonly limited to Fitzpatrick skin types I-IV
- Depth of penetration limited due to heat transfer into the epidermis


### AEROLASE:

- High energy with deep dermal penetration
- Uniquely gentle treatment avoids adverse effects
- Increased safety profile for Fitzpatrick skin types IV-VI and tanned skin
- Absorption in all skin chromophores for comprehensive therapy
- No skin cooling or anesthetics needed
- No skin contact by the handpiece



After 2 Treatments

Photo courtesy of Avanti Aesthetics



After 4 Treatments

Photo courtesy of Brian Johnson, MD and Tiffany Crews, LE

aerolase®

914.345.8300 | [information@aerolase.com](mailto:information@aerolase.com) | [aerolase.com](http://aerolase.com)

@aerolase

MAIN SPONSORS

PLATINUM SPONSORS



sanofi | REGENERON

Lilly

GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS







CONGRESS



AMSTERDAM

25-28 SEPTEMBER 2024

SAVE THE DATE



SYMPOSIUM



ST JULIAN'S - MALTA

16-18 MAY 2024

DEEP KNOWING  
TO KEEP GROWING





**EA** CONGRESS  
**DV**



**BERLIN**

11-14 OCTOBER 2023

[eadvcongress2023.org](https://eadvcongress2023.org)